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C1q is a protein complex whose deficiency is associated with the occurrence of the 
prototypical autoimmune disease, systemic lupus erythematosus (SLE), in both 
human patients and murine models. C1q is the first sensor component of the classical 
pathway of complement activation and intricately involved in the clearance of 
apoptotic cells. The prevalent form of C1q (Normal) found in human serum is a 
complex consisting of 18 polypeptide chains composed of C1q A, B and C genes. In 
this study, a smaller low molecular weight (LMW) form of C1q produced by human 
macrophages and dendritic cells was investigated. This alternative form of C1q, 
termed as LMW C1q was not only smaller in size but was composed of a differential 
dimeric composition, thus structurally different from the Normal form of C1q. 
Functionally LMW C1q was significantly deficient in its capacity to elicit 
complement activation due to a decreased binding affinity for immobilized IgG and 
IgM. Macrophages, believed to be the dominant physiological source of C1q, are 
generally divided into classical or alternative macrophages based on their respective 
cytokine stimulation, IFN-γ or IL-4 respectively. LMW C1q expression in 
macrophages was upregulated in the presence of IFN-γ stimulation and suppressed in 
IL-4 stimulation, an expression profile mimicking that of Normal C1q. However in 
the presence of M-CSF, the expression of LMW and Normal C1q is differentially 
regulated.  
 
A recombinant mammalian expression system and purification protocol for LMW 




are the sentinels of the immune system implicated in the bridging of the innate and 
adaptive immune system. Human monocytes differentiated to DCs in the presence of 
LMW C1q enhanced the secretion of IL-12p70 and decreased the secretion of IL-10 
in the presence of LPS and IFN-γ stimulation; conversely Normal C1q suppressed IL-
12p70 and enhanced IL-10 secretion. DCs primed with LMW C1q enhanced Th-1 
differentiation of allogenic T cells in mixed lymphocyte reactions, with concomitant 
increase in IFN-γ secretion and parallel increase in T cell proliferation. DCs primed 
with LMW C1q exhibited a decreased capacity for apoptotic cell uptake, and a 
cytokine profile biased towards an inflammatory setting (increased IL-12p70 and 
decreased IL-10), thus impacting the nature in which self antigens are presented to T 
cells. Remarkably Normal C1q has the exact opposite profile for T cell differentiation 
and apoptotic cell uptake. Indeed titrating LMW C1q levels against that of Normal 
C1q revealed that a balance in the ratio of LMW/Normal C1q might be pivotal in 
deciding the eventual adaptive immune response. This study strives to understand an 
alternative dimension of how C1q synthesis in its two forms (Normal/LMW) could 
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Chapter 1 Introduction 
1.1 General Overview of the Immune System 
 
The immune system is an elegantly designed biological network of components 
evolved over time not only to discriminate invading foreign pathogens from host 
tissues but also to provide constant surveillance against endogenous neoplastic lesions 
from gaining a foothold. To defend against a horde of constantly evolving pathogens, 
there is a need to develop an arsenal of defence mechanisms that could recognize a 
diverse repertoire of micro-organisms. The ability to detect various pathogens is at the 
same time balanced by the need to prevent an over-zealous attack on its host tissue. 
Thus central to the theme of the immune system is the overarching function to 
discriminate non-self from self. The non-self components could arise from pathogenic 
micro-organisms or host tissues that have become cancerous, and the self components 
are protected from the immune system by the maintenance of central and peripheral 
tolerance.  
 
Conceptually the immune system could be divided into two arms namely the innate 
and adaptive immunity. The innate immunity is primarily designed to signal the first 
sign of an invading foreign presence and acts to respond rapidly as the first line of 
defence. Innate cells are equipped with a range of pathogen recognition receptors 
(PRR) such as Toll-like receptors (TLRs), C-type lectin receptors (CLRs), RIG-I-like 
receptors (RLRs) or NOD-like receptors (NLRs) located either on the surface of cells 
as transmembrane receptors (e.g. TLR-4), intracellularly in endosomal compartments 
(e.g. TLR-3/9) or cytosolic compartments (e.g. RLRS or NLRs) (Takeuchi and Akira 




molecular patterns (PAMPs) found in foreign pathogens and results in secretion of 
inflammatory cytokines/chemokines or cell associated morphological changes and 
surface receptor expression. The secretion of inflammatory cytokines allows paracrine 
regulation of surrounding cells or the autocrine regulation of the initial cell to skew 
immune responses that are appropriate for the type of invading organism. The 
secretion of chemokines allows the recruitment of further immune cells to quickly 
target the pathogens either for ingestion or to simply prevent their further spread. The 
complement system is an intricate part of the innate immune system which could 
independently bind to surface components of the pathogens and results in an 
inflammatory proteolytic cascade that result in (a) opsonisation to promote uptake by 
phagocytes, (b) the creation of membrane attack complexes that lyse the pathogens or 
(c) release of anaphylatoxins to promote inflammation and recruitment of innate 
effector cells. Multiple arms of the innate immunity would interact at the site of 
infection to result in a combination of inflammatory response to limit the infection. 
Although the innate cells respond to PAMPs, its effector mechanisms for dealing with 
pathogens tend to result in excessive damage to host tissue. Persistent inflammation is 
detrimental to the host organism, in such an event there is a need for a more targeted 
response to direct the damage onto the pathogens and to reduce collateral damage on 
host tissues.  
 
The adaptive immunity is equipped with an amazing range of receptors on T cells and 
B cells that are created from the seemingly random nature of VDJ gene segment 
recombination responsible for T cell receptors (TCR) or B cell receptors (BCR) in 
primary lymphoid organs such as the thymus and bone marrow respectively. This 




with a potentially large variety of pathogens. The innate immune system although 
relatively static in its ability to deal with the wide variety of invading organisms (as a 
result of germline encoded PRRs), it does play an important role in a constant random 
surveillance of the environment. Professional antigen presenting cells (APCs) such as 
dendritic cells (DCs) constantly purview the environment through macro-pinocytosis , 
process and present antigens onto major histocompatibility complex (MHC). Upon 
detection of a foreign pathogen through its PRRs, DCs undergoes a process of 
maturation which involves the upregulation of costimulatory molecules (e.g. CD80 
and CD86) and the expression of chemokines receptors such as CCR7. The mature 
DCs then migrate to secondary lymphoid tissues such as the lymph nodes where it 
interacts with naïve T cells. The creation of random TCRs on T cells result only in a 
small number of specific TCRs for each specific pathogen. The interaction of DCs 
carrying the pathogen specific antigen presented on MHCs with the cognate specific 
TCRs on T cell, allows the clonal expansion of specific T cells. The type of T cell 
differentiation (Th1, Th2, Th17) depends on the cytokines that are secreted from the 
DCs, which ultimately depends on the resultant combination of PRRs activated. As 
the type of T cell differentiation determines the resultant form of immune response 
(e.g cell mediated, humoral, etc), it would seem that DCs play a pivotal role in 
bridging the innate and adaptive immunity to orchestrate a symphony of immune 













1.2.1 The Role of Dendritic cells in microbial sensing  
 
The discovery of Langerhan cells (epidermal DCs) by Paul Langerhans in 1868 led to 
initial speculations that these were cutaneous nerve cells (Langerhans 1868) . Almost 
a century later, in 1973, Steinman and Cohn coined the term “Dendritic cells” based 
on the morphology of certain spleenic cells (Steinman and Cohn 1973) whose 
significance was later noted when it was determined that DCs could stimulate potent 
allogenic proliferation of lymphocytes. The initial years of DC biology was mired in 
the painstaking purification from tissues and were studied by few investigators due to 
low yield. However the discovery of cytokine driven techniques to differentiate DCs 
in vitro (Caux, Dezutter-Dambuyant et al. 1992; Inaba, Inaba et al. 1992; Romani, 
Gruner et al. 1994; Sallusto and Lanzavecchia 1994), allowed the rapid explosion of 
studies on DCs.  
 
It is now established through decades of investigation that DCs are pivotal in bridging 
the innate and adaptive immunity. They act primarily as sentinels to survey the 
environment through macropinocytosis, endocytosis and phagocytosis. Their ability to 
sense their environment stem from their expression of an impressive array of PRRs 
such as TLRs. A total of 10 TLRs have been identified in humans and 13 TLRs in 
mice (though TLR 10 in mice is a pseudogene) (Akira, Uematsu et al. 2006).  The 
TLRs are broadly classified into two distinct clusters due to their cellular localization 
(Table 1), either extracellularly on the cell surface or intracellularly located in 
endosomal compartments as transmembrane receptors. The restricted 
compartmentalization of the endosomal TLRs could reflect the need to reduce 




Though there is increasing evidence that DCs could respond to endogenous danger 
associated molecular patterns (DAMPs) derived from host tissue damage and 
inflammation such as heat shock proteins (HSPs), high mobility group box 1 protein 
(HMGB1) and uric acid (Nace, Evankovich et al. 2012).   
 
Table 1 : Human TLRs. Adapted from (Takeuchi and Akira 2010) 




TLR1 Triacyl Lipoprotein Bacteria 
TLR 2 Lipoprotein Bacteria, viruses, 
parasites. 
TLR 4 LPS Bacteria, Viruses. 
TLR 5 Flagellin Bacteria 
TLR 6  Diacyl Lipoprotein Bacteria, Viruses. 
Endosomal-
Lysosomes 
TLR 3 dsRNA Viruses 
TLR 7 ssRNA Viruses, Bacteria.  
TLR 8 ssRNA Viruses, Bacteria. 
TLR 9 CpG DNA Viruses, Bacteria, 
protozoa 
TLR 10 Unknown Unknown 
 
The selective activation of specific TLRs could yield distinct types of immune 
responses. For instance, LPS from Escherichia coli stimulates DCs through TLR4 
culminating in a Th1 response through IL-12 secretion, whereas Porphyromonas 
gingivalis activates TL2 resulting in a Th2 response from IL-10 secretion (Pulendran, 
Kumar et al. 2001). Generating the right form of response is essential in eliminating 
the pathogen, in leprosy, the tuberculoid form of the diseases result in Th1 response 
which limits the infection, whereas in the lepromatous form, an induction of Th2 




Immature DCs possess high endocytic and phagocytic capacity for enhanced antigen 
capture but expresses low levels of MHC class II molecules and co-stimulatory 
molecules such as CD80 and CD86. Utilising PRRs such as TLRs, DCs matured upon 
sensing microbial presence, resulting in a series of changes. This complex procedure 
of maturation involves transcriptional changes in the order of thousand of genes as 
exemplified by NFκB activation (Kawai and Akira 2007), thus the matured DC could 
be considered a distinct cell type. Maturation of DC involves (a) cytoskeletal 
reorganization and the acquisition of cellular mobility through up regulation of 
chemokines receptors such as CCR7 (responding to chemokines CCL19 and CCL21) 
(Trombetta and Mellman 2005) and the down regulation of chemokines receptors 
such as CCR1,CCR5 and CCR6; (b) the loss of endocytic and phagocytic receptors; 
(c) expression of high levels of antigen presenting molecules such as MHC II (Cella, 
Engering et al. 1997); (d) increased expression of co-stimulatory molecules such as 
CD40, CD80 and CD86; (e) secretion of coordinated waves of chemokines (Piqueras, 
Connolly et al. 2006); (f) and finally the secretion of cytokines that polarizes the 
adaptive immunity.  
 
Consequently the matured DCs migrate to the secondary lymphoid organs such as 
lymph nodes via the afferent lymphatics towards the T cell region (Randolph, Angeli 
et al. 2005).  The functional matured DCs scans through the numerous naïve T cells , 
and activates the specific cognate TCR which binds to the antigen loaded MHC on the 
DC. The matured DC is highly efficient in stimulating naïve T cells via 3 distinct 
signals; (a) the antigen specific MHC; (b) CD80/86 stimulation of CD28 receptor on 
the cognate T cell; (c) and finally the secretion of cytokines which polarises the T cell 




Most cells have the intrinsic capacity (except for red blood cells) to present 
intracellular antigens, processed via proteasome mediated means, onto MHC Class I 
while most phagocytes have the additional capacity to present exogenously derived 
antigens onto MHC Class II. DCs are capable of cross presentation of exogenously 
derived antigens onto MHC Class I thereby activating naïve CD8 T cells into 
cytotoxic cells. This pathway is particularly significant for the presentation of viral 
antigens which do not infect hematopoietic cells (Buckwalter and Albert 2009). 
However recent evidence reflects that the reverse could also occur, specifically 
endogenous antigen could also be presented onto MHC Class II in certain 
circumstances. DCs are capable of delivering cytosolic antigen into the MHC II 
compartment via an autophagosome mediated mechanism (Buckwalter and Albert 
2009; Uhl, Kepp et al. 2009)   
 
The polarisation of T helper responses depend on the cytokines secreted by the APCs 
(i.e DCs); (a) the differentiation of Th1 requires the hallmark cytokine of the Th1 
pathway , IL-12p70 produced from DCs (Trinchieri 2003); (b) the differentiation of 
Th2 largely depends on IL-4 and OX40L (Ito, Wang et al. 2005); (c) and the 
differentiation of Th17 is promoted by TGF-β, IL-6, IL-21 and IL-23(Korn, Bettelli et 
al. 2009). Each T helper response is targeted towards a specific form of protection 
against pathogens, for instance Th1 is believed to protect against intracellular 
pathogens whereas Th2 is responsible for humoral immunity against parasites. Th17 
is recently discovered and characterized, it is believed to aid in the defence against 






1.2.2 The Role of Dendritic Cells in Maintenance of Tolerance 
 
Regulatory T cells or TREG are divided into two classes based on their developmental 
origin, namely, the natural TREG and the inducible TREG (Peterson 2012). Briefly, 







markers, while inducible TREG arise from naive TH0 cells under the influence of 
cytokines. The various subsets of inducible TREG, are differentiated from TH0 in the 



















). Immature DCs or DCs primed 
in the presence of microbial stimulation could secrete IL-10 or TGF-β, which 
subsequently result in the development of inducible TREG , that either maintains 
tolerance or limit the state of inflammation (Abraham and Medzhitov 2011). These 
inducible TREG act via three main mechanisms, (a) the secretion of soluble factors 
such as cytokines (IL-10 or TGF-β) (Annacker, Asseman et al. 2003), (b) cell contact 
dependent mechanisms via CTLA4 binding to DCs (Read, Malmstrom et al. 2000) , 
(c) competition for growth factors with the over-expression of IL-2 receptors which 
depletes IL-2 from effector T cells (Pandiyan, Zheng et al. 2007), to induce 
suppression.  
 
In the thymus, the site of T cell development, a subset of regulatory DCs called 




 thymocytes, and 
maintain central tolerance against host antigens (Brocker, Riedinger et al. 1997). In 
essence, tolerogenic DCs have been shown to exert significant effects in the 




Makrigiannakis et al. 2010) and is starting to generate significant interest in the 
clinical management of autoimmune conditions (Boks, Kager-Groenland et al. 2012).  
 
1.3.1 Human Dendritic Cells Subsets 
 
Investigations into the nature of DCs reveal a striking variety of distinct DC subsets 
each characterized by different anatomical locations (Sato and Fujita 2007), migratory 
homing tendencies (Randolph, Ochando et al. 2008), developmental origin (Auffray, 
Sieweke et al. 2009), distinct expression of PRRs (Ueno, Klechevsky et al. 2007), and 
thus distinct functionalities. To expedite the functional characterization of DC subsets, 
investigators have utilised a spectrum of cell markers to define distinct DC subsets. 
Though the true significance and functionality of certain markers in the DC subsets 
are not entirely understood, there has been increasing interest to utilise these markers 
as a target for clinical application(Steinman 2012).  In a non-human primate study, a 
fusion HIV-gag p24 with monoclonal antibody against DEC205, was utilised as a DC 
target vaccine, allowed the generation of a large CD8
+ 
T cell response (Flynn, 
Kastenmuller et al. 2011) .  
 
Clearly with future clarifications into the nature of each distinct DC subset, a more 
targeted approach in orchestrating the desired immunological outcome could be 
achieved. As there is much confusion in the differences between the murine and 
human counterparts in DC subsets, this introduction will continue only in further 
discussion with the human DC subsets. A summary of murine DC subsets is 
illustrated (Table 2) and well review in other articles (Pulendran, Tang et al. 2008). As 




forms of human DCs; (a) Langerhan cells (LCs); (b) Dermal/ Interstitial DCs (DDC-
IDCs); (c) Monocyte derived DCs (moDCs); (d) Plasmacytoid DC (PDC); will be 
explored in further detail.         
 
Table 2: Murine DC Subsets. Adapted from (Pulendran, Tang et al. 2008).  









T cell rich areas High IL-12p70 
and Low IL-10 
Th1 (except in 
LP) 
Cross presentation 
to CD8+ T cells  
CD8α-CD11b+ 





Marginal Zones (spleen), 
Subcapsular sinus (LN), 
Subepithelial dome (PP) 
Low IL-12p70 
and High IL-10 
Th2 (except in LP 







PP T cell rich areas in 
subepithelial dome, 
Follicle associated 
epithelium, B cell follicle  
High IL-12p70 










Marginal Zones (spleen), 
T cell rich areas (LN) 
IFN-α (except 
in PP) 







of skin, LN, 
MLN 
Epithelium of skin, 









Dermis of skin,  









Unknown Unknown During 
inflammation, 
Unknown Th 










Table 3: Cell surface markers of Human Dendritic cells. Adapted from (Rossi 
and Young 2005).  
DC 
subset 






LCs + (m-) - - + - + (m-) + (m-) + (m+) + U 
DDC-
IDCs 
+ + + + - - - + (m+) + U 
moDCs + + + + + - - + (m+) + -/+ 
pDCs - U - - + - - - (m+) ++ + 
The myeloid/Conventional DCs (LCs, DDC-IDCs and moDCs) are MHC IIbright, CD80++/+++, CD86+++, CD14-,CD11c+ which 
increases with maturation. PDCs express much lower levels of MHC and costimulatory molecules than their conventional 
counterparts. However all DCs express CD83+ upon full maturation.  Abbreviation; m+, increases with maturation; m-, deceases 
with maturation; U, Unknown; +/- , indicates degree of expression.  
 
1.3.2 Human Dendritic Cells Subsets: Langerhan Cells 
 
The LCs are DCs that localized at the epithelial surfaces of skin and mucosa. 
Interestingly as opposed to murine LCs which are believed to be regenerated through 
self renewal from perhaps endogenous skin/fetal progenitors, human LCs seem to be 
derived from bone marrow (Katz, Tamaki et al. 1979).  Indeed CD34
+
 hematopoietic 
progenitor cells (HPCs) obtained from human bone marrow or umbilical cord blood 
cultured under the influence of GM-CSF, TNF-α (Caux, Dezutter-Dambuyant et al. 
1992) could give rise to LCs with the expression of Langerin, E-cadherin and the 
characteristic Birbeck granules (Valladeau, Duvert-Frances et al. 1999). The presence 
of c-kit ligand can enhance the yield of LCs in synergistic combination with GM-CSF 
and TNF-α, but do not influence differentiation of LCs (Szabolcs, Moore et al. 1995). 
However, the presence of TGF-β supports the differentiation of LCs especially under 
serum free conditions (Szabolcs, Moore et al. 1995; Gatti, Velleca et al. 2000). The 












PBMCs) are also found in the blood, and could give rise to similar LCs (Ito, Inaba et 
al. 1999).  
 
Human LCs isolated from the skin expresses TLR1,2,3,6 and 10 but lack TLR4,5 and 
9 (Flacher, Bouschbacher et al. 2006). The expression of TLR 7 and 8 on LCs are still 
unknown. This restricted expression of TLRs could have an impact on the type of 
pathogens LCs tends to target. Interestingly, LCs derived from CD34
+ 
HPC seems 
superior in cross presentation to cytotoxic CD8
+
 T cells (Ratzinger, Baggers et al. 
2004), in the absence of bioactive IL12-p70 secretion. This feature is in concordance 
with murine LCs counterpart, where studies have shown that murine LCs migrates in 
response to MIP-3α (Ratzinger, Baggers et al. 2004), and exhibit differential 
migration kinetics and localization tendencies compared to DDC-IDCs. Specifically 
murine LCs migrates slowly to the lymph nodes with peak arrival 3 to 4 days after 
application of sensitizer, while immune responses are already well under way 
(Kissenpfennig, Henri et al. 2005). More importantly LCs migrates specifically to the 
deep paracortex of the T cell zone (as opposed to DDC-IDC which migrates to the B 
cell follicles), which seems to correlate well with human LCs in the efficient 
induction of cytotoxic CD8
+
 T cells, and seems to suggest the importance of LCs in 
mediating cellular immunity.  
 
1.3.3 Human Dendritic Cells Subsets: Dermal/Interstitial Dendritic Cells 
 
DDC-IDCs are DCs that localized to the sub-epithelial tissues of dermis of the skin, 
and the interstitial tissues of solid organs. Similar to LCs, DDC-IDCs are DCs that 
could be cultured from CD34
+




blood under the influence of GM-CSF and TNF-α.  The developmental pathway of the 
DDC-IDCs is different in the aspect that a CD14
+
 intermediate phase occurs during 
the differentiation of DDC-IDCs (Caux, Vanbervliet et al. 1996). In contrast to LCs, 
DDC-IDCs expresses TLR 1-8, with the additional expression of TLR 2, 4 and 5, 
DDC-IDCs are better equipped to detect bacterial PAMPs (van der Aar, Sylva-
Steenland et al. 2007).  
 
Human DDC-IDCs are able to secrete IL-10 in response to CD40L, a feature which is 
missing in LCs (de Saint-Vis, Fugier-Vivier et al. 1998). In addition, murine DDC-
IDCs preferentially migrate to B cell follicle areas (Kissenpfennig, Henri et al. 2005), 
and human DDC-IDCs are able to induce the differentiation of naïve B cells into IgM 
secreting plasma cells via the secretion of IL-6 and IL-12 (Caux, Massacrier et al. 
1997; Dubois, Massacrier et al. 1998). The cytokine and migratory profile of DDC-
IDCs indicate a preferential induction of humoral immunity, in contrast to LCs which 
seems to indicate a preference for cellular mediated immunity.  
     
1.3.4 Human Dendritic Cells Subsets: Plasmacytoid Dendritic Cells 
  











 cells which lack the myeloid marker CD11c (Grouard, Rissoan 
et al. 1997; Dzionek, Fuchs et al. 2000). The generation of human PDCs could be 
achieved by culturing CD34
+
 HPCs with Flt-3L and thrombopoietin, though its yield 
is still significantly lower than that of the conventional DCs (e.g. LCs, DDC-IDCs, 
moDCs) achieved with cytokine driven methods. PDCs express high levels of CD123, 
 
 
a receptor for IL-3, and it has been supported that IL-3 increases viability of PDCs 
(Caux, Vanbervliet et al. 1996).     
 
PDCs isolated from blood reflect a lower expression of MHC and costimulatory 
molecules as compared to conventional counterparts (e.g. LCs, DDC-IDCs, moDCs), 
and a corresponding weaker ability to capture, process and present antigens 
(O'Doherty, Peng et al. 1994). PDCs are the only human DCs subset to express TLR9 
(Kadowaki, Ho et al. 2001), and most notably known for its ability to secrete copious 




 DCs seem to express higher levels of IDO and is thought to 
represent a subset of tolerogenic DCs (Grohmann, Orabona et al. 2002). PDCs 
express high levels of CD123and has been shown to induce IL-10 producing T regs 
(Ito, Yang et al. 2007). Thus in addition to its anti-viral role, PDCs might too 
participate in the maintenance of peripheral tolerance.    
 
1.3.5 Human Dendritic Cells Subsets: Monocyte Derived Dendritic Cells 
 
The most commonly studied human DCs are the moDCs as a result of the relative 
ease of obtaining human blood samples and the high percentage of monocytes found 
in human blood (ranging from 15-30% of PBMCs depending on immunological status 
of donor). With the realisation that monocytes could be differentiated and cultured 
into DCs with IL-4 and GM-CSF, the generation of moDCs became widespread 




blood myeloid DCs and in the presence of TGF-β (in addition to GM-CSF and IL-4), 
moDCs resembles LCs (Geissmann, Prost et al. 1998).    
 
Studies in mice and humans, indicate that moDCs most likely reflect a population of 
DCs that result from inflammation rather than the steady state DCs. Ken Shortman 
showed that in mice deficient in GM-CSF and GM-CSF receptor, normal number of 
DCs could be found in steady state (Vremec, Lieschke et al. 1997).The transfer of 
GM-CSF receptor deficient monocytes into wild type mice fail to develop into DCs 
(Shortman and Naik 2007). In addition in the presence of Flt-3L administration to 
healthy human volunteers increases the blood myeloid DC by 48 fold and PDCs by 13 
fold (Pulendran, Banchereau et al. 2000). This correlates well with the murine 
counterpart, where Flt-3L deficient mice reflected a dramatic decrease in DCs found 
in peripheral and lymphoid tissues. The most striking evidence that moDCs are 
probably inflammatory DCs come from the study where direct injection of LPS or 
gram negative bacteria into mice, resulted in dramatic increase of DCs in peripheral 
lymph nodes due to the migration and differentiation of monocytes (Cheong, Matos et 
al. 2010). In support of its inflammatory role recent evidence suggest that human 
moDCs are the most potent stimulators of NK cell proliferation and cytotoxicity 
among the conventional DCs (Munz, Dao et al. 2005) and possibly the likely 
candidate DC for the activation of NKT cells (Rossi and Young 2005). 
 
This study relies heavily on the usage of moDCs as a model DC to investigate the 
regulatory properties of C1q, a key mediator of the classical complement pathway. 
The significance of C1q and its impact on DCs in mediating the adaptive immune 




1.4 General Overview of Complement System  
 
Complement was initially discovered by Nobel Prize winner, Jules Bordet during the 
1900s, when he noticed that the bacteriolytic effect of antibodies could be enhanced 
by serum components. This activity could be negated by heating, thus the factors 
involved are heat liable. Since these factors could ‘complement’ the effects of 
antibody, it was given the name complement. Presently it is known that complement 
activation could proceed even in the absence of antibodies due to the direct binding of 
the upstream mediators of complement to PAMPs located on the surface of foreign 
pathogens. 
 
 Complement activation could occur on foreign pathogenic surfaces or endogenous 
host apoptotic cells through 3 major pathways (Fig 1), namely the (a) classical 
pathway, (b) lectin pathway and (c) alternative pathway. A fourth pathway involving 
proteases known as the extrinsic protease pathway has also gain prominence in recent 
years (Ricklin, Hajishengallis et al. 2010).    
 
The classical pathway can be initiated through either the direct binding of C1q to the 
target surface via PAMPs (pathogenic surfaces) or apoptotic markers (host cell), or 
alternatively through the indirect binding of C1q to host pattern recognition molecules 
(PRMs) which have bound to the target. PRMs such as IgG/IgM, or C reactive protein 
(CRP) could recruit C1q as part of the C1 complex (C1qC1r2C1s2). The binding of 
C1q results in a conformational change that results in the autocatalytic cleavage of 
C1r which cleaves C1s (Gaboriaud, Thielens et al. 2004). The activation of the C1s 




of a previously hidden thioester bond in C4b results in the covalent deposition of C4b 
onto the target surface. The deposited C4b recruits C2, which positions it optimally 
for C1s cleavage into a smaller non-proteolytic C2b fragment and a larger C2a 
fragment which contains the catalytic protease site, resulting in the formation of the 
classical pathway C3 convertase (C4bC2a). The formation of the C3 convertase is a 
common point in the complement activation cascade intersected by the 3 main 
pathways (classical, lectin and alternative).  
       
 
Figure 1: Complement Activation via Classical, Lectin, Alternative and Extrinsic protease pathway on 
a foreign pathogen surface. This figure is adapted from (Ricklin, Hajishengallis et al. 2010). 
Abbreviation CRP: C Reactive Protein, MBL: Mannose Binding Lectin, MAC: Membrane Attack 
Complex, MASPs: MBL-associated serine proteases, LPS: Lipopolysaccharide. 
 
The lectin pathway possesses analogously similar sensor molecules to detect 
carbohydrate moieties on target surfaces. The sensor molecules, mannose binding 




and upon binding to their target’s carbohydrate moieties, recruits MBL-associated 
serine proteases (MASPs) that work similarly to the classical pathway’s C1r and C1s.    
Recruited MASP-2 cleaves both C4 and C2 resulting in the formation of the C3 
convertase (C4bC2a), in contrast MASP-1 could only cleave C2 thus playing a role of 
which accelerates the formation of the C3 convertase rather than initiation (Dobo, 
Harmat et al. 2009).  
 
The alternative pathway results in the generation of two forms of C3 convertase, a 
fluid phase (C3H20Bb) or a bound form (C3bBb). The fluid phase C3 convertase is 
formed constantly by the tick over of fluid C3 natural hydrolysis forming C3H20
 
(Pangburn, Schreiber et al. 1981). This allows a constant probing of targets by the 
alternative pathway of complement activation, which is kept in check on host cells by 
the presence of complement regulatory proteins. C3H20 recruits factor B and is cleaved 
by factor D to form the fluid phase C3 convertase (C3H20Bb). The fluid phase C3 
convertase cleaves C3 into C3a and C3b, which allows the covalent binding of C3b 
onto the target surface via a short lived thioester moiety. The presence of bound C3b 
recruits factor B and is cleaved by factor D to form the bound form of C3 convertase 
(C3bBb). The presence of properdin acts either to stabilise the bound C3 convertase 
or could act as a sensor molecule by recognising PAMPs or DAMPs and recruit fluid 
C3b to form de novo bound C3 convertase (Fearon and Austen 1975; Spitzer, 
Mitchell et al. 2007) .    
 
Once the C3 convertase (either C4bC2a or C3bBb) is formed on the target surface, 
additional C3b will opsonise the target, and eventually result in the formation of C5 




C5b, the fluid form of C5b recruits C6 and C7. This exposes a hydrophobic site on C7 
and allows the insertion of C5bC6C7 into the target membrane. This complex recruits 
C8 and several units of C9 to form a lytic membrane complex known as the 
membrane attack complex (MAC). The end result of complement activation is the (a) 
opsonisation of the target surface with C3b (and its cleaved fragments) that facilitates 
phagocytosis and uptake through binding with complement receptors, (b) the release 
of anaphylatoxins which recruits inflammatory cells, and (c) the formation of the 
MAC terminating in cell lysis. The complement activation pathway is highly 
regulated by fluid phase and cell surface bound complement regulatory proteins which 
can fine tune the extent to which the pathway proceeds downstream (Sjoberg, Trouw 
et al. 2009).    
 
The fourth pathway that could activate complement is the extrinsic protease pathway 
that includes proteases such as thrombin, plasmin, elastase, and plasma kallikrein. For 
instance during coagulation, activated factor XII can activate the classical pathway 
through C1 cleavage (Ghebrehiwet, Silverberg et al. 1981), and thrombin can directly 
cleave C5 generating C5a without passing through the C3 convertase (Huber-Lang, 
Sarma et al. 2006). In addition C5a could enhance coagulation and inhibit fibrinolysis 
(Ritis, Doumas et al. 2006). Although intuitively the crosstalk between the 
coagulation cascade and complement activation seems link to the need of enhancing 
clotting and preventing microbial spread at the site of injury, the actual physiological 
significance is still unknown.   
 
Since the initial discovery by Jules Bordet, the functions of the complement system 




against invading microbes.  The complement system impacts on the shaping of the 
adaptive immune response through its interaction with T cells (Strainic, Liu et al. 
2008; Sacks 2010) and B cells (Fischer and Hugli 1997; Ottonello, Corcione et al. 
1999), maintenance of homeostatic conditions such as clearance of apoptotic debris 
(Gullstrand, Martensson et al. 2009), development (Shinjyo, Stahlberg et al. 2009), 
tissue repair (Nozaki, Raisler et al. 2006) and metabolism (Raisz, Sandberg et al. 
1974; Niculescu and Rus 2001). In the next section, an interesting candidate of the 
complement system, C1q, will be further elaborated.  
 
1.5.1 Structure of C1q 
 
The human C1q protein complex is encoded by 3 distinct genes, namely C1q A, B 
and C on a 24-kb stretch of DNA located on chromosome 1p in the order A-C-B 
(Reid 1985; Sellar, Blake et al. 1991). Each of the C1q chains consists of 81 amino 
acids N-terminal collagenous region and a C-terminal globular head of 136 amino 
acids (Fig 2). The C1q complex consists of a total of 18 polypeptide chains assembled 
from 6 C1q A, 6 C1q B and 6 C1q C chains. The individual chains are linked through 
disulphide bonds located at the N-terminal (at amino acid position 4 for every chain), 
resulting in C1q A-B and C1q C-C dimers. The dimers are believed to form a doublet 
of C1q chains consisting of C1q A-B:C-C:B-A bounded together by a mixture of 
covalent and non-covalent interactions. The complete C1q complex consists of 3 of 
such doublets, thus a total of 18 polypeptide chains. Due to the formation of globular 
heads from a heterotrimeric assembly of C1q A-B:C at the C-terminal ends of each 
chain, the C1q complex is commonly termed as a hexameric complex of 




studies (Shelton, Yonemasu et al. 1972) reflects 6 globular heads (C1q A-B: C) at the 
C-terminal ends, linked with the entire complex at the N-terminal collagenous stalk. 
The N-terminal collagenous region of C1q chains are characterized by Gly-X-Y 
repeats, where X is often proline and Y could be either hydroxylproline or 
hydroxylysine (Reid 1974; Myllyharju 2003).    
 
  
Figure 2: C1q Chains organization adapted from (Ghebrehiwet, Hosszu et al. 2012). The C1q complex 
consists of 3 distinct genes encoded by C1q A,B and C. The C1q A-B and C-C chains forms dimers via 
disulphide bonds, and eventually forms a complex of 18 polypeptide chains of 6 C1q A, 6 C1q B and 6 
C1q C chains. Abbreviations: aa: amino acids, c-domain: collagenous domain, g-domain: globular 
domain, da: Daltons.  
 
The 460 kDa C1q Complex is capable of binding to a variety of endogenous host 
ligands (e.g. CRP, IgG/IgM) (Cooper 1985; Szalai, Agrawal et al. 1999) and foreign 




binding ability has been attributed mainly to the globular heads (gC1q) (Gaboriaud, 
Frachet et al. 2011).  
 
The gC1q was isolated through the selective cleavage of the collagenous domains 
with the use of collagenase (Knobel, Heusser et al. 1974) and the X-ray crystal 
structure of gC1q was resolved at 1.9 angstroms (Gaboriaud, Juanhuix et al. 2003). 
The crystal structure revealed a spherical heterotrimeric assembly of C1q ABC 
(gC1q) of a diameter of 50 angstroms. With the aid of the apical view of the gC1q, the 
order of C1q chains are arranged in clockwise manner C1q A, B and C. This allowed 
the authors to derive a 3D model reconstruction of the collagenous triple helix, and 
finally reconstruct the entire C1q complex (Gaboriaud, Juanhuix et al. 2003; 
Gaboriaud, Thielens et al. 2004).  
  
 
Figure 3: Structure of C1q adapted from (Gaboriaud, Frachet et al. 2011). The C1q chains are labelled 
accordingly; C1q A: Blue, C1q B: Green, C1q C: Red.  
 
Interestingly the C1q model (Fig 3) indicated that C1q B in gC1q was exposed 
outwards from the central cone of the C1q complex, whereas C1q A and C1q C in 




consisting of two 5-stranded β sheet whose strands are anti-parallel for each 
individual C1q chain. Overall the gC1q structure was homologous to that of the TNF 
family (Eck and Sprang 1989). It revealed a charge distribution with the apical side of 
gC1q being positively charged due the presence of lysine residues and a hydrophobic 
area on the base of gC1q. A Ca
2+
 ion located at the apex of gC1q is coordinated by 
oxygen ligands contributed by C1q A and B, but not connected to C1q C. The Ca
2+
 
which is exposed to solvent has been postulated to play a significant functional role, 
where the loss of Ca
2+
 has been suggested to induce a change in the electric vector of 
the gC1q, influencing the recognition of targets such as CRP and IgG  (Roumenina, 
Kantardjiev et al. 2005).  
 
Due to the nature of the heterotrimeric assembly of the spherical gC1q, certain surface 
residues of each chain are exposed to solvent, whereas the rest are most likely 
interacting with the opposite cognate C1q chains. The exposed residues of each chain 
revealed that C1q A and C1q C presents a combination of positive and negative 
charges, whereas C1q B predominantly exposes positively charged residues. Since 
each chain in gC1q display a unique surface charge distribution and overall charge, it 
is likely the exposed surface of each chain mediates differential binding properties, 
explaining the versatile binding affinity with a variety of ligands.  
      
Figure 4 Model of C1 activation adapted from 
(Gaboriaud, Frachet et al. 2011). The yellow 





The authors propose an enticing model of how C1 activation, where C1q binding with 
cognate ligands activate the tetramer C1r2C1s2, is affected depending on which C1q 
chains are mediating the binding in the gC1q. As previously stated C1q B in the gC1q 
faces outwards from the cone of C1q (Fig 3), whereas the C1q A and C chains are 
facing inwards. It would seem that ligands binding to C1q B such as IgG result in 
strong complement activation, and ligands such as DNA, heparin sulfate and 
phosphatidylserine which binds to C1q C (as shown by X-ray crystallography) results 
in weaker complement activation (Paidassi, Tacnet-Delorme et al. 2008; Garlatti, 
Chouquet et al. 2010). Similar studies on C1r catalytic domain through X-ray 
crystallography indicated that an outward movement C1q stems is necessary for 
triggering C1 activation (Bally, Rossi et al. 2009; Brier, Pflieger et al. 2010). Thus the 
site of the ligand binding on gC1q whether on C1q B or C1qAC, results in different 
C1 activation levels (Fig 4).   
 
1.5.2 Physiological Origin of C1q biosynthesis 
 
Majority of complement proteins could be produced by hepatocytes from the liver 
(Colten, Strunk et al. 1986). The dominance of the liver as the main site of production 
for these complements is clearly reflected by clinical liver transplantations, where the 
presence of normal or mutant MBL correlates with the genotype of the donor liver 
rather than the recipient (Bouwman, Roos et al. 2005). In contrast, the  main site of 
C1q production seems to be extra-hepatic in origin, specifically it has been 
demonstrated by murine bone marrow transplantation experiments that the dominant 
source of C1q is hematopoietic in origin (Petry, Botto et al. 2001). C1qa
-/-
 deficient 




levels restored, whereas wild type mice which were irradiated and transplanted with 
bone marrow from C1qa
-/-
 deficient mice had undetectable levels of C1q.  
 
C1q expression has been documented in a wide variety of cell types including; (a) 
macrophages (Muller, Hanauske-Abel et al. 1978; Loos, Martin et al. 1989; Kolosov, 
Kolosova et al. 1996), (b) DCs (Vegh, Goyarts et al. 2003; Castellano, Woltman et al. 
2004), (c) epithelial cells (Colten 1976), (d) mesenchymal cells (Morris, Colten et al. 
1978), (e) fibroblasts (Reid and Solomon 1977; Gulati, Lemercier et al. 1993) and (f) 
trophoblasts (Bulla, Agostinis et al. 2008; Agostinis, Bulla et al. 2010). It is 
interesting to note that the autocrine and paracrine secretion of C1q in the vicinity of 
DCs, can have a significant impact on the shaping of adaptive immunity (van Kooten, 
Fiore et al. 2008).  
 
1.5.3 Functions of C1q: General Overview 
 
Broadly the functions of C1q can be classified in two main categories, namely the 
classical and the non-classical functions. Traditionally C1q has been associated with 
the activation of the classical pathway where C1q acts as the sensor component of the 
C1 complex, and plays a role as one of the first line of defence in innate immunity. 
Indeed the ability of C1q to bind to immobilized IgG/IgM or directly to PAMPs such 
as LPS, Outer membrane protein k (Ompk) of Klesbsiella pneumonaie, together with 
notable increase in disease susceptibility to polymicrobial peritonitis, meningitis, 
Salmonella infections and pneumonia in C1q deficient patients and mice, has 




et al. 1996; Celik, Stover et al. 2001; Warren, Mastroeni et al. 2002; Pickering, Macor 
et al. 2008; Roumenina, Popov et al. 2008).   
 
In addition to the established classical role of C1q as an innate immune pathogen 
sensor, several emerging new roles have surface over the years. C1q has been found 
to be involved in; (a) Immuno-modulation of DCs (Castellano, Woltman et al. 2007; 
Csomor, Bajtay et al. 2007), (b) angiogenesis and wound healing (Bossi, Rizzi et al. 
2011), (c) chemotaxis of immune and mesenchymal stromal cells (Leigh, 
Ghebrehiwet et al. 1998; Qiu, Marquez-Curtis et al. 2012), (d) cell adhesion (Bordin, 
Ghebrehiwet et al. 1990), (e) production of reactive oxygen species by neutrophils 
(Goodman, Anderson et al. 1995), (f) T cell activation and cytokine regulation, and 
negative selection of B cells (Chen, Gaddipati et al. 1994; Ferry, Potter et al. 2007; 
van Montfoort, de Jong et al. 2007), (g) clearance of apoptotic cells (Navratil, 
Watkins et al. 2001; Ogden, Kowalewski et al. 2005), and (h) synaptic refinement of 
optic nerve during development (Stevens, Allen et al. 2007). As the list of C1q roles is 
quite extensive, only selected relevant functions will be elaborated.  
 
1.5.4 Functions of C1q: Clearance of apoptotic cells 
 
Cell death occurs constantly as a result of daily attrition. To prevent unnecessary 
activation of the immune system and tissue damage, there is a need to control cell 
death. Apoptosis refers to the programmed cell death mechanistic processes that allow 
cell death to occur in a controlled manner without excessive inflammation. The first 




came from the observation of an accumulation of apoptotic cells in the glomeruli of 
C1qa
-/-
 mice (Botto 1998; Botto, Dell'Agnola et al. 1998). 
 
During the process of apoptosis, the cell membrane undergoes a series of changes 
which result in the exposure of “eat me” signals such as phosphatidylserine and DNA. 
The exposure of such signals recruits C1q directly or indirectly through other PRMs 
such as CRP and IgM (Kim, Gershov et al. 2003; Nauta, Daha et al. 2003). Direct 
binding of C1q to apoptotic cells was shown to occur via the gC1q heads with the 
induction of C1q mediated complement activation and the deposition of C4 and C3 
(Nauta, Trouw et al. 2002). Surface plasmon resonance (SPR) and X-ray 
crystallographic studies reveal the direct binding of gC1q to the phosphoserine moiety 
within phosphatidylserine (Paidassi, Tacnet-Delorme et al. 2008). The exposure of 
DNA on cell surface occurs during apoptosis, and the treatment of apoptotic cells with 
DNAse fail to activate complement (Elward, Griffiths et al. 2005). The direct binding 
of DNA to C1q was shown to occur through the pentose moiety of DNA, the deoxy-
D-ribose, and subsequently DNA-C1q binding was resolved with X-ray 
crystallographic studies (Garlatti, Chouquet et al. 2010).  Mice deficient in serum IgM 
was shown to have significant reduction in intra-peritoneal clearance of apoptotic 
cells, with correspondingly marked reduction in complement activation and C3 
deposition (Ogden, Kowalewski et al. 2005). The naturally ciruculating IgM that 
targets apoptotic cells was later shown to predominantly target phosphorylcholine , 
which is exposed during apoptosis as well as a ROS degraded product of 
polyunsaturated lipids, malondialdehyde (Chen, Park et al. 2009). These IgM specific 
antibodies were shown to recruit C1q and mediate serum dependent phagocytic 




After the recruitment of C1q to apoptotic cells by the various aforementioned 
mechanisms, two main pathways facilitate the C1q-mediated clearance by phagocytes, 
namely the traditional complement activation pathway and non-complement activated 
pathway. C1q recruitment to apoptotic cells could result in complement activation and 
the opsonisation of the apoptotic cells, but unlike pathogenic targets, it is regulated by 
fluid phase complement regulatory proteins such as C4BP and FH (Trouw, Bengtsson 
et al. 2007). Apoptotic cells recruit C4BP and FH, which allows C1q mediated C3 
deposition but generally prevents the inflammatory downstream cascade of 
complement activation (e.g MAC formation). The deposition of C3 and its derivatives 
allow facilitates the uptake of apoptotic cells via phagocytic complement receptors 
(e.g. iC3b via CR3) on phagocytes.   
 
C1q mediated phagocytic clearance can occur alternatively via complement activation 
independent means such as the calreticulin/CD91 complex located on phagocytes 
(Ogden, deCathelineau et al. 2001; Vandivier, Ogden et al. 2002). After C1q 
recruitment to apoptotic cell surface, C1q binds to calreticulin and mediates 
macropinocytosis through the adaptor molecule CD91. However recent evidence also 
indicate that calreticulin exposure also occurs on apoptotic cells and could mediate 
gC1q binding (Paidassi, Tacnet-Delorme et al. 2011).  
 
Interestingly C1q could pre-prime phagocytes for enhanced phagocytic capacity (Teh, 
Yeo et al. 2011; Galvan, Foreman et al. 2012). Monocytes cultured in the presence of 
immobilized C1q and differentiated into moDCs, significantly increase the phagocytic 
capacity of moDCs to ingest apoptotic cells (Teh, Yeo et al. 2011). Likewise, 




phagocytic ability for apoptotic cells, and was shown to be dependent on the C1q 
mediated expression of Mer tyrosine kinase in macrophages (Galvan, Foreman et al. 
2012).  Macrophages from Mer deficient mice (Mertik
-/-
), failed to respond to C1q’s 
enhanced engulfment of apoptotic cells.  
 
In light of these evidence, it would seem that C1q could enhance phagocytic clearance 
of apoptotic cells via 3 mechanisms; (a) recruitment of C1q to apoptotic cells, 
resulting in complement activation and opsonisation to facilitate phagocytosis, (b) 
recruitment of C1q to apoptotic cells to mediate binding of putative C1q receptors on 
phagocytes and lastly (c) priming of phagocytes for enhancement engulfment.  
 
 1.5.5 Functions of C1q: Immuno-modulation of DCs 
 
Investigators utilise a wide variety of formats to test the effect of C1q on DCs (Table 
4). The effects of C1q on DC modulation seem highly dependent on which ligand the 
system is using to test the expression of cytokines or function, perhaps reflecting the 
multifaceted nature in which DCs responds to the environment.  
 
In the absence of microbial components such as LPS, the presence of immobilized 
C1q (C1q coated plates) conditions moDCs to be more pro-inflammatory, with 
increased expression of CD80, CD83, CD86, CCR7 and secretion of IL-12p70 
(Csomor, Bajtay et al. 2007). These C1qDCs, induces allogenic proliferation of T 





In the presence of LPS stimulation, C1q suppresses the expression of pro-
inflammatory cytokines and surface expression of co-stimulatory molecules (Yamada, 
Oritani et al. 2004; Castellano, Woltman et al. 2007; Fraser, Laust et al. 2009; Teh, 
Yeo et al. 2011). The presence of C1q (either soluble or immobilized format) results 
in the differentiation of monocytes into moDCs which respond to LPS stimulation 
with a decrease in expression of IL-6, IL-12p40, TNF-α and IL-23 compared to non-
C1q differentiated moDCs (Castellano, Woltman et al. 2007; Teh, Yeo et al. 2011). 
Alternatively soluble C1q added simultaneously with LPS after the differentiation of 
BMDCs, resulted in a drop in IL-12p40 levels, and correspondingly C1qa
-/-
 mice with 
intraperitoneal injection of LPS, had lower serum levels of IL-12p40 compared to 
wild type mice (Yamada, Oritani et al. 2004). Human moDCs after differentiation 
from monocytes were also seeded onto plates of coated C1q, and resulted in 
suppression of IL-1B, TNF-α and MCP-1in the presence of LPS (Fraser, Laust et al. 
2009). 
 
Interestingly in the presence of soluble C1q, PDCs decrease its secretion of IFN-α in 
response to CpG stimulation or immune complexes (IC) (Lood, Gullstrand et al. 
2009) with significance relevance to SLE and C1q deficiency. BMDCs stimulated in 
the presence of CpG and C1q, reflected a drop in IL-12p40 and TNF-α as compared to 
BMDCs stimulated in the absence of C1q (Yamada, Oritani et al. 2004).   
 
In contrast, the injection of male specific irradiated thymocytes with the HY antigen, 
resulted in decreased levels of IL-12p70 and IFN-γ in female C1qa-/- mice (Baruah, 
Dumitriu et al. 2009). In this experimental setup, the mechanism in which DCs 




12p70 secretion, and subsequently enhanced IFN-γ expression by T cells. Though 
another group indicated that CD40L mediated IL-12p70 secretion by moDCs are 
suppressed with C1q added during the differentiation phase from monocytes to 
moDCs (Castellano, Woltman et al. 2007).  Overall it would seem that C1q has 
significant capacity to influence DC differentiation, maturation and ability to respond 
to different ligands, thereby playing a role in shaping the downstream adaptive 
immunity.      
Table 4: Immuno-Modulation of DCs by C1q  
Form of 
stimulation  
DC Subset Modality of C1q 
testing 
Effects of C1q addition References 
Nil 
Human moDCs moDCs after DF 
were cultured on 
immobilized C1q 
C1q increased nuclear translocation of 
NFκB.C1q increased expression of co-
stimulatory molecules and CCR7. 
C1q increases T cell proliferation, IFN-γ, 
TNF-α and IL-10 expression in MLR.  




and C1qa-/- mice 
 
Addition of Soluble 
C1q after DF of 
DCs  
C1q inhibited IL-12p40 production by LPS 
of BDMCs in vitro.  
C1qa-/- mice had increased IL-12p40 in 
serum upon intra-peritoneal LPS injection. 
(Yamada, Oritani et 
al. 2004) 
Human moDCs Addition of Soluble 
C1q during DF of 
DCs 
C1q decreased expression of Co-stimulatory 
molecules and CCR7 upon LPS stimulation.  
C1q inhibited expression of IL-6, TNF-α 
and IL-10 upon LPS stimulation.  
C1q decreased allogenic proliferation of T 
cells and secrete less IFN-γ in MLR. 
(Castellano, 
Woltman et al. 2007) 
Human moDCs Monocytes cultured 
in presence of 
immobilized C1q 
and DF to moDCs 
C1q decrease expression of IL-6, TNF-α, IL-
12p40 and IL-23 and increases IL-10 upon 
LPS exposure. C1q decreases secretion of 
IL-12p70 with LPS and IFN-γ stimulation.  
(Teh, Yeo et al. 
2011) 
Human moDCs moDCs after DF 
were cultured on 
immobilized C1q 
 
ACs incubated with 
soluble C1q 
C1q decrease expression of IL-1B, IL-10, 
TNF-α, and MCP-1.  
 
 
C1q-ACs increases expression of IL-10, 
TNF-α, MCP-1 and decreases MIP-1α in the 
presence of LPS stimulation. 
(Fraser, Laust et al. 
2009) 
CpG 
Murine BMDCs Addition of Soluble 
C1q after DF of 
DCs 
C1q inhibited IL-12p40 and TNF-α 
production by CpG of BMDCs in vitro. 
(Yamada, Oritani et 
al. 2004) 
Human PDCs Addition of soluble 
C1q to PDCs 
C1q inhibited IFN-α, IL-6,IL-8 and TNF-α 
expression by PDCs. 
(Lood, Gullstrand et 
al. 2009) 
CD40L 
Human moDCs Addition of Soluble 
C1q during DF of 
DCs 
C1q decreased expression of IL-12p70 upon 
stimulation with CD40L. 
(Castellano, 
Woltman et al. 2007) 
C1q a-/-BMDCs C1qa-/- BMDCs and 
reconstitution with 
soluble C1q after 
DF of DCs. 
C1qa-/- BMDC exhibit decease expression 
of IL-12p70 upon exposure to CD40L 
ligation by either anti-CD40 or CD40L 
transfected fibroblast. 
(Baruah, Dumitriu et 
al. 2009) 
IC 
Human PDCs Addition of soluble 
C1q to PDCs 
C1q inhibited IFN-α, IL-6,IL-8 and TNF-α 
expression by PDCs. 










soluble C1q after 
DF of DCs. 
C1qa-/- BMDCs and mice exhibit decrease 
expression of IL-12p70, IFN-γ and IL-2 
upon exposure to gender specific HY 
antigens alone or on apoptotic thymocytes in 
MLR setting.  
(Baruah, Dumitriu et 
al. 2009) 
Abbreviations: BMDCs; Bone Marrow derived DCs, DF: differentiation, IC: Immune Complex, HY: Male specific MHC antigen 




1.5.6 Functions of C1q: Migration of immune cells and wound healing 
 
As previously alluded, C1q possesses a myriad number of non-classical roles, one of 
which is migration. C1q acts as a chemotactic factor for a variety of immune cells, 
namely eosinophils, mast cells, neutrophils and dendritic cells (Ghebrehiwet, Kew et 
al. 1995; Kuna, Iyer et al. 1996; Leigh, Ghebrehiwet et al. 1998; Vegh, Kew et al. 
2006). Immune cells such as neutrophils which play a first responder role in 
inflammation and infection, have been observed to migrate towards areas of tissue 
damage in response to chemotactic gradients of C1q (Leigh, Ghebrehiwet et al. 1998). 
In addition C1q could trigger production of ROS such as superoxide by neutrophils 
via a CD18 dependent mechanism (Goodman, Anderson et al. 1995). DCs which are 
the sentinels of the immune system, respond to C1q chemotactic gradient via binding 
to gC1q and cC1q receptors found on DCs (Vegh, Kew et al. 2006), and intriguingly 
this occurs only for immature DCs and not matured DCs. 
 
 Fibroblasts which plays a critical role in wound healing through the secretion of 
ECM proteins and collagen, respond to C1q chemotactic gradient through an increase 
of cytosolic Ca
2+
 and subsequent hyperpolarizing response in K
+
 channels (Oiki and 
Okada 1988). Mesenchymal stromal cells known for their potential in tissue 
regeneration, migrate to sites of tissue damage and inflammation. C1q has been 
shown to induce migration of mesenchymal stromal cells in a dose dependent manner 
and primes its response to a second chemotactic factor, SDF-1 (Stromal cell derived 
factor 1) (Qiu, Marquez-Curtis et al. 2012). So it would seem that C1q plays a role not 
only in recruiting a spectrum of immune cells to areas of inflammation and tissue 




1.5.7 Functions of C1q: Other non-classical functions of C1q 
   
C1q is intricately involved in the shaping of the adaptive immunity. Utilising a souble 
hapten-antigen conjugate, it was shown that an antigen specific T cell dependent 
humoral response was defective in C1qa
-/-
 mice (Cutler, Botto et al. 1998). 
Specifically there was a decrease in IgG2a and IgG3 isotype antigen specific 
antibodies in C1qa
-/-
 compared to wild type, due to a defective IFN-γ production by 
the antigen specific T cells. The authors speculated that the IFN-γ was required for the 
isotype switch to IgG2a and possibly IgG3. 
 
In another study with immune complexes, it was shown that C1qa
-/-
 mice had a 
decreased capacity to present immune complexes (OVA-IgG) to OVA specific CD8
+
 
T cells adoptively transferred into C1qa
-/-
 mice, reflected by a drop in OVA specific 
CD8
+
 proliferation (van Montfoort, de Jong et al. 2007). This defect could be 
compensated by pre-incubating the immune complex with C1q.     
 
Direct addition of C1q to B cells have shown an increase capacity for B cells to 
secrete immunoglobulins in the absence of enhanced B cell proliferation (Young, 
Ambrus et al. 1991). In contrast, another study utilised an autoimmune transgenic 
model of an intracellular neo-self antigen (mHEL-KK) and a corresponding high 
affinity antigen specific Ig (MD4 Ig
HEL
) to examine B cell selection in C1qa
-/-
 mice. 
The absence of C1q resulted in increased positive selection of autoreactive B1b B 
cells, leading to the secretion of autoreactive IgM autoantibodies and a concomitant 




C1q plays a dual role in enhancing B cell secretion of Ig but also in maintaining B cell 
tolerance.   
 
On the other end of the spectrum, C1q plays an unusual developmental role in 
synaptic refinement of the optic nerve in mice (Stevens, Allen et al. 2007). C1qa
-/-
 
mice demonstrated abnormal segregation of the ipsilateral and contralateral optic 
nerve innervation to dorsal lateral geniculate nuclei (dLGN), due to the improper 
removal of vestigial optic nerve innervations.  
 
The diverse spectrum of C1q functions ranging from homeostatic clearance of 
apoptotic cells to immunological defence and the shaping of adaptive immunity could 
be partially explained by the versatile ligand binding capacity of the gC1q area.  
 
1.6.1 C1q and Systemic Lupus Erythematosus  
   
Systemic lupus Erythematosus is a systemic autoimmune disease characterized by the 
targeting of multiple organs, manifesting complications such as nephritis, central 
nervous system vasculitis, pulmonary hypertension, interstitial lung disease and stroke 
(Fairhurst, Wandstrat et al. 2006). The disease prevalence in Asia generally falls 
between the range of 30-50/100 000 population (Osio-Salido and Manapat-Reyes 
2010). The American Rheumatism Association (ARA) defines 11 clinical 
representations as diagnostic criteria for SLE, where the presence of any 4 of the 11 
diseases features qualifying as a definite diagnosis of SLE (Tan, Cohen et al. 1982). 
The strongest clinical indicator is high levels of anti-nuclear antibodies (ANAs) with a 




systemic disease, the targeting of the kidney is by far the most serious clinical 
pathology, with many of the clinical manifestations correlating with morbidity and 
death being associated with renal failure (Balow 2005).  
 
Over the years many genes (>25) have been implicated as susceptibility factors which 
predispose individuals to SLE (Moser, Kelly et al. 2009). Hereditary deficiency of 
C1q was one of the earliest recognized monogenic causes resulting in SLE, with the 
first clinical case reported in 1977 (Izzet Berkel, Sanal et al. 1977). Since then only 64 
cases of C1q deficiency have been reported globally (Schejbel, Skattum et al. 2011). 
Though the relative occurrence of C1q deficiency is low, it does open a window to 
understanding how a single genetic deficiency could penetrate through a supposedly 
multigenic disease with heterogeneous clinical presentations, and perhaps allow 
greater insight to the disease pathology.  
 
The penetrance of homozygous C1q deficiency resulting in SLE is high, affecting 
nearly 88-93% of C1q deficient cases (the recent drop in penetrance reflect the 
improvement in clinical diagnostics of younger C1q deficient patients that have yet to 
exhibit the disease symptoms) (Cheng and Anderson 2012). This genetic association 
is further supported by surveys of general population in Switzerland (4000 army 
recruits) and Japan (145,000 blood donors) which revealed no healthy individuals 
with C1q deficiency (Hassig A, Borel JF et al. 1964; Inai, Akagaki et al. 1989). C1q 
deficient patients exhibit multi-organ SLE-related symptoms such as photosensitivity 
malar rash, aphthous oral ulcers, angioedema, chronic glomerulonephritis, arthritis, 





Concomitant with clinical findings, murine studies reveal that in autoimmune prone 
mice such as (129xC57BL/6) and MLR/Mp, indicated that C1qa
-/-
 mice develop SLE 
like symptoms such as marked production of autoantibodies, earlier onset and severity 
of glomerulonephritis and increased mortality (Botto, Dell'Agnola et al. 1998; 
Mitchell, Pickering et al. 2002).     
 
Two hypotheses have been proposed to explain how C1q deficiency might be 
associated with SLE, namely the “waste disposal hypothesis” and the “tolerance 
hypothesis” (Lewis and Botto 2006).The two hypotheses are not mutually exclusive 
and possibly work in parallel.  In the waste disposal hypothesis, it is believed that the 
ineffectual clearance of apoptotic debris contributes to the break down of peripheral 
tolerance. Injection of syngeneic apoptotic thymocytes in normal mice resulted in the 
development of antinuclear, anti-ssDNA and anti-cardiolipin antibodies with 
deposition of ICs in the glomeruli (Mevorach, Zhou et al. 1998). These findings 
correlate with the increased presence of apoptotic bodies in the glomeruli of C1qa
-/-
 
mice (Botto, Dell'Agnola et al. 1998) and that human macrophages from SLE 
individuals demonstrated an impaired capacity to phagocytose apoptotic cells 
(Herrmann, Voll et al. 1998). These studies are firmly supported by a wide panel of 
investigations that indicate C1q plays a definite role in the clearance of apoptotic 
cells, as discussed earlier (section 1.5.4). According to the waste disposal hypothesis, 
it is postulated that excess apoptotic/necrotic debris from delayed clearance, might 
result in presentation of self antigens by DCs in an inflammatory setting, with the 





 The tolerance hypothesis postulates that C1q could play an active role in maintaining 
tolerance at the level of the adaptive immunity. In particular, the authors suggest that 
C1q plays a role in B cell tolerance, and in the absence of C1q, there would be 
increased production of autoantibodies and the generation of autoreactive B cells. 
This hypothesis is supported by investigations that revealed C1qa-/- mice exhibited 
increased positive selection of autoreactive B1b B cells, which leads to the increased 
secretion of autoreactive IgM autoantibodies and a concomitant defect in negative 
selection of conventional B cells (Ferry, Potter et al. 2007). This hypothesis could also 
be extended to the concept that C1q plays a significant role in shaping the adaptive 
immune response (not just B cells), where a deficiency in C1q might effectively skew 
the immune system leading to a more inflammatory setting which is prone to a break 
down in peripheral tolerance.    
 
Though the evidence tilting towards a protective role for C1q in the context of SLE is 
impressive, controversial issues still remain. Firstly there is evidence that in SLE 
patients (not C1q deficient), the classical pathway is initiated by C1q and leads to 
tissue damage and depositions of complement proteins in the inflamed tissues of SLE 
patients (Botto and Walport 2002). Secondly autoantibodies against C1q have been 
detected in 30% of SLE patients (Seelen, Trouw et al. 2003), and a pathogenic role 
has been implicated where anti-C1q amplifies the C1q mediated complement 
activation at immune complex depositions (Trouw, Groeneveld et al. 2004). Thirdly a 
low form of C1q has been expressed at significantly higher levels in SLE patients 
(Hoekzema, Hannema et al. 1985). This paradoxical nature in which C1q interplays 
with SLE, both protective and pathogenic at the same time, suggests that the actual 




1.6.2 C1q and other diseases  
 
The link between SLE and C1q is the fundamental cornerstone and platform that not 
only broaden but allowed a deeper understanding of several physiological functions 
that C1q possesses. The commonality that connects C1q, SLE and other implicated 
diseases, is the same underlying basic functions of C1q reflected merely in a different 
context. Just as SLE aids in understanding C1q, the other diseases provide a window 
of opportunity to understanding how C1q behaves in a different scenario, and how it 
interplays with the larger biological system at hand. C1q has been implicated with a 
wide spectrum of diseases ranging from neurodegenerative diseases, atherosclerosis, 
carcinogenesis, antibody-dependent enhancement in viral infection, to pre-eclampsia 
(Takada and Kawaoka 2003; Tenner and Fonseca 2006; Haskard, Boyle et al. 2008; 
Ghebrehiwet, Hosszu et al. 2012).  
 
Investigations into C1q and neurodegenerative diseases such as Alzheimer’s disease 
(AD), revealed a dual role for C1q in the pathology of the disease. AD is a 
neurodegenerative disorder characterized by the loss of cognitive function from 
synaptic and neuronal loss and the presence of neurofibrillary tangles, β-amyloid 
plaque deposition, and glial inflammatory events. AD prone mice with overexpression 
of amyolid precursor protein (APP) or mutant APP (Tg2576) were crossed with C1q 
deficient mice (Q
-/-




 mice. Both models reflected a 
50-60% drop in astrocytic reactivity, and 50% lower microglial immunoreactivity 
(Fonseca, Zhou et al. 2004). In vivo deposition of C1q and other complement proteins 
and resultant complement activation have been previously shown to be associated 




Zanjani, Finch et al. 2005). The authors postulated that the significant decrease in 
activated microglial and astrocytes seen in C1q deficient animals stems from the lack 
of classical pathway complement activation, which normally recruits the immune cells 
via the release of C3a and/or C5a (Yao, Harvath et al. 1990). The concomitant drop in 
activated glia is accompanied with improved neuronal integrity as depicted by 
increased presence of the synaptophysin marker, MAP-2 (Fonseca, Zhou et al. 2004). 
However the timing of the complement activation at the fibrillary β-amyloid plaques 
coincides with the later onset of the disease rather than the initial phase, thus 
complement activation plays a role in exacerbating the later phase of the disease. 
However in contrast to the pathogenic role of C1q in AD, other studies indicated that 
transgenic mice models overexpressing Crry, a murine fluid phase complementary 
regulatory that inhibits conversion of C3 to C3b, β-amyloid plaques deposition was 
higher than the wild type, with corresponding elevated loss of synaptic integrity 
(Wyss-Coray, Yan et al. 2002). The author postulated that the lack of microglia lead 
to decrease clearance of β-amyloid plaques and resultant increase in degenerating 
neurons. Indeed C1q has been found to play a role in the microglia mediated clearance 
of apoptotic neurons and blebs (Fraser, Pisalyaput et al. 2010). Hence C1q has found 
to play a protective role in delaying the onset of the disease through the clearance of 
apoptotic debris and possibly plaques, and a pathogenic role in exacerbating the 
disease in the later phase through complement activation.  
 
In another form of neurodegenerative disease, transmissible spongiform 
encephalopathies (TSE) which is perpetuated by prions, C1q is implicated with a 
pathogenic role.   Murine conventional DCs cultured in the presence of the protease 






 were used (Flores-Langarica, Sebti et al. 2009). Indeed C1qa-/- 
mice reflected a delayed onset of in the manifestations of the disease, following 
injection of TSE reagents (Klein, Kaeser et al. 2001; Mabbott, Bruce et al. 2001). The 
authors believed that C1q is involved firstly either in the retention of PrPsc in 
follicular DCs, or secondly in the transport of PrP
sc 
from the intestinal lumen by 
conventional DCs to lymphoid tissues and finally the central nervous system. 
Interestingly complement activation on prions is enhanced when it converts from the 
normal form to the pathogenic form, PrPsc (Mitchell, Kirby et al. 2007). 
 
Complements and atherosclerosis have long been recognized to be associated, the 
developing atherosclerotic lesion have several PRMs such as immobilized 
immunologobulins, CRP, apoptotic cells, enzymatically treated LDL (low density 
lipoprotein), that trigger the activation of the classical pathway (Haskard, Boyle et al. 
2008). For instance LDL that is enzymatically treated by protease followed by 
cholesterol esterase led to significant C1 activation (Biro, Thielens et al. 2007). 
Mediators released by the activation of the classical pathway such as C3a and C5a 
have found to play a role activating atherosclerotic plaque macrophages and induction 
of vascular smooth muscle cell proliferation (Kastl, Speidl et al. 2006; Verdeguer, 
Castro et al. 2007). The pathogenic capacity of C1q was reflected in a vein graft 
model utilising a hypercholesterolaemic transgenic mice, ApoE3-Leiden,  which 
revealed presence of C1q in lesions 4 weeks after surgery, and its effects on vein graft 
thickening could be inhibited with a Crry-Ig fusion protein or a C3 cobra venom 
inhibitor (Schepers, de Vries et al. 2006). In contrast to its pathogenic role, C1q seems 









presence of apoptotic cells (Bhatia, Yun et al. 2007). This dual role in C1q displaying 
a protective role in early onset and a pathogenic role in later onset, is remarkably 
similar to that proposed in C1q and AD.    
 
Surprisingly C1q has been shown to induce the activation of tumor suppressor 
protein, WWOX (WW domain-containing oxidoreductase) via its phosphorylation 
and nuclear translocation, thereby exerting its pro-apoptotic properties in suppressing 
carcinogenesis in prostate cancer cells (Hong, Sze et al. 2009). In a study conducted 
on 74 cases of primary hematopoietic neoplasia and 20 leukemia cell lines, 
aberrations or absence of WWOX was detected in 51% of the primary cases, and 55% 
of the cell lines (Ishii, Vecchione et al. 2003). In view of the significance of WWOX 
in carcinogenesis, it would be interesting to monitor the development of C1q in the 
area of carcinogenesis. In the aspect of C1q, it is interesting to note that C1q plays not 
only a role in the clearance of apoptotic cells but in certain circumstances the 
induction of apoptosis itself.    
 
It has long been noted that female SLE patients exhibits greater risks of spontaneous 
miscarragies and pre-eclampsia(Smyth and Garovic 2009).  Human fetal trophoblast 
cells secret and express C1q on their cell surface to facilitate invasion of the deciduas 
(Agostinis, Bulla et al. 2010) and pregnant C1qa
-/-
 mice indicated increased fetal death 
with features resembling human pre-eclampsia (Singh, Ahmed et al. 2011).  
 
It would seem that the wide spectrum of physiological functions and pathological 
conditions that are implicated by C1q, justifies the intense scrutiny of its basic 




revisited with greater emphasis, and how this might affect the view of the truly 
multifaceted nature of C1q.   
 
1.7 Low molecular weight C1q and the rationale of the project  
 
C1q is a complex of 18 polypeptide chains and the resultant formation is that of a 
bouquet of tulips. The question that begs is whether C1q always synthesized and 
secreted in the same manner of the complex typically found in serum, could variations 
of the complex exist? Particular C1q is a combination of 3 separate forms of 
polypeptides, namely C1q A, C1q B and C1q C, could permutations of the various 
chains result in a different form of C1q complex? 
 
Indeed examining the C1q family of proteins grouped based on the homologous 
region of gC1q (Ghai, Waters et al. 2007), highlighted the presence of an interesting 
member of this family, adiponectin. Adiponectin remarkably resembles C1q in terms 
of its generic regions, the same collagenous regions and a similar globular head 
region, indeed, even the general structure of adiponectin is the same with that of C1q, 
with a bouquet of tulips (Radjainia, Wang et al. 2008). Intriguingly adiponectin is 
expressed in various oligomeric forms, namely, trimers, a dimer of trimers and higher 
multimers of trimers (Tsao, Murrey et al. 2002; Tsao, Tomas et al. 2003). 
Interestingly the different oligomers are formed via different association of disulphide 
bonds using different cysteine residues, a possible regulatory mechanism to determine 
which type of complex is formed (Tsao, Tomas et al. 2003). The different oligomeric 




functions, for instance the high molecular weight and dimer of trimers of adiponectin 
can activate NFκB signalling but not the trimeric form (Tsao, Murrey et al. 2002).  
 
Within the family of complements, MBL has long been known to exist in a variety of 
oligomeric states (Teillet, Dublet et al. 2005), with the different forms exhibiting 
differential affinity for ligands.  
 
With such precedence, could C1q too exist in a variety of oligomeric state?  Indeed 
examining back in literature reveal certain studies which suggested that a novel low 
molecular weight (LMW) form of C1q exist (Hoekzema, Hannema et al. 1985; 
Hoekzema, Brouwer et al. 1989; Hoekzema, Swaak et al. 1990). Initially highlighted 
in the presence of SLE patient sera, it was found to be highly expressed in SLE 
patients compared to healthy controls (Hoekzema, Hannema et al. 1985). Later it was 
shown to be produced by macrophages , and possesses a different form of disulphide 
binding as compared to the normal form of C1q (Hoekzema, Brouwer et al. 1989), 
reminiscent of the oligomeric forms of adiponectin, which too possesses a different 
disulphide bonding. It was shown that the LMW C1q possesses a much lower intrinsic 
capacity to initiate complement activation as compared to the normal form of C1q. 
 
 As the field of C1q has progressed tremendously since the 1990s, no one has yet to 
examine the various functions known to Normal C1q such as the immuno-regulation 
of DCs and the phagocytosis of apoptotic cells in the context of LMW C1q. The 
pathological mechanisms implied by LMW C1q in SLE have not been examined in 





If LMW C1q truly exists, it would add another layer of complexity to which how C1q 
functions are regulated. In which context or scenarios are C1q complexes 
preferentially synthesized in, and what possible physiological or biochemical 
functions could this LMW C1q be involved in? In light of the myriad number of 
functions that has been attributed to normal C1q, and the sometimes contradicting 
nature of dual roles revealed in knock out models, it is imperative to determine 
whether if such a form of C1q really exist, and if so, how does it interplay with the 
normal form of C1q.  
 
In summary the following main objectives of the project are listed below:  
 
1. Determine and validate the existence of LMW C1q in macrophages and DCs. 
Validate the differential presence of disulphide bonds and capacity of 
complement activation. 
 
2. In which scenarios are LMW C1q or Normal C1q preferentially synthesized? 
What is the expression profile of LMW C1q and Normal C1q in various 
contexts?  
 
3. Establish a methodology to obtain sufficient LMW C1q for further study 
 
4. In light of the importance of DCs in the regulation and shaping of the immune 
system, how does LMW C1q shape DC’s functions? Does it affect the 
cytokine expression, T cell proliferation and antigen presentation of apoptotic 
cells via uptake?  
 
 
Chapter 2 Materials and Method 
Note: All media and reagents are labelled with company in section 2.4 
2.1 Cell biology Techniques  
 
2.1.1 Isolation of human monocytes from buffy coat 
Enriched peripheral blood leukocytes were obtained from the National University 
Hospital (NUH) Blood Bank, in the form of buffy coat preparations derived from 
healthy donors, with Institutional Review Board approval. The buffy coat is extracted 
from blood packs with sterile 18 gauge syringe, and diluted with approximately equal 
volume of PBS to a total volume of 30ml in 50ml fulcrum tube. The 30ml of diluted 
sample is gently layered upon 12.5ml of Ficoll-Paque Plus in another 50ml fulcrum 
tube and centrifuged for 30mins at 400g without breaks. The peripheral blood 
mononuclear cells (PBMCs) from the milky white interphase between the ficoll and 
the serum, is resuspended and washed 2 times at 200g for 15mins, and a subsequent 2 
times at 100g for 10mins in a total of 50ml PBS each time. The samples are 
resuspended in 20ml of warm RPMI containing 5% (v/v) BCS, 100 units/ml of 
penicillin and 100μg/ml of streptomycin, into each T-75 flask for 1.5 hrs at 37oC, 5% 
CO2.  
 
Non-adherent cells mainly lymphocytes are removed by four consecutive washes with 
10ml of pre-warm RPMI culture media (as previously stated). The adherent cells, 
mainly monocytes are harvested by gentle scrapping. Monocytes isolated are >90% 




2.1.2 Culturing of Human Monocyte-Derived Dendritic cells and Macrophages 
 
The isolated human monocytes are cultured in 6 or 12 well tissue culture plates at a 
density of 1.5x10
6
 cells/ml in RPMI culture media containing 10% (v/v) BCS,100 
units/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine, 1mM sodium 
pyruvate and 0.0012% (v/v) β-mercaptoethanol in their respective cytokines. For 
moDCs, the monocytes are cultured in the presence of 20ng/ml GM-CSF and 40ng/ml 
M-CSF for 6 days at 37
o
C, 5%CO2. For monocyte derived macrophages (moMAC), 
the monocytes are cultured in either in the presence of 20ng/ml M-CSF for 6 days at 
37
o
C, 5%CO2 and are known as MMF, or in the presence of 20ng/ml GM-CSF for 6 
days at 37
o
C, 5%CO2 and are known as GMMF. Every 2 days, the differentiating cells 
are replenished with fresh media that is half the volume of the original volume, with 
respective cytokines.  
 
For C1qDCs, the 6 wells or 12 wells plates are coated with 10μg/ml of Normal or 
LMW C1q diluted in PBS, or as control 10μg/ml BSA diluted in PBS for 1.5 hours in 
incubator at 37
o
C (typically done when the PBMCs are in the adherent phase during 
monocyte isolation) and washed twice with 1ml PBS before adding monocytes with 
their respective cytokines.    
 
2.1.3 Isolation of naïve CD4
+
 T cells from human PBMCs 
 
Floating PBMCs aspirated from monocyte isolation after the adhesion phase are 
supplemented to a total of 20% BCS (7.5ml of BCS to 40ml of floating PBMCs in 5% 
BCS) and incubated overnight at 37
o




hospital are normally late, thus isolation of T cells is done consistently the next day).  
T cell isolation proceeds via negative selection as recommended from manufacturer’s 
instructions utilising the naïve CD4
+
 T cell isolation kit II. Briefly, the PBMCs are 
counted, spun down at 600g for 5mins and resuspended at 10
7
 cells per 40μl in MACS 
buffer, and incubated with 10μl (for every original 40μl) of primary antibodies 
conjugated with biotin (negative selection, thus a cocktail of antibody targeting all 
cells except CD4) for 10mins on ice. Subsequently, 20μl (for every original 40μl) of 
anti-biotin antibodies conjugated with metallic microbeads is directly added into 
sample and incubated for 15mins on ice. Cells are washed by centrifugation and 
resuspended in 500μl of MACS buffer, and layered gently onto LS magnetic column 
and separated with MidiMACS. The LS column is flushed with 3 times with 3ml of 
MACS buffer and the eluted naïve CD4
+
 T cells are collected.        
 
2.1.4 Cell line culture 
 
All cell lines are obtained via American Type Culture collection (ATCC) 
(Rockville,MD) and kept in T-75 flasks with a total of 20ml of media in humified 
incubator at 37
o
C in the presence of 5% CO2. The cell culturing conditions are 
summarised as below:  
 
Table 5: Cell Line Culturing 
Cell Line Media Passage Condition  
HEK 293T  DMEM, 10% (v/v) BCS, 100 units/ml Penicillin, 
100μg/ml Streptomycin, 2mM L-glutamine.   
Passage at 1:20 ratio, every 4 
days. Spin down at 350g for 
5mins. Cells harvested with 




Jurkat RPMI, 10% (v/v) FCS, 100 units/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine, 1mM 
sodium pyruvate and 0.0012% (v/v) β-
mercaptoethanol. 
Passage at 1:20 ratio, every 4 
days. Spin down at 500g for 
5mins. Cells are aspirated. 
Raw 264.7 DMEM, 10% (v/v) BCS, 100 units/ml Penicillin, 
100μg/ml Streptomycin, 2mM L-glutamine.   
Passage at 1:5 ratio, every 3 
days. Spin down at 450g for 
5mins. Cells are harvested by 
gentle scrapping.  
Thp-1 RPMI, 10% (v/v) FCS, 100 units/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine, 1mM 
sodium pyruvate and 0.0012% (v/v) β-
mercaptoethanol. 
Passage at 1:5 ratio, every 4 
days. Spin down at 600g for 
5mins. Cells are aspirated.  
Abbreviations: HEK; Human Emryonic Kidney, EDTA; Ethylenediaminetetraacetic Acid 
 
2.1.5 Mixed Lymphocyte Reaction 
 
CD4 naïve T cells are purified from PBMCs collected from a separate allogenic donor 
via negative MACS selection (see section 2.1.3) as per manufacturer instructions. The 





DCs) ratio in a 96 well format at a total of 200μl volume. The 
cells are stimulated with 500ng/ml LPS and/or 100ng/ml IFN-γ in RPMI media with 
10% (v/v) heat inactivated BCS, 100 units/ml penicillin, 10μg/ml streptomycin and 
incubated for 7 days at 37
o
C in the presence of 5% CO2. Similar DC or T cell only 
controls are performed with the same stimulations. The supernatant is aspirated and 
stored at -20
o
C till ELISA was performed against secreted IFN-γ. Intracellular 
cytokines were assayed by stimulating the 7
th
 day cells with 100ng/ml phorbol 12-
myristate 13-acetate and 1μg/ml ionomycin for 2hrs, and plugging the cells with 
5μg/ml brefledin A for 4hrs. The cells are fixed and permeabilized with using the 




mins on ice with anti CD4-Pacific Blue and anti-IFN-γ-PE or their isotypes for flow 
cytometry analysis.    
  
2.1.6 T cell Proliferation Assay 
 
The naïve CD4 T cells were isolated from human PBMCs via negative selection 
MACS (see section 2.1.4) and are stained with 1μM Carboxyfluorescein succinimidyl 
ester (CFSE) as previously described (Quah, Warren et al. 2007). Briefly T cells are 
stained in 1μM CFSE diluted in 5% (v/v) FCS in PBS for 5mins at room temperature. 
The T cells are washed twice and resuspended in RPMI media containing 10% heat 
inactivated BCS, 100 units/ml penicillin , 10μg/ml streptomycin and finally added to 




 DC) or only T cells as control and stimulated with 
500 ng/ml  LPS and 100 ng/ml IFN-γ. Non stained T cells are stained with mock PBS 
control and undergoes the same procedure as above. The cells are cultured for 7 days 
at 37
o








 day with 1% (v/v) 
paraformaldehyde, stored at 4 degrees for flow cytometry analysis.  
 
2.1.7 Phagocytosis of apoptotic Jurkat cells by DCs 
 
Jurkat cells are labelled with 2μM CFSE as per manufacturer instructions. Briefly 
jurkat cells are resuspended at 10 million/ml in 0.1% (w/v) BSA PBS with 2μM 
CFSE for 10 mins at 37
0
C and quenched twice with cold PBS. The labelled jurkat 
cells are resuspended at 2x10
6
/ml in serum free RPMI with 100 units/ml 




XLE-1000 UV Crosslinker (254nm lamp) as previously described (Teh, Yeo et al. 
2011). The UV-irradiated jurkat cells are incubated at 37
o
C  in the presence of 5% 





) in RPMI media containing 10% (v/v) human serum,100 units/ml 
penicillin, 10μg/ml streptomycin. The apoptotic cell-DC mixture is placed at 37oC for 
1, 1.5 or 2hrs, while the control cells are placed on ice. The cells are then quenched 
with trypan blue (2 mg/ml in 20mM sodium acetate and 150mM NaCl, pH 4.4) for 
5mins on ice to remove CFSE signal from non-phagocytosed apoptotic cells. The 
cells are then stained with anti-CD11c-PE for 30mins, washed twice and fixed with 
1% (w/v) paraformaldehyde. 
 
2.1.8 Treatment of DCs with apoptotic cells 
 
Jurkat cells are resuspended at 2x10
6
/ml in serum free RPMI with 100 units/ml 
penicillin,100μg/ml streptomycin and UV-irradiated for 5mins with Spectrolink Select 
XLE-1000 UV Crosslinker (254nm lamp) as previously described (Teh, Yeo et al. 
2011). The DCs were harvested and added with the apoptotic cells (AC) at different 
ratios of (1 AC cell: 1 DC, 10 AC cells: 1 DC, 20 AC cells: 1 DC, AC cell only or DC 
only, where 1 DC: 1x 20
5
 cells) for 24 hours in RPMI media with 10% heat 
inactivated BCS, 100 units/ml penicillin, 100μg/ml streptomycin in a total volume of 
200 μl in 96 well format. After 24 hours, the cells are stimulated with 500μg/ml LPS 







2.1.9 Determination of Cell viability 
 
Annexin-V and propidium iodide staining  
 
The Annexin-V-FITC Apoptosis Detection Kit II was used for this assay. A total of 
1x10
5
 cells were used per staining reaction and resuspended with 100 μl of Annexin-
V binding buffer and 5 μl of Annexin-V-FITC and 5μl of propidium iodide (PI) were 
added to each reaction and incubated for 15 mins at room temperature in the dark 
(aluminium foiled). After incubation, 400 μl of Annexin-V binding buffer was added 
to each reaction. Cells were analyzed by flow cytometry immediately. 
 
Lactate Dehydrogenase release assay  
 
 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released upon cell lysis. 
The CytoTox 96 Non-Radioactive Cytotoxicity Assay was used to measure LDH 
levels in medium to assess cell death in accordance to the manufacturer’s protocols. 
Briefly, cells were cultured as per condition (media,stimulations) in different 
experimental settings in 100μl format, and are known as test wells.  Additional wells 
of the cells were set aside for measuring total LDH released from all cells in the well 
and into the media after complete lysis and are known as total LDH wells. Media 
control wells with no cells, with just the media are also setup. Thus after the 
experimental setup is completed, the supernatant of the test wells were spun down and 
aspirated into new plates and 10μl of lysis buffer to the test wells, media control wells 
and the total LDH wells for 45mins at room temperature. A total of 50μl per well was 




each well and incubated at room temperature for 30mins. Finally, 50μl of stop 
solution is added to each individual well, and the absorbance is read at 490nm. To 
calculate the percentage of cell death based on LDH release, this formula is used: 
 
Percentage cell death = (Test wells-Media control wells) / (Total LDH wells-Media Control wells) x 100%     
 
2.1.10 Collection of secreted C1q from Dendritic cells and Macrophages 
 
DCs or macrophages were washed twice with PBS and resuspended into a protein free 
media, CD-hybridoma, supplemented with 100 units/ml penicillin and 100μg/ml 
streptomycin, at 1-2 x10
6 
cells/ml. The cells were cultured in a humified incubator at 
37
o
C in the presence of 5%CO2 for 72hrs to allow for secretion of endogenous C1q 
into media. The supernatant is aspirated and spun down at 600g for 5mins and filtered 
through 0.22μm to remove any cells debris. The sample is concentrated with 
ultracentrifuge tubes (Amicon Ultra-4, Millipore) to approximately 250μl volume and 
subsequently passed through FPLC (AKATA, GE-Healthcare) and resolved with size 
exclusion column, Superose 6 10x300 in 1ml fractions with gel filtration buffer 
(50mM Tris pH 7.4, 500mM NaCl).   
 
2.1.11 Calcium phosphate transfection in HEK293T cells 
 
HEK293T cells were transfected via calcium phosphate method with 25μg of C1q A, 
B and C plasmids cloned onto pCDNA 3.1 in 1:1:1 ratio adapted from (Sambrook and 
Russell 2006). Briefly HEK293T cells were cultured in 10% (v/v) BCS, 100 units/ml 




day prior to transfection in T-75 flask. The cells are allowed to divide for 21-24hrs. 
The supernatant was aspirated and replaced with fresh culture media for allow to 
incubate for 1hr at 37
o
C in the presence of 5% CO2.  A total of 25μg of plasmid is 
added to 100μl of 2.5 M CaCl2 and top up with 0.1 TE buffer (1mM Tris-HCL, 
0.1mM EDTA, pH 7.6) to 1ml.  1 ml of 2x HEPES buffer (140mM NaCl, 1.5mM 
Na2HPO4, 50mM HEPES, pH 7.05) was added rapidly to mixture and allowed to 
stand at room temperature for exactly 1 min and immediately added to HEK293T 
cells.  The T-75 flask of cells is incubated for 4hrs at 37
o
C, washed twice with warm 
PBS and replaced with 20ml of serum free media designed for 293T cells, 
SFMHEK293 and incubated for 48 hrs. The supernatant is aspirated, spun down at 
350g for 5 mins and filtered through 0.22μm to remove cell debris.  
 
2.1.12 Electroporation of Raw 264.7 
 
Raw 264.7 is cultured as per normal, and passage 1:3 ratio into new T-75 flask and 
incubated for 21-24 hours prior to electroporation. The confluency prior to 
electroporation should be 70-80%. The cells are washed with PBS, and harvested 
through gentle scrapping in DMEM supplemented with 10% (v/v) FCS, 100 units/ml 
penicillin, 100μg/ml streptomycin and 2mM L-glutamine. The cells are spun down 
and washed twice in PBS, and resuspended in 3.75 x 10
7
 cells/ml. A master mix of 
plasmid mixture is created with a total of 25-50μg of plasmid (1:1:1 ratio of C1q A,B 
and C), and top up to 50μl with nuclease free water. 200 μl of cells (2.5x107 cells/ml) 
is mixed with the 50μl of plasmid mix and added to each cuvette. The Biorad Gene 
Pulser Xcel electroporator machine is calibrated to the following settings : (a) Select 




4mm cuvette.  The cuvette is gently tapped at the side to agitate cells, and 
electroporated. The cuvette is allowed to stand for 10mins at room temperature. The 
cells are then aspirated and spun down at 450g for 5mins at 4
o
C. The cells are 
resuspended into the various expression media and stimulations for the next 48 hours 
in a humified incubator at 37
o
C in the presence of 5% CO2.  
 
2.2 Molecular Biology Techniques 
 
2.2.1 Polymerase Chain Reaction  
 
Polymerase chain reaction (PCR) reaction tube is typically prepared in the following 
order as such; (a) 5μl of Pfu (Pyrococcus furiosus) DNA polymerase 10x buffer 
containing MgS04, (b) 1μl of dNTPs, (c) 5μl each of 10μM of forward and reverse 
primers respectively, (d) 1μl of DNA sample, (e) 32.5μl of nuclease free water (or top 
up to final volume of 50μl), (f) 0.5μl of Pfu DNA polymerase. The DNA thermal 
cycler (MJ Research, Waltham, MA) is setup with the following protocol typically as 
such; (a) Initial denaturation of 95
o
C for 5mins, (b) 95
o
C for 1min, (c) Annealing 
temperature specific for primers (~52-60
o
c) for 1min, (d) extension temperature 72
o
C 
for 2mins, (e) repeat for 35 cycles for b to d, (f) final extension for 10 mins, (g) 
maintain at 4 degrees for indefinite period. The PCR primer annealing temperature 
used is 2
o
C below the lower Tm (melting temperature) of the pair of primers. The 
extension time for a particular PCR reaction depends on the length of the amplified 
target sequence. For Pfu polymerase, extension was carried out at 2 min/kb of 




    
2.2.2 Resolving PCR products with agarose gel 
 
The DNA/PCR product are resolved typically with 1% agarose gel containing gel red 
stain (1:25000) in Tris-Acetate-EDTA buffer (TAE) using a Hoefer HE 33 mini 
horizontal submarine unit (GE-Healthcare) at 100V. Briefly 0.5g of agarose is added 
to 50ml of TAE buffer and heated 100
o
C with microwave. Mixture is allowed to cool 
to approximately 60
o
C (by touch) and 2μl of GelRed stain is added with swirling. The 
agarose mixture is poured onto a cassette with the appropriate plastic well mount. 
Upon solidifying, the agarose gel is placed into the electrophoresis unit with TAE 
buffer. The PCR product (9 parts) is added to 10X DNA Loading dye (1 part), and 
loaded into wells. The PCR products are typically run at 100v, and resolution is aided 
with DNA standards of required size. The gels are visualized with a UV illuminator 
and captured with a digital camera unit.  
 
 2.2.3 Preparation of DNA sample for sequencing  
 
The DNA sequencing reaction was carried out with BigDye Terminator v3.1 Cycle 
Sequencing kit in accordance with manufacturer’s recommendations with a few 
adaptations. Briefly the 20μl reaction was setup in the following order: (a) 5pmol of 
Sequencing primer (for one direction), (b) 3μl of  Sequencing buffer from kit, (c) 300 
ng of DNA sample, (d) top up to 18μl with nuclease free water, (e) lastly add the 2μl 
of  BigDye ready reaction premix. Run the reaction in the thermal cycler with the 
following setup: (a) denaturation at 96
o
C for 30s, (b) primer annealing at 50
o
C for 
15s, (c) extension at 60
o






C for indefinite period. The DNA product is precipitated in a 1.5ml eppendorf tube 
with, (a) 3μl sodium acetate pH 4.6, (b) 7μl nuclease free water, (c) 20μl of DNA 
products, (d) 70μl of 100% ethanol in -20oC for 30mins, and subsequently spun down 
at top speed  with Eppendorf microcentrifuge 5424 (Eppendorf, Hamburg, Germany) 
for 30 mins. The supernatant is aspirated and the DNA pellet washed with 70μl of 
70% ethanol and spun down at top speed for 10mins. The supernatant is aspirated and 
the pellet is stored at -20
o
C till sent to sequencing lab.       
 
2.2.4 Purification of DNA from agarose gel/solution 
 
The DNA band or product from solution is purified utilising the Illustra GFX PCR 
DNA and Gel band Purification kit as per manufacturer’s recommendations. The 
agarose gels are viewed under UV illumination and excised, into an eppendorf tube 
previously weighed. The weight of the excised gel is obtained by subtracting its 
current weight from the weight of the eppendorf tube. 100μl of capture buffer 
(minimum 300μl) is added for every 0.1g of excised gel and heated to 60oC.  Sample 
mixture is transferred to GFX column and incubated for 1min, and spun down at 
16000g for 30s. The column is washed with 500μl wash buffer and spun down at 
16000g for 30s, the waste is discarded, and the column is incubated with 40μl of 
nuclease free water for 5-10mins. The purified DNA is eluted by 16000g for 1min.  
 
For purification of DNA product from solution, 100μl of the solution is added to 
500μl of capture buffer, mixed and loaded onto the GFX column, and proceed as 






2.2.5 Restriction Endonuclease Digestion  
 
The restriction digestion was performed for DNA products at 37
o
C for 2-4 hours in 
the water bath with a reaction volume of 50μl, as setup: (a) 40μl of DNA sample 
(typically 2-5μg of DNA), (b) 5μl of 10x restriction buffer (or as specified), (c) 0.5μl 
of BSA (10μg/ml), (d) 1.25μl restriction enzyme (10-25 units), (e) top up to 50μl with 
nuclease free water.  
 
2.2.6 Ligation of DNA insert into Vector 
 
DNA ligation of restricted DNA inserts and vector is carried out in 10 l ligation 
reaction volume with T4 DNA ligase and T4 DNA ligase buffer overnight at room 
temperature. Briefly the amount of DNA insert to vector insert is calculated base on 
the following equation for a molar vector to insert ratio of 1:3:  
 
Amount of insert (ng) 
= 3x ((ng of vector) x size of DNA insert (Kb)) / (Vector size (Kb)) 
 
Thus the 10ul reaction is setup as follows: (a) X μl of vector as calculated, (b) Y μl of 
vector as calculated, (c) 0.1μl of T4 DNA ligase enzyme, (d) 1μl of T4 DNA ligase 





2.2.7 Bacterial transformation with plasmid DNA  
 
The Escherichia coli (E. coli) strain DH5 (Invitrogen, Carlsbad, CA) was used for 
plasmid propagation (Hanahan 1983). For long term storage, the bacteria were 
cryopreserved in LB (Luria-Bertani) medium containing 20% glycerol at -80
o
C. The 
plasmid and the vial of DH5 is thawed on ice. Approximately 1μg of DNA plasmid 
is added to the vial of DH5 , and incubated on ice for 30mins. Next the mixture is 
heat shock at 42
o
C for 90s, and immediately incubated on ice for 5mins. At this step, 
for plasmid just ligated with DNA inserts, 200μl of SOC (Super Optimal Broth with 
Catabolite repression) media is added to the mixture, and incubated for 1 hour at 37
o
C 
on a shaking platform at 200 RPM, after which 50μl of the sample is squirted on a LA 
plate (LB plate with 100μg/ml ampicillin). For intact plasmids, after the incubation on 
ice for 5mins, 2μl of the transformed bacteria is added to 50μl of SOC, and plated on 
a LA plate. For both forms of plasmid transformed bacteria, the LA plates are cultured 
overnight at 37
o
C.        
 
2.2.8 Cloning of gene of interest into target vector 
 
Firstly cloning primer pairs specific to the gene of interest are synthesized. For the 5
1
 
forward primer, the design is as follow: (3 random nucleotides to allow restriction 




interest)(Kozak sequence: GCCACC)( 5
1
 end of gene of interest starting with ATG 
start codon, extending to a suitable length into gene). For the 3
1
 reverse primer, the 
design is as follow: (3 random nucleotides to allow restriction enzyme to sit 
on)(reverse complement of another restriction enzyme cutting site not appearing in 
gene of interest)(reverse complement of 3
1
 end of gene of interest of suitable length). 
The primers are checked for specificity, primer pair interactions, primer secondary 
structures and suitable Tm. Next the gene of interest is cloned from DNA product with 
the cloning primers in a PCR reaction (section 2.2.1) and resolved in a agarose gel 
(section 2.2.2). The specific PCR band is excised under UV illumination and purified 
(section 2.2.4). Restriction digestion is performed for the purified DNA insert and 
separately for the vector of interest (section 2.2.5). Next the restricted products are run 
on a agarose gel and the desired restricted products are excised and purified. The 
restricted products are ligated as stated (section 2.2.6) and the newly ligated plasmid 
with the DNA insert is transformed into competent bacteria (section 2.2.7). The 
amplified plasmids are purified (section 2.2.9).  
 
2.2.9 Purification of Plasmids from transformed bacteria 
 
QIAGEN plasmid Maxi kit was used for the purification of plasmids from 
transformed bacteria. Briefly, a single transformed bacteria colony (section 2.2.7) was 
picked from a LA (100μg/ml ampicillin) plate and inoculated into a starter culture of 
2 ml of LA broth. The culture was grown for 8 hr at 37
o
C with shaking at 200 rpm. 
400μl of this starter culture was added into 200 ml of LA broth and cultured for 12-16 
hr at 37
o




centrifugation at 3,000x g for 15 min at 4
o
C and re-suspended in 10 ml of 
resuspension buffer P1 containing 100 μg/ml RNase A. 10 ml of lysis buffer P2 was 
then added, mixed thoroughly and incubated for 5 min at room temperature. 10 ml of 
ice-chilled neutralization buffer P3 then added immediately mixed and incubated on 
ice for 20 min. The cell lysate was centrifuged at  20,000x g for 30 min at 4oC. The 
supernatant was collected into a fresh centrifuge tube and loaded onto a QIAGEN-tip 
500 column which was pre-equilibrated with 10 ml of equilibration buffer QB. The 
sample was allowed to drip through the column via gravity flow. The column was 
then washed twice with 30ml wash buffer QC before the resin-bound DNA was eluted 
with 15 ml of elution buffer QF. To precipitate the eluted DNA, 10.5 ml isopropanol 
was added and centrifuged at  20,000x g for 30 min at 4oC. The DNA pellet was 
dissolved with 5 ml of 70% (v/v) ethanol at room temperature and centrifuged at  
15,000x g for 10 min. The DNA pellet was air-dried, dissolved in 400μl of nuclease 




2.3 Protein Chemistry Techniques 
 
2.3.1 Protein Quantification 
 
Protein concentration was determined via the Braford assay using the Bio-Rad protein 
assay kit. Briefly, seven serial dilutions of a standard BSA solution were prepared, 
starting with concentration of 400μg/ml to 6.25μg/ml and a final blank. 10μl of each 




well microtiter plate. The dye reagent was diluted (1 part Dye Reagent Concentrate 
with 4 parts distilled water) and filtered through 0.45μm filter unit. 200μl of the dye 
was then added to each well and incubated at room temperature for 5 min. 
Absorbance was measured at 595 nm with the aid of Model 680 Microplate reader 
(Bio-Rad). The standard curve was constructed by plotting the known BSA 
concentrations versus absorbance at 595 nm and sample concentrations determined 
from the curve. 
 
2.3.2 SDS-PAGE separation of Proteins 
 
For the loading of samples derived from supernatant or Fast Performance Liquid 
Chromatography (FPLC) fractions, equal volumes of samples are utilised. For the 
loading of cell lysate samples, protein quantification is first performed (section 2.3.1), 
and typically 25-50μg of total cell lysate is loaded per sample condition. The 5X 
Laemmli buffer is prepared with fresh dithioreitol (DTT) if reduction of disulphide 
bonds is required, and added to the individual samples (4 parts sample to 1 part 5X 
Laemmli buffer). The samples are spun down and heated at 100
o
C for 5-10mins, and 
spun down before loading into the wells of the SDS-PAGE (SDS-Polyacrylamide Gel 
Electrophoresis) gel with the protein standards. The samples are run at 100V till 
required resolution is achieved as visualized by the migration of the protein standards.    
 




The Blue silver stain is a colloidal coomassie stain and was prepared as previously 
described (Candiano, Bruschi et al. 2004). After the proteins are resolved via SDS-
PAGE, the gel is soaked in distilled water for 10mins x 3 with shaking to remove the 
SDS complex from the proteins. The gel is then soaked in the Blue silver stain for no 
less than 12 hours, and subsequently destained with sufficient volume of distilled 
water. The gels are then scanned or dried for safekeeping. The detection limit of the 
Blue silver stain is approximately 1ng of protein, its sensitivity is in-between that of 
the conventional silver staining and coomassie stain (Candiano, Bruschi et al. 2004).      
 
2.3.4 Silver Staining 
 
The silver staining technique adopted was described as previously (Chevallet, Luche 
et al. 2006). As the sensitivity of silver staining is high, all reagents utilized are ultra-
pure, with distilled water filtered with 0.22μm and all gels manipulations handled 
with non-powdered latex gloves or nitrile gloves.  All buffers utilized in running the 
SDS-PAGE are freshly made and containers thoroughly bleached and rinsed with 
distilled water. The proteins are resolved via SDS-PAGE, and the gels are soaked in 
fixation solution containing 30% (v/v) ethanol, 10% (v/v) acetic acid for 30mins x 3, 
or alternatively fixated overnight. The fixated gels are washed twice with 20% ethanol 
for 10mins x 2, and subsequently in distilled water for 10mins x 2. The gels are then 
immersed in the sensitizer solution containing 0.02% (w/v) sodium thiosulfate 
(pentahydrate salt) for 1min. The gels are then washed twice in distilled water for 
1min each. Next the gels are soaked in 12mM silver nitrate for 2 hours and 




freshly prepared developer solution containing 3% (w/v) potassium carbonate, 
0.00025 % (v/v) formalin (or 250μl formalin per litre),  0.0000125 % (w/v) sodium 
thiosulfate (or 125μl of a 10%(w/v) sodium thiosulfate per litre) with gentle swirling 
till the required intensity is obtained. The gels are then drained and placed into the 
stop solution containing 4% (w/v) Tris and 2% (v/v) acetic acid for 30 mins and 
washed twice with distilled water for 30mins each. The gels are then scanned or dried 
for safekeeping.  
 
2.3.5 Western blotting  
 
The proteins are firstly resolved in SDS-PAGE and electroblotted onto a 
polyvinylidene difluoride (PVDF) membrane with the Bio-Rad TransBlot Transfer 
Cell set in chilled transfer buffer and ice packs on a magnetic stirrer platform. The 
transfer is typically run at constant voltage of 100V for 1-1.5hours. The PVDF 
membrane is then blocked with 5% (w/v) non-fat milk in 0.1% (v/v) TBST for 1 hour 
with shaking. The blocked membrane is washed once with 0.1% (v/v) TBST and 
incubated with the primary antibody in 5% (w/v) BSA, 0.1% (w/v) NaN3 in 0.1% 
(v/v) TBST overnight in the cold. The primary antibody is aspirated and kept at 4
o
C. 
The membrane is washed 3 x 10 mins with 0.1% TBST and incubated with secondary 
antibody conjugated with alkaline phosphatise enzyme (1:2500) in 5% (w/v) non-fat 
milk in 0.1% (v/v) TBST for 1 hour at room temperature with shaking. The membrane 
is then washed 3 x 5 mins with 0.1% (v/v) TBST and probed with 600μl (per 





For reprobing of membrane after chemiluminescent detection, the membrane is first 
washed 3 x 5mins with 0.1% (v/v) TBST and incubated with 10ml of western blot 
stripping buffer in sealed ziplock bags at 50
o
C for 20mins in a water bath with 
occasional agitation. The membrane is then retrieved and washed 3 x 5 mins with 
0.1% (v/v) TBST and blocked in 5% (w/v) non-fat milk in 0.1% (v/v) TBST for 
30mins. The stripping efficacy could be tested with the addition of chemiluminescent 
substrate in the absence of antibodies. After the stripping, the membrane is ready for 
reprobing with primary and secondary antibodies.  
 
2.3.6 FPLC separation of proteins via gel filtration  
 
The separation of proteins via size is performed with FPLC (AKATA, GE-
Healthcare) and resolved with size exclusion column, Superose 6 10x300 in 1ml 
fractions with gel filtration buffer (50mM Tris pH 7.4, 500mM NaCl). Briefly the 
pumps are washed and the column is equilibrated with the gel filtration buffer for 1.5 
column volume (approximately 35ml) at a flow rate of 0.5ml/min. The samples are 
loaded at a fix volume of 250μl with the aid of a syringe and the sample is injected 
into the 500μl loop and a volume of 500μl gel filtration buffer injects the sample from 
the loop into the column. The sample is resolved in the column with the same gel 
filtration buffer at 0.5ml/min into 1ml fractions. The resolved fractions are 
immediately collected and kept at 4
o
C till further examination. A similar procedure 







2.3.7 Enzyme Linked Immunoabsorbent Assay  
 
For the detection of human cytokines secreted from DCs, the experimental setup is 
typically designed in a 96 well format with minimum of 5x10
4
 cells per well, and 
stimulated either with 500ng/ml LPS, 100ng/ml IFN-γ, and varying ratios of T cells or 
apoptotic cells in 100-200μl total volume. The supernatant is typically spun down to 
reduce cell debris and transferred to a new plate and stored in -20
o
C until further 
examination. The secreted cytokines are detected with the aid of commercially 
available enzyme linked immunoabsorbent assay (ELISA) kits, BD OptEIA ELISA 
set for IL-6, IL-8, IL-10, IL-12p70, and IFN-γ. The ELISAs are executed as in 
accordance with manufacturer’s instructions. Briefly, the respective capture 
antibodies diluted (1:250) into coating buffer (0.1M sodium carbonate, pH 9.5) and 
are coated onto 96 well Maxisorp Nunc plates 100μl per well overnight at 4oC. The 
plates are washed 3x with 200μl of 0.05% (v/v) PBST per well and blocked with 
200μl of Assay diluents (10% (v/v) heat inactivated FCS in PBS) per well for 1 hour 
at room temperature. After blocking, the wells are wash 3x with 0.05% PBST and the 
respective cytokine standards and samples are added in the proper dilutions in the 
same assay diluents to a total volume of 100μl per well. The plate is incubated 
overnight at 4
o
C and subsequently washed 5x with 0.05% (v/v) PBST. The 




diluents (1:250) and added into each well in a total of 100μl per well, and incubated at 
room temperature for 1 hour. The wells are washed 7x with 0.05% (v/v) PBST and 
100μl of TMB substrate is added into each well and allowed to develop in the dark for 
15-30mins. The ELISA is stop with 50μl of stop solution (1M Sulphuric acid) per 
well, and the absorbance at 450nm is read immediately with the Model 680 
Microplate reader (Bio-Rad). The linearized standard curve was constructed by 
plotting the known cytokine concentrations versus that of the absorbance reading (Log 
scale). The absolute concentration of each sample was derived by comparing against 
the standard curve and back-multiplying with the dilution factors used for each 
sample. The experimental setup is typically designed in triplicates.     
 
2.3.8 Flow Cytometry  
 
For Surface staining:  
After experimental manipulations, the cells are spun down and transferred into 1.5ml 
eppendorf tubes and stained with the respective antibodies conjugated with 
fluorochromes diluted in FACS buffer (1:100) for 30 mins on ice, with occasional 
agitation.  The cells are then spun down at 600g for 5mins at 4
o
C and wash twice with 
1ml of FACS buffer.  The cells are fixed with 600μl of 1% (w/v) paraformaldehyde 
and kept at 4
o
C in the dark till further examination. The cells are then run through the 
Dako Cyan flow cytometer using the required lasers, and data acquisition and analysis 





For Intracellular staining: 
The cells were harvested and spun down at 600g for 5mins, and fixation and 
permeabilization is performed simultaneously with BD Cytofix/Cytoperm Kit. 
Briefly, the cells are fixed with 100μl of Fixation/Permeabilization solution for 
20mins on ice (alternatively overnight at 4
o
C). The cells are washed twice with 200μl 
of the Perm/Wash solution and incubated with fluorochrome conjugated antibodies 
diluted in the same Perm/Wash solution in a volume of 50μl for 30mins on ice. Next 
the cells are washed twice with 200μl of the Perm/Wash solution and resuspended 
finally into 600μl of PBS awaiting analysis. The cells are then run through the Dako 
Cyan flow cytometer using the required lasers, and data acquisition and analysis is 
performed using the Summit 4.3 software (Dako-Cytomation).   
 
2.3.9 Confocal Microscopy  
 
Glass cover slips were autoclaved and lay onto 24 well plates, and DCs after 6 days of 
differentiation were harvested, and seeded at 1.5x10
5
 cells per glass cover slip, in 
500μl of RPMI media containing 10% (v/v) heat inactivated BCS, 100units/ml of 
penicillin and 100μg/ml of streptomycin for 24 hours at 37oC in the presence of 5% 
CO2. Non-adherent DCs were aspirated and equal volume of apoptotic cells stained 
with CFSE were added to the DCs in the presence of 10% (v/v) human serum in 
RPMI in a volume of 200μl for each well. The DCs are allowed to phagocytose for 1 
hour, and subsequently wash twice with 1ml of warm PBS. The cells are fixed with 




1ml of warm PBS. The cells are then incubated with 0.1% saponin in PBS for 20mins 
and washed twice with 1ml warm PBS. The cells are then incubated with rhodamine-
phallodin (1:100) in 0.1% saponin PBS for 30 mins at room temperature, and washed 
twice with 1ml PBS. The coverslips were then mounted onto glass slides with 
Fluorosave and allowed to solidify for 1 hour in the dark before storing at 4
o
C. The 
confocal images are taken using Leica TCS SP5 Confocal Microscope System and 
images utilising oil immersion at various objectives. The images are then analyzed 
with Leica Application Suite software.  
 
 2.3.10 Conjugating Antibodies to CNBr beads  
 
The rabbit anti-C1q antibodies (gift from Prof Bob Sim) are dialyzed with coupling 
buffer 0.1 M Na3PO4, 0.5M NaCl pH 7.5). The CNBr beads are activated as per 
manufacturer’s instructions, in a setup containing vacuum pump. Briefly, 1g of the 
beads is placed into a 15ml fulcrum tube and top to 15ml with 1mM HCl. The 
fulcrum tube is rotated at 4
o
C for 10mins.The beads are drained of the HCl, and are 
passed through another 200ml of 1mM HCl, and passed through another 200ml of 
chilled distilled water to remove the HCl. The activated beads are added to the 
dialyzed antibodies and rotated overnight at 4
o
C.  The beads are then drained off, and 
passed through with 30ml of coupling buffer. The beads are then block with 200ml of 
1M ethanolamine and subsequently washed with 3 alternative cycles of 30ml of acidic 
(0.1M sodium acetate, 0.5M NaCl, pH 3.5) and 30ml of basic (0.1M Tris-HCl, 0.5M 
NaCl, pH8.0) washes. The beads are then washed with 30ml of buffer containing 




Approximately the beads are coupled with 20mg per 1g of original beads, which 
inflates to 3-3.5ml volume after the entire process.     
 
 
2.3.11 Purification of LMW C1q 
 
The sample (either directly from human serum or transfected from HEK293T) is 
passed through an affinity column packed with CNBr beads coupled to rabbit anti-
human C1q (gift from Bob Sim). Briefly the affinity column is equilibrated with 5 
column volumes of 150mM NaCl, 1mm EDTA, 50mM Tris pH 7.4 buffer, and the 
sample is passed through column via gravity flow. The column is then washed 5 
column volume of 1M NaCl, 1mM EDTA, 50mM Tris pH 7.4 buffer and eluted with 
150mM NaCl, 0.05 M Na2HPO4, pH 11.5 buffer and neutralized to pH 7.4. Sample is 
concentrated and dialyzed with sterile PBS in ultracentrifuge tube (Amicon ultra 4 
Millipore) and filtered sterile with 0.22μm and quantified with Braford Assay. 
 
2.3.12 C1q – IgG/IgM binding Assay 
 
The binding assay is designed in a Maxisorp Nunc 96 well format. The wells are 
coated with either 100μl of 1μg/ml of human IgM or 300ng/ml of human IgG in 
coating buffer (0.1M sodium carbonate, pH 9.5) and incubated overnight at 4oC. The 




in TBS for 1 hour at room temperature. The wells are washed 3x with 0.05% (v/v) 
TBST and the C1q standards and samples (dialyzed in TBS) are added into the well, 
diluted in TBS in a total volume of 100μl. The plate is incubated overnight at 4oC. 
The wells are washed 3x with 0.05% (v/v) TBST and 100μl of goat anti-human C1q 
(1:50 000) diluted in 1% (w/v) BSA in 0.05% (v/v) TBST is added to each well and 
incubated at room temperature for one hour. The wells are washed 4 x with 0.05% 
(v/v) TBST and 100μl of rabbit anti-goat HRP conjugated antibody (1:2500) diluted 
in 1% (w/v) BSA in 0.05% (v/v) TBST is added to each well for 1 hour at room 
temperature. The wells are washed 4 x with 0.05% (v/v) TBST and 100μl of TMB 
substrate is added into each well and allowed to develop in the dark for 15-30mins. 
The development is stopped with 50μl of stop solution (1M Sulphuric acid) per well, 
and the absorbance at 450nm is read immediately with the Model 680 Microplate 
reader (Bio-Rad). The linearized standard curve was constructed by plotting the 
known C1q concentrations versus that of the absorbance reading (Log scale). The 
binding affinity of each sample was derived by comparing against the standard curve 
and back-multiplying with the dilution factors used for each sample. The experimental 
setup is typically designed in triplicates.  
 
2.3.13 Complement Activation Assay 
 
The complement activation via the classical pathway was detected using the Wieslab 
TM Complement system screen, COMPL 300 kit with some modifications. The 




serum. The various controls (positive, negative, blank) were also added. The plate was 
allowed to incubate for 1 hour at 37
o
C and washed 3x 300μl of wash buffer. 100μl of 
conjugate is added to each well and incubated at room temperature for 1 hour and 
washed 3x with 300μl of wash buffer. 100μl of substrate solution is added and 
allowed to develop for 30mins and stop with 100μl of the stop solution. The 
absorbance is read off at 405nm with the Model 680 Microplate reader (Bio-Rad).    




Table6 : List of Reagents 
Category Item Name/Description Company of 
purchase 
Antibodies Anti-CD1a PE, Anti-CD80 PE, Anti-CD83 PE, 
Anti-86 PE, Anti-CCR7 PE  
Ancell 
Anti-CD-4 Pacific Blue BD (Becton Dickson and 
company) Biosciences 
Anti-CD11c PE  BD (Becton Dickson and 
company) Biosciences 
Anti-CD14 FITC , Anti-MHC I Ancell 
Anti-Human C1q (polyclonal) Goat  Quidel  
Anti-IFN-γ PE eBioscience 
Human IgG or IgM (non-conjugated) Sigma-Aldrich 
Secondary antibodies for western blot 
Anti-rabbit/goat/mouse antibody alkaline phosphate 
conjugate. 
Bio-Rad, Hercules, CA. 
Antibiotics Ampicilin  Merck 
Penicillin/ Streptomycin PAN Biotech GmbH 
Chemicals Agarose (Seakem LE) Cambrex 





BigDye Terminator v3.1 Cycle Sequencing kit Applied Biosystems, Life 
Technologies.  
Bio-Rad Protein Assay kit Bio-Rad, Hercules, CA.  
B-mercaptoethanol GIBCO, Invitrogen, Life 
Technologies 
Brefeldin-A Gift 
BSA (common protein usage) Sigma-Aldrich 
BSA (restriction digestion) Promega 
CFSE (Carboxyfluorescein succinimidyl ester) Molecular Probe, 
Invitrogen 
CNBr beads Sigma-Aldrich 
Cytofix/Cytoperm Cell Fixation and 
Permeabilization reagent  
BD (Becton Dickson and 
company) Biosciences  
CytoTox 96 Non-Radioactive Cytotoxicity Assay Promega 
Ficoll-Paque Plus  GE-Healthcare 
FluoroSave Calbiochem  
Gel Filtration Calibration kit GE-Healthcare 
GelRed Stain Biotium 
Illustra GFX PCR DNA and Gel band Purification 
kit 
GE-Healthcare 
Immun-Star AP Chemiluminescent substrate Bio-Rad, Hercules, CA. 
Ionomycin  Gift 
PMA (Phorbol 12-Myristate 13-Acetate) Gift 
QIAGEN plasmid Maxi kit QIAGEN GmbH, Hilden, 
Germany 




Wieslab Complement system screen, COMPL 300 
kit 
Wieslab 
Cytokines Recombinant IL-4 R&D Systems, Inc. 
Recombinant GM-CSF R&D Systems, Inc. 
Recombinant IFN-γ R&D Systems, Inc. 
Recombinant M-CSF R&D Systems, Inc. 
ELISA BD OptEIA ELISA Set for IL-6, IL-8, IL-10, IL-
12p70 and IFN-γ. 
BD (Becton Dickson and 
company) Biosciences 
Enzyme Pfu (Pyrococcus furiosus) DNA polymerase and its 
10X buffer.  
Promega 





Flasks T-75 filtered cap Nunc 
Magnetic 
Sorting beads 
Naïve CD4+T cell 
 isolation kit II  
Militenyi Biotec 
Media SFMHEK293  Hyclone, ThermoScientific 
CD-hybridoma  GIBCO, Invitrogen, Life 
Technologies 




Macrophage SFM GIBCO, Invitrogen, Life 
Technologies.  




 X Vivo15 Lonza 
Media 
Supplements 
Bovine Calf Serum (BCS) Hyclone Thermo Scientific 
Fetal Calf Serum (FCS)  
L-glutamine Caisson Laboratories Inc 
Sodium pyruvate GIBCO, Invitrogen, Life 
Technologies 
PAMPs LPS (Escherichia coli: 05:55) Sigma-Aldrich 
Plates All wells: 6,12,24,48 and 96 wells.  Nunc 
Plasmids pCDNA 3.1 A  
A 5.5 kb cloning vector for CMV promoter-driven 
constitutive protein expression. Expressed protein 
can be incorporated site directed mutagenesis with 
C-terminal myc/His-tags.  
Invitrogen, Life 
Technologies 












Underline Sequence refers to restriction site for 
Kpn1 (5
1
) and Ecor1 (3
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). The blue highlighted 
sequence refers to the Kozah sequence and the red 
highlighted sequence is start/stop codon. 
AITbiotech, Singapore 
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) SP6:  
ATTTAGGTGACACTATAG 
AITbiotech, Singapore 
Protein Human C1q  Sigma-Aldrich  
Western blot 
membrane 
Polyvinylidene difluoride (PVDF) membrane 
(Immuno-Blot PVDF) 









Table 7:List of Buffers  
Buffer Constituents/Preparation 
Blue Silver Stain 0.12% (w/v) G-250 Coomassie Dye, 10% (w/v) ammonium sulfate, 
10%(v/v) phosphoric acid, 20% (v/v) methanol.   
Coupling buffer  0.1 M Na3PO4, 0.5M NaCl pH 7.5 in distilled water.  
FACS wash buffer 2.5% (v/v) heat in activated FBS, 0.05% NaN3 in PBS.  
Gel Filtration Buffer 
(used in FPLC) 
Prepared as following: 50mM Tris pH 7.4, 500mM NaCl, 0.1% NaN3 in 





Prepared with the following constituents: 250mM Tris-HCL pH 6.8, 50% 
(v/v), 10% (w/v) SDS, 0.05% (w/v) Bromophenol Blue. If reducing buffer is 
required, 0.5M DTT (Dithiothreitol) is added fresh prior to use.   
LB (Luria Bertani) 
Broth / LA Broth 
25g of LB powder is added to 1 litre of distilled water and autoclaved.  
Final concentration of constituents: 1% (w/v) Bacto-tryptone, 0.5% (w/v) 
Yeast extract, 0.5% (w/v) NaCl, pH 7.5.  
For antibiotic selection, 100μg/ml of ampicillin is used.  
LB Agar Plate / LA 
Agar Plate 
The preparation of LB agar is the same as LB broth (above) with the addition 
of 15g/L of Bacto Agar, and autoclaved.  
For antibiotic selection, 100μg/ml of ampicillin is used. 
MACS buffer 0.5% (w/v) BSA (Bovine Serum Albumin), 2mM EDTA in PBS.  
PBS / PBS-T Diluted from 10x PBS (1st Base company) with 0.22μm filter sterile purified 
water, adjust to pH 7.4with HCL, and filtered sterile in biohazard hood with 
0.22μm 1litre filter unit using a vacuum pump. The 1x PBS is then 
autoclaved.  
Final constituents of 1x PBS are : 1.76 mM KH2PO4, 10.4 mM Na2HPO4 , 
137 mM NaCl, 2.7mM KCL. 




Prepared as 10X stock consisting of: 250mM Tris-base, 2.5M Glycine, 1% 
(w/v) SDS. Diluted to 1x with distilled water.  
SDS-PAGE Gel The stacking gel is prepared with the following constituents:  
For 1 mini-SDS-PAGE gel; 3.05ml of distilled water, 1.25ml of 0.5M Tris-
HCL pH 6.8, 50μl of 10% (w/v) SDS, 650μl of 30% 
Acrylamide/Bisacrylamide 29:1 (3.3% C), 25μl of 10% (w/v) Ammonium 





The 12.5% resolving gel is prepared with the following constituents:  
For 1 mini-SDS-PAGE gel; 3.17ml of distilled water, 2.5ml of 1.5M Tris-
HCL pH 8.8, 100μl of 10% (w/v) SDS, 4.16ml of 30% 
Acrylamide/Bisacrylamide 29:1 (3.3% C), 50μl of 10% (w/v) Ammonium 
Persulfate,  and 5μl of Tetramethylethylenediamine (TEMED).  
Stripping buffer (for 
western blot) 
Prepared with the following constituents: 62.5 mM Tris-HCL pH 6.8, 2% 
(w/v) SDS, 0.1M 2-mercaptoethanol in distilled water.  
TAE  Prepared as 50X TAE stock: 2M Tris, 1M Acetic acid, 0.1M EDTA at pH 
7.8 in distilled water.  
TBS/ TBS-T TBS is prepared with the following constituents: 50mM Tris-HCl, 150mM 
NaCl at pH 7.4 unless otherwise stated.   
TBS-T : 0.1% (v/v) Tween 20 TBS.  
For blocking buffer in western blot, additional 5% (w/v) non-fat milk powder 
is added to TBST.  
Transfer Buffer 
(western blot) 
Prepared as a 10X stock with the following: 250mM Tris-base, 1.92 M 
glycine. For 1 litre of 1x transfer buffer, add 100ml of 10x transfer buffer to 
700ml of distilled water, and 200ml of methanol. The 1x transfer buffer is 
chilled at 4 degrees prior to use.   
 
 
2.5 Statistical Analysis 
 
Figures presented are representative of at least 3 independent experiments unless 
otherwise noted. Data were expressed as mean values of experimental triplicates with 
standard error. Test for statistical significance were performed with the Student’s two 









Chapter 3: LMW C1q from Macrophages and Dendritic Cells 
Chapter 3.1 In-vitro culture of monocytes to macrophages or dendritic cells 
 
The main cell models utilised in this study are human monocyte derived macrophages 
and dendritic cells. As previously stated (section 1.3.5), these macrophages and 
dendritic cells typically represent inflammatory cells rather than steady state cells as 
shown by (Cheong, Matos et al. 2010), as injection of LPS into mice resulted in 
differentiation of monocytes into dendritic cells that infiltrated the lymph nodes. The 
study of human macrophages and dendritic cells is constrained by the availability and 
yield of human samples, thus we obtained our ready supply from healthy donor’s 
blood donation via the hospital blood bank in the form of buffy coat. These buffy 
coats are then processed via Ficol-paque density centrifugation and monocytes are 
separated via adherence to plastic flasks. The purify of monocytes is typically > 90% , 
as depicted by the CD14 stain (Fig 5a).  
 
The differentiation of monocytes to macrophages in the presence of M-CSF (20ng/ml) 





, and are termed as MMFs (Fig 5b). Dendritic cells are differentiated from 
monocytes in the presence of IL-4 (40ng/ml) and GM-CSF (20ng/ml) for 6 days, and 




, and are termed as 
GMDCs (Fig 5c). The surface expression of three typical donors is shown (Fig 5). 
The typical yield of monocytes that is obtained from donors after adherence and 
washing, ranges from 6 to 45 x 10
6
 cells per buffy coat donor (Fig 5c). Thus 
















5: Surface Phenotype of macrophages and dendritic cells, and the typical yield of monocytes. Fig 5a 
Purity of monocytes depicted by CD14 and CD1a stain. Fig 5(b-c): The typical phenotypic expression 
from 3 separate donors of CD1a, CD14 of MMF or GMDC after 6 days of culture from monocytes. Fig 
5 (d): The typical yield of monocytes per buffy coat donor after adherence and washing, as reflected by 
8 separate donors.  
 
Morphogically GMDCs progressively develop dendritic like processes (hence the 
name) as it differentiates from monocytes to DCs across 6 days (Figure 6). They tend 
to form large clusters when cultured in sufficiently high densities and are adherent to 
the typical plastic culture wells. The GMDCs were harvested on day 6 and stimulated 
with the microbial ligand LPS which activates TLR4, and causes cell maturation. 
Specifically, stimulation with LPS for 24 hours causes the increase of surface 
molecules (Fig 7) such as the co-stimulatory molecules CD80, CD86 and maturation 
markers CD83, and the upregulation of chemokines receptor CCR7 which facilitates 
the migration of DCs to the lymph nodes through its chemokines ligands such as 
CCL19. Antigen presentation molecules such as MHC-I is also up-regulated upon 





Figure 6: Morphology of monocytes during its differentiation to dendritic cells. The monocytes are 
viewed across several days, and pictures were taken for day 2, 4, and 6 from initiating its differentiation 
to GMDCs, under the IX81 inverted microscope equipped with the MicroPublisher 5.0 RTV imaging 
system (Olympus). Phase contrast images were captured using the Image-pro MC software. 10x and 
20x objectives were used. As the monocytes differentiate, they start to form characteristic dendritic like 








Figure 7: Cell surface markers of GMDCs upon maturation with LPS. The GMDCs were stimulated 
with LPS for 24 hours and examined via flow cytometry for the surface expression of 
CD80,CD83,CD86,MHC-I and CCR7. Upon stimulation the co-stimulatory molecules, chemokines 






3.2 Examining Secreted C1q from macrophages and dendritic cells  
 
The objective of the project was to ascertain the possibility that C1q was secreted in 
various complex forms. Since the dominant physiological synthetic origin of C1q is 
believed to arise from a hematopoietic source as shown by bone marrow transfer 
experiments (section 1.5.2) (Petry, Botto et al. 2001), and macrophages are also 
believed to be the dominant producers of C1q in vivo due to their prevalence, it was 
intuitive to first examine this source of secreted C1q.  
 
To examine the secreted form of C1q from macrophages, there is a need to either 
label endogenously produced C1q (e.g. through radioactive or isotopic labelling) or 
utilise a system which is devoid of bovine C1q contamination from media 
supplements such as BCS. Isotopic labelling followed by mass spectrometric analysis 
is costly and radioactive labelling still requires a method of purification to 
differentiate other forms of secreted endogenous protein from C1q. Simply put the 
chosen strategy was to culture MMF or GMDCs in serum free media, and perform 
size exclusion via fast performance liquid chromatography (FPLC) and perform 
western blot against C1q to determine if secreted C1q comes in different complex 
forms.  
 
Hence a panel of serum free media was tested, specifically; MMF was harvested after 
differentiation from monocytes and seeded equally into various media in the presence 
of M-CSF (20ng/ml). A cell viability assay was performed to determine if these serum 




(Fig 8). No significant difference in cell death is noted for the various serum free 
media as compared to normal culture media typically used for macrophages (10% 
(v/v) BCS, RPMI and other supplements). The residual 10-15% cell death in normal 
cell culture and the serum free media probably arise from the harvesting process, 
where MMFs are scrapped and seeded onto new wells with the media.  The RPMI 
only media, without BCS supplement was included as a positive control for cell death 
(Fig 8).  The serum free media CD-hybridoma was chosen as it is chemically defined 
and had no protein precipitation when concentrated for FPLC size exclusion.   
 
         
 
The MMFs were cultured from monocytes and seeded onto the serum free media, CD-
hybridoma at a density of approximately 1.5x10
6
 cells/ml with 20ng/ml M-CSF for 72 
hours. The supernatant was collected, spun down and filtered through 0.22μm to 
remove any cell debris, and subsequently processed via size exclusion using the 
AKATA FPLC platform.  
Figure 8: LDH release from 
macrophages cultured in various 
media. Briefly, macrophages are 
seeded into various media for 72hrs 
in the presence of M-CSF (20ng/ml), 
and tested for the release of LDH. ** 
p< 0.01, as tested with unpaired T 





Figure 9: Size exclusion of secreted C1q from macrophages and dendritic cells. The samples were 
passed through Superose 6 10x300 in 1ml fractions, and western blot was performed against human 
C1q for fractions A6 to B4 (6-19ml). A positive control human C1q (Sigma) obtained from human 
serum was processed similarly. The three chains of C1q ABC, runs in the same order with A (29 kDa) 
>B (26 kDa) >C (22 kDa) in each lane (Tohgi, Utsugisawa et al. 2000), the differential intensity of 
each chain could arise from the affinity of the antibody to each chain.  
 
The samples were passed through a Superose 6 10x300 size exclusion column and 
resolved in 1ml fractions. Western blot against the fractions were performed against 
human C1q (Fig 9). For the positive control, human C1q (Sigma) obtained from 
human serum, the peak occurred within the fractions (A11-A12). Interestingly, for the 
secreted C1q from MMFs and GMDCs, the dominant peak occurred at fractions 
(A15-B1), though a weaker peak coinciding with serum C1q occurred at fractions 
(A11-A12) for MMFs. As of now, the smaller C1q in fractions A15-B1 shall be 
termed as LMW C1q and the larger C1q in fractions A11-A12 typical of serum C1q 





Figure 10: Comparison of C1q profile from GMMF and MMF. Figure 10 (a) GMMF cultured from 
GM-CSF (20ng/ml) for 6 days from monocytes and incubated in serum free media CD-hybridoma was 
processed via size exclusion, and detected with western blot against C1q. The MMF secreted profile 
from the same donor is included as a comparison with western blot against C1q. Figure 10 (b) The 
relative difference of Normal (A11-A12) and LMW (A15-B1) C1q is compared within the same 
western blot for MMF and GMMF from the same donor. Figure 10 (c) Densitometry analysis is 




Another form of macrophages cultured with GM-CSF (20ng/ml) from monocytes for 
6 days termed as GMMF was compared with MMF (Fig 10). As before, the GMMF 
was incubated in serum free CD-hybridoma for 72 hours in the presence of GM-CSF, 
and the supernatant was processed via size exclusion. Western blot against C1q was 
done for the fractions obtained from gel filtration, and a comparison was done against 
MMFs obtained from the same donor. It was observed as before MMF has more 
LMW C1q as compared to Normal C1q (Fig 10a and 10c), as shown by western blot 
and densitometry analysis of the western blot. Interestingly, GMMF has comparable 
levels of LMW and Normal C1q (Fig 10a and 10c), and when compared with MMF 
from the same donor, GMMF has significantly higher levels of Normal C1q (Fig 10b 
and 10c).  
 
GMMF and MMF have been reported to have antagonistic transcriptional regulation 
of several genes (Brocheriou, Maouche et al. 2011), and this antagonistic regulation 
has some implication in the aspect of artherosclerosis. Though the underlying 
mechanistic reasons for the differential regulation of Normal and LMW C1q in the 
GM-CSF/M-CSF axis are unknown, this is the first indication that LMW C1q’s 
expression and secretion is controlled.  
 
Next the approximate size of LMW C1q was determined via running a gel filtration 
calibration standards for the same buffer and column. Four different sizes were 
utilised, thyroglobulin (669 kDa), ferritin (440 kDa), adolase (158 kDa) and 
ovalbumin (43 kDa). Though the standards cannot be compared directly against LMW 




depends on its hydrodynamic radius or shape, it does give an approximate idea of the 
difference in size between Normal and LMW C1q. From the elution profile of the gel 
calibration standards, Normal C1q elutes near to thyroglobulin and LMW C1q elutes 
near aldolase (Fig 11), thus LMW C1q should be approximately 3-4 times smaller 
than Normal C1q, giving LMW C1q an approximate size around 150-100 kDa.  In the 
next section, the basic dimeric subunit structure of LMW C1q will be examined.  
 
 
Figure 11: Calibration of Gel filtration column with known standards. The column Superose 6 10x300 
was calibrated with standards of known sizes; thyroglobulin (669 kDa), ferritin (440 kDa), aldolase 







3.3 Dimeric Subunit Structure of LMW C1q 
 
The basic dimeric subunit structure of Normal C1q is its C1q A-B and C1q C-C 
dimers (section 1.5.1). It was previously reported that LMW C1q has a different 
dimeric structure compared to Normal C1q, with the possibility of AC dimers and 
some faint B dimers (section 1.7) based on the calculation of sizes. In addition, 
adiponectin varying forms of complexes depended on differential regulation of 
disulphide chains (section 1.7), reminiscent of that of C1q. The exact identities of the 
LMW C1q dimers have not been checked with western blot chain specific antibodies.  
 
As with the previous experimental setup, MMF were incubated in serum free media, 
CD-hybridoma for 72 hours and processed via size exclusion. The Normal and LMW 
C1q fractions were put through non-reducing western blot with antibodies targeting 
against all chains of C1q or against individual chains. 
  
 
Figure 12: Non-reducing western blot of the dimeric subunit of Normal and LMW C1q. The samples 
were separately run in 10% SDS-PAGE with the various antibodies. AB: refers to C1q AB dimers and 





The polyclonal anti-C1q targeting against all chains of C1q, indicated presence of 
dimers within the region between expected for AB and CC (Fig 12). This proves that 
LMW C1q do contain a different dimeric structure as compared to Normal C1q. The 
combination of the chain specific antibodies leads to the conclusion that a variety of 
dimers could exist: A-A, A-C, B-C and C-C. Judging from multiple western blot runs, 
it is most likely the dominant non-reduced chains are AC and probably AA, and a 
weaker contribution from B-C and C-C. Note that Anti-C1q C specific antibody 
picked up the presence of CC dimers, the same dimer was also picked up in the 
antibody against all chains during the higher exposure times (as seen faintly). 
 
The presence of different dimers indicates that LMW C1q probably do not arise from 
dissociation of Normal C1q. This differential dimeric structure gives confidence to the 
notion that LMW C1q is a conformationally different complex, and not just a smaller 
complex when compared to Normal C1q. Indeed when view in combination of the 
data obtained from the differential expression of Normal and LMW C1q from the 
GM-CSF/M-CSF axis (Fig 10), had LMW C1q arise from dissociation, the LMW C1q 
from GMMF should correspondingly increase, and the ratio should not differ from 
that of MMF. This indicates that LMW C1q is a structurally different complex whose 
expression and formation is precisely regulated perhaps at the level of disulphide 







3.4 Classical pathway Activation by Normal and LMW C1q 
 
The classical pathway of complement activation is one of the pivotal roles of C1q, 
thus the LMW C1q was tested for its ability to initiate complement activation. The 
secreted C1q from MMFs was collected and processed via size exclusion as before, 
and the fractions were dialyzed into TBS. Complement activation, specifically the 
classical pathway was tested with the aid of Wieslab complement activation kit. The 
samples were diluted in the diluents provided by the kit and 1μl of C1q deficient 
serum (Calbiochem) was added into each well.  
 
Equal volumes of sample fractions were tested with the kit, and remarkably even 
though LMW C1q is significantly over-represented in the fraction, its ability to initate 
complement activation was considerably lower as compared to Normal C1q (Fig 13).   
 
Since C1q binds to immobilized antibodies to initiate complement activation, a 
binding assay for C1q-IgG and C1q-IgM was developed. Briefly, either human IgG or 
IgM was coated on 96 wells, and were blocked with BSA, and subsequently tested 
with a dose titration of Normal C1q (Sigma) and detected with anti-C1q antibodies 
and HRP conjugated enzymes. The binding assay showed a linear relationship of 
immobilized antibodies binding to C1q for the dynamic range of 62.5ng/ml to 






Fig 13: LMW C1q is significantly weaker in its ability to initiate classical pathway complement 
activation as compared to Normal C1q. MMF samples were processed via size exclusion as before and 
added in equal volume to the Wieslab Complement Activation kit in the presence of C1q deficient 
serum. The western blot against C1q shows the amount of C1q present in the tested fractions.    
 
The MMFs fractions from size exclusion were tested in the binding assay, and 
indicated that LMW C1q is significantly weaker in its ability to binding to 
immobilized antibodies, both IgG and IgM (Fig 15a-b). Hence its weaker complement 
activation probably arises from its weaker ability to binding to immobilized 
antibodies. Note that the complement activation assay indicated weaker activation, 
however this was not picked up in the binding assay. This is probably because the 
complement activation assay has higher sensitivity from the multiple layers of 





Figure 14: The linear dynamic range of the C1q-IgG or C1q-IgM binding assay. The assay was 
designed to determine the binding affinity of C1q to immobilized antibodies. The Normal C1q (Sigma) 
was used to determine the linear dynamic range, which extends from 62.5ng/ml to 1000ng/ml. Each 





Figure 15: Binding affinity of LMW C1q to immobilized antibodies. Fig 15a-b: MMFs samples were 
processed via size exclusion and the fractions were added in equal volumes to the C1q-IgG or C1q-IgM 
binding assay, and experiment was conducted in duplicates. Fig 15c: The loading amount from western 




3.5 Expression profile of secretion of C1q upon cell stimulation 
 
Macrophages could respond to various external stimuli and differentially regulate 
their gene transcription and protein expression. Particularly it was interesting to 
examine if the presence of certain stimuli such as IFN-γ, IL-4, LPS and IFN-α, would 
differently regulate the ratio of Normal/LMW C1q ratio. In addition, since GMMF 
and MMF has been shown to differ in their ratio of C1q forms (Fig 10), it was further 
examined if the presence of M-CSF could influence the various stimulations in terms 
of Normal/LMW C1q ratio.  
 
Specifically, MMFs were harvested and seeded onto wells with the serum free media 
and stimulated with various conditions (IFN-γ alone, M-CSF alone or IFNγ and M-
CSF) for 72 hours, and the expression of Normal and LMW C1q was examined via 
western blot against C1q for the fractions that went through size exclusion by FPLC 
(Fig 16). As with previous experiment, M-CSF (20ng/ml) alone MMFs displayed 
higher levels of LMW C1q as compared to Normal C1q (7.4 fold difference, Fig 16c). 
With the additional presence of IFN-γ (100ng/ml) with M-CSF (20ng/ml), MMFs 
increases their expression of Normal C1q by 3.65 fold, and similarly for LMW C1q, 
M-CSF and IFN-γ synergise to increase expression of LMW C1q. However when M-
CSF was taken out of the equation for IFN-γ alone, the expression of Normal C1q 
actually increases, indicating that M-CSF suppresses IFN-γ induction of Normal C1q 
(Fig 16b and 16c). On the other hand, for LMW C1q, when M-CSF was removed, for 
IFN-γ alone MMFs, the expression of LMW C1q decreases, indicating that M-CSF 






Figure 16: Differential Expression of Normal and LMW C1q in the presence of IFN-γ and M-CSF. 
MMFs were harvested and stimulated with (Fig 16a-b) either M-CSF (20ng/ml) and/or IFN-γ 
(100ng/ml) for 72 hours in CD-hybridoma. The secreted samples were processed via FPLC gel 
filtration and examined with western blot. Densitometry Analysis was performed with ImageJ (Fig 




Next the ability of IL-4 to regulated Normal/LMW C1q ratio was examined in the 
context of M-CSF. Similar to previous experimental setup, the MMFs were stimulated 
either with M-CSF (20ng/ml) and/or IL-4 (40ng/ml), and the samples were processed 
via FPLC size exclusion and examined with western blot against C1q.  
 
It was shown that IL-4 has the ability to dramtically down-regulate expression and 
secretion of Normal C1q and LMW C1q (Fig 17). Interstingly while M-CSF had little 
effect on IL-4 down-regulation of Normal C1q, M-CSF could rescue IL-4’s effect on 
LMW C1q to that of M-CSF alone levels (Fig 17).   
 
The IFN-γ and IL-4 axis in the perspective of macrophages is typically refered to the 
classical or alternatively activated macrophages respectively (Martinez, Helming et al. 
2009). It would seem that in the context of C1q, IFN-γ increases total C1q expression, 
particularly in favour of Normal C1q (Fig 16) , whereas IL-4 decreases total C1q 
expression, particularly for LMW C1q (Fig 17). Interestingly, M-CSF decreases 
Normal C1q induction by IFN-γ but synergises in the expression of LMW C1q (Fig 
16). In contrast, M-CSF had no visible effect on IL-4 suppression on Normal C1q, but 
could dramatically rescue IL-4 suppression in the context of LMW C1q (Fig 17). 
Although the mechanism and physiological reason for the differential regulation of 
Normal/LMW C1q particularly in the context of M-CSF for the IFN-γ/IL-4 axis is 
unknown, it does intuitively reason that given the ratio of Normal/LMW C1q differs 
in varying context, it seem unlikely LMW C1q is a disocciated product from Normal 






Figure 17: Differential Expression of Normal and LMW C1q in the presence of IL-4 and M-CSF. 
MMFs were harvested and stimulated with (Fig 17a-b) either M-CSF (20ng/ml) and/or IL-4 (40ng/ml) 
for 72 hours in CD-hybridoma. The secreted samples were processed via FPLC gel filtration and 




Next the expression profile of Normal/LMW C1q was examined in the context of 
LPS. The MMFs were stimulated in the presence of LPS (500ng/ml) and/or M-CSF 
(20ng/ml) for 72 hours and processed via size exclusion. The presence of LPS 
suppress the expression of total C1q, and M-CSF had no effect on LPS’ suppression 
for both Normal and LMW C1q (Fig 18a and 18c). LPS is a microbial pathogen 
ligand typically found on gram negative bacteria and stimulates immune cells via 
TLR-4. The stimulation of immune cells with LPS, simulates the presence of 
microbial pathogen, and is normally used as a maturation stimuli. This maturation 
stimuli overides the typical inductive/sygnergistic influence that M-CSF has on LMW 
C1q. 
 
IFN-α is a major cytokine involved in the pathogenesis of SLE (Su, Lu et al. 2012), 
similarily, the effect of IFN-α (200 units/ml) was examined in the context of C1q 
expression. Interestingly, the presence of IFN-α suppresses both forms of C1q and M-
CSF had no effect on IFN-α suppressive effects (Fig 18b and 18c). Note that for this 
donor (Fig 18b), its basal level (for M-CSF alone) of Normal C1q is higher than 
LMW C1q, generally for most donors (> 95%), the LMW C1q is typically higher at 
the basal level. This might just reflect the different immune status of the donors or a 
particular genetic preference for one form of C1q. 
 
In summary, the presence of M-CSF has the ability to regulate IFN-γ/IL-4 effects on 
Normal and LMW C1q but had no effect on LPS/IFN-α suppressive effects on total 






Figure 18: Differential Expression of Normal and LMW C1q in the presence of LPS/IFN-α and M-
CSF. MMFs were harvested and stimulated with (Fig 18a-b) M-CSF (20ng/ml) and/or LPS 
(500ng/ml)/IFN-α (200 units/ml) for 72 hours in CD-hybridoma. The secreted samples were processed 
via FPLC gel filtration and examined with western blot. Densitometry Analysis was performed with 




Table 8: Summary of Stimulations on MMF expression of Normal/LMW C1q. 
  
Stimulation Without M-CSF With M-CSF 
Normal C1q LMW C1q Normal C1q LMW C1q 
IFN-γ + + - + 
IL-4 - - Nil + 
LPS - - Nil Nil 
IFN-α - - Nil Nil 

















Chapter 4: Recombinant Expression and Purification of LMW C1q 
4.1 Overview on the approach to study functionality of LMW C1q 
 
To further investigate the role of LMW C1q in DC regulation, there is a need to purify 
and obtain sufficient yield of LMW C1q. The MMFs produce approximately around 
250ng/ml of total C1q (Fig 19a) per 1.5x10
6
 cells/ml, and with a yield of 23.6x10
6
 
cells per buffy coat (section 3.1), this amounts to an average of 4μg of total C1q per 
buffy coat. However the yield is expected to drop after purification and separation of 
LMW C1q from Normal C1q, as well as from other secreted proteins from MMF. For 
instance when the secreted supernatant is processed via size exclusion, the amount of 
LMW C1q at the B1 fraction is usually around 250ng/ml from an initial 2.5μg of total 
C1q (Fig 19b), with the yield expected to drop with further purification as the B1 
fraction still contain other proteins. To perform functional studies on DCs, it is 
estimated that around 5-10μg of protein is required per well. It is technically 
challenging and laborious to establish a protocol for purification of LMW C1q from 
buffy coat to achieve the required protein yield for functional studies on DCs.  
 
Alternatives to buffy coat were explored; the first potential source of LMW C1q that 
was examined was the human serum. Since the human blood typically contains 
around 100-200μg/ml of C1q (van Kooten, Fiore et al. 2008) , this was the first 
primary target to be examined. Simultaneously a recombinant expression platform to 
produce LMW C1q was established as an alternative source as well as a potential 




mammalian expression system was favoured as complex formation is required. Two 
main transfection techniques were explored for the recombinant expression system, 




Figure 19: Amount of C1q from MMFs and GMDCs prior and after size exclusion.  
Figure 19a shows the typical amount of total C1q from MMFs and GMDCs seeded at 1.5x10
6
 cells/ml 
for 72 hours for four separate donors, and the C1q (Sigma) standard as a semi-quantitative comparison 
(the secreted C1q from MMFs and GMDCs and the C1q standard was run in the same membrane).  
Figure 19b shows the amount of C1q after size exclusion via Superose 6 10x300 in 1ml fractions for 
C1q (Sigma) and secreted C1q from MMFs. The C1q (Sigma) standard is depicted, and 2.5μg of total 
C1q (Sigma) was loaded into the column, while 10ml of MMFs supernatant (from 1.5x10
6
 cells/ml) 






4.2 Establishing a purification protocol for LMW C1q 
 
As previously highlighted, the human serum presents as a potential source of LMW 
C1q, thus to determine if LMW C1q is present, the human serum (60x dilution or a 
total of 5μl) was process via size exclusion with Superose 6 10x300 in 1ml fractions 
with FPLC and the fractions were examined under non-reducing conditions to 
examine the dimers (Fig 20). Majority of C1q in the human serum presents itself as 
Normal C1q (A11-A12) with the AB and CC dimers (Fig 20a), though a relatively 
weak band with a dimer below the AB band exists at the LMW C1q fraction (B1).  
This band was further verified with the specific antibodies against each chain, and the 
presence of dimers similar to that found in MMFs were present (Fig 20b). However as 
it can be seen, the strong presence of Normal C1q, makes it hard to totally remove the 
presence of Normal C1q from the LMW C1q fractions. Thus the option to purify 
LMW C1q from human serum would be challenging, instead the human serum will be 
utilised as a platform to optimise the steps necessary to purify total C1q.  
 
To purify C1q from the samples, an affinity column using anti-C1q beads was 
prepared and packed into a column. Briefly 20mg of rabbit anti-human C1q (gift from 
Bob Sim) was conjugated to 1 gram of cyanogens bromide beads, and the beads were 
blocked and washed with alternative acidic and basic washes. To determine if the 
Anti-C1q beads work, 1μg of C1q (Sigma) was diluted into PBS and incubated with 







Figure 20: Detecting LMW C1q in human serum. Figure 20a, the non-reducing western blot was run 
for the size exclusion fractions obtained from human serum (5μl) with the polyclonal anti-C1q. Figure 
20b, the same samples were run with chain specific antibodies to examine the C1q dimers in non-
reducing conditions.  
 
The beads were incubated with C1q overnight and the beads were spun down, the 
supernatant was aspirated and examined with western blot against C1q. The 
unspecific IgG acts as immobilized antibodies which is a natural ligand binding 
partner for C1q thus acting as a positive control for the experiment. The empty beads 
were prepared the same way with blocking and acidic and basic washes, and act as the 
negative control. The unspecific IgG was able to deplete the supernatant of most of 
the C1q (Fig 21), and the anti-C1q beads were very efficient in capturing C1q from 






Figure 21: Determining the capturing efficacy of Anti-C1q beads. The beads were conjugated either 
with unspecific human IgG, anti-C1q or merely just empty. The beads were incubated with 1μg of C1q 
(Sigma) overnight and the beads were spun down, and the supernatant was aspirated and examined 
with western blot against C1q. The loading controls are presented below.  
 
As the next step of purification requires the elution of C1q from the anti-C1q beads, 
the effects of pH on C1q was tested. Specifically, 5μg of C1q (Sigma) was incubated 
with various pH (3-12) for 10 mins on ice and neutralized to pH 7.4. The samples 
were then processed via size exclusion with the Superose 6 10x300 in 1ml fractions 
with FPLC. The fractions are then examined with western blot against C1q. It would 
seem that extreme pH affects the polymerisation of C1q, interestingly, extreme acidic 
pH of 3 to 4 resulted in larger forms of C1q or extreme basic pH of 12 also resulted in 
larger forms (Fig 22). As all samples were neutralised prior to loading in the column, 
and considering the larger volume of the column to that of the sample (200μl to 
24ml), the effects of pH contamination on the resolution of the protein size exclusion 
is not possible. The results indicated that C1q is relatively stable as a complex 
between pH 5 to pH11.5 (Fig 22), thus the two furthest limits pH 5 and pH 11.5 was 






Figure 22: The effect of pH on the oligomerization of C1q. 5μg of C1q (Sigma) was incubated in 
various pH for 10 mins on ice and neutralised to pH 7.4. The samples are injected into Superose 6 10 x 
300 column with FPLC and resolved in 1ml fractions. The fractions were examined with western blot 










Figure 23: The elution of C1q from Anti-C1q column with pH 5 or pH 11.5. The human serum samples 
(50ml) was loaded onto the anti-C1q column and washed with 1M NaCl, 1mM EDTA in Tris pH 7.4 
and eluted with pH 5 or pH 11.5 in 1ml fractions. The eluted samples are then run in SDS-PAGE and 







The human serum samples (50ml) was loaded onto the anti-C1q column and allowed 
to flow via gravity, and the column was washed with 5 column volume of 1M NaCl, 
1mM EDTA in Tris pH 7.4, and subsequently eluted with either pH 5 or pH 11.5 into 
1ml fractions. The eluted samples were neutralised to pH 7.4 and run in SDS-PAGE 
and stained with coomassie (Fig 23). Both pH 5 and pH 11.5 allowed the elution of 
C1q from the column, though pH 11.5 had much stronger and intense bands as 
compared to pH 5.  
 
However the presence of contaminants as well as the over-representation of Normal 
C1q in human serum makes it difficult to continue utilising human serum as a source 
of purifying LMW C1q. The process of purification with anti-C1q beads is however 
retained and utilised in the purification of LMW C1q from recombinant expression of 
LMW C1q.   
 
4.3 Cloning of C1q ABC into pCDNA 3.1A Vector 
 
The human C1q A, B or C genes were cloned into the vector, pCDNA 3.1A which 
contains a constitutive CMV (Cytomegalovirus) promoter and an ampicillin resistance 
gene for selection. Briefly cloning primers specific for human C1q was used to clone 
the gene, and directionally specific restriction endonucleases were used to cleave the 
gene inserts and vector. The restricted components were then ligated and selected with 
ampicillin. The colonies were screen for vectors with the target inserts with vector 








sequenced and checked for potential mutations (Fig 24). In addition to the gene 
sequence, a Kozak sequence (GCCACC) was added 5
1
 prior to each ATG start site of 








Figure 24: Sequencing results of cloned human C1q genes in pCDNA 3.1A vector. The human C1q A, 
B or C gene was cloned into pCDNA 3.1A and sequenced with vector primers, and checked against the 
NCBI website for sequence validation. Fig 24a-c shows the respective blastx of the gene insert 
sequence against that of the NCBI human C1q A,B or C respectively.    
 
4.4 Electroporation of Raw 264.7 cells with C1q ABC genes 
 
 
The murine macrophages cell line Raw 264.7 was tested for transfection of C1q ABC 
genes via electroporation. The cells were harvested and electroporated with 25μg of 
total plasmid (C1q A: B: C at 1:1:1 ratio), and allowed to express the recombinant 
C1q into a serum free expression media for 48 hours. The supernatant was 
subsequently collected and examined for C1q with western blot. Firstly several forms 
of expression media were tested (Fig 25), and intriguingly X-Vivo media resulted in 
aberrant forms of reduced C1q chains. The most compatible serum free media were 
the CD-hybridoma media or HEK293SFM media, or the combination of the both (1:1 




combination of HEK293SFM and CD-hybridoma media, thus this was used for the 
later experiments.   
 
  
Figure 25: Electroporation of Raw 264.7 with C1q ABC genes in various expression media. Several 
forms of expression were tested, namely HI-BCS: Heat inactivated BCS DMEM, 293SFM: 
HEK293SFM media, X-Vivo media, CD: CD-hybridoma media, and combinations of the media, 
293CD: HEK293SFM and CD-hybridoma, 293X: HEK293SFM and X-Vivo, and XCD: X-Vivo and 
CD-hybridoma. The Raw 264.7 cells were harvested and electroporated with 25μg of plasmid and 
incubated in the various forms of expression media for 48 hours. The supernatant was harvested, and 
examined for C1q with western blot. The HI-BCS media control is depicted, indicating the presence of 
bovine C1q, thus the need for serum free media.  C1q control (Sigma) is at 1μg/ml.  
 
 
Next two forms of electroporation protocols previously tested for Raw 264.7 cells 
were compared. Protocol 1 (Michael F. Carey, Craig L. Peterson et al. 2008) consisted 
of the following parameters for electroporation: 250V, 960 uF capacitance, and 
infinite resistance, in an electroporation media consisting of DMEM supplemented 
with 10% (v/v) FCS, 100 units/ml penicillin, 100μg/ml streptomycin and 2mM L-
glutamine. Protocol 2 (Chen, Tan et al. 2011) consisted of the following parameters 
for electroporation: 300V, 975 uF capacitance, infinite resistance, in an 
electroporation media consisting of serum free RPMI. The cells were spun down and 
resuspended into the serum free expression media (CD-hybridoma and 




performed for the supernatant (Fig 26). Protocol 1 expresses significantly more C1q 
as compared to protocol 2, thus protocol 1 is further optimised.      
 
 
Figure 26: Comparing two methods of electroporation. Two protocols were tested (details in main text), 
and the amount of plasmid utilised is stated, with pCDNA vector as a negative control. The 
concentration of C1q control (Sigma) is 1μg/ml.   
 
 
Next protocol 1 was further optimized with various stimulations during the expression 
phase, murine IFN-γ (100ng/ml) or chloroquine (10μM). IFN-γ has been shown to be 
able to induce expression of both Normal and LMW C1q (Fig 16) and chloroquine is 
typically used to alter the pH of endosomal compartments, thereby reducing 
degradation of plasmids taken up by electroporation. The results indicated no increase 
in expression of C1q with chloroquine or IFN-γ (Fig 27a). A check for dimers 
indicated the absence of LMW C1q dimers (Fig 27b), and higher exposure of the film 
indicated no presence either. Thus this expression system was deemed unsuitable for 
expression of LMW C1q, and the reasons why the expression did not produce LMW 
C1q was not pursued. Instead a separate human mammalian expression is tested in the 







Figure 27: The optimisation of C1q expression from electroporation of Raw 264.7. The Raw 264.7 
cells were electroporated with various amounts of plasmids containing human C1q ABC (1:1:1 ratio), 
and incubated in serum free media for 48 hours in various stimulations, murine IFN-γ (100ng/ml) or 
chloroquine (10μM). The reducing and non-reducing western blot against C1q was performed for the 
supernatant.  
 
4.5 Calcium phosphate transfection of HEK293T with C1qABC 
 
 
Calcium phosphate transfection of human C1qABC genes into a number of 
mammalian cell lines was tested, ranging from HepG2, MCF7, Hela and HEK293T. 
The HEK293T kidney embroyonic cell line is the most successful, with the other cell 
lines either having no detectable protein expression or very weak levels. Calcium 
phosphate transfection was performed on HEK293T, and 4 main variables were 
tested, (a) transfection duration, (b) plasmid concentration, (c) cell density and (d) 
plasmid ratio of C1qABC (Fig 28) by examining the secreted C1q via western blot. 
Briefly the plasmids are conjugated to calcium phosphate particles which are taken up 
by the cells during transfection, for 50μg/ml of total plasmid, there is a dose 
dependent increase in transfection efficiency from 2-6 hours of transfection duration 




peaks at 4 hours and drops precipitously at 6hours. Based on the results, a 
compromise between transfection and plasmid concentration was chosen, thus the 
optimal balance was 25μg/ml of plasmid for 4hours of transfection.  
 
Next cell density or confluency was tested with varying amount of cells seeded onto 
the T-75 flask prior to the day of transfection, with a range of 4,6,10 and 15 million 
cells being tested. From the results, the peak transfection efficiency was obtained 6 
million cells and a consistent drop in efficiency onwards (Fig 28b and 28d). From 
observation, seeding of 6 million cells typically results in 60% confluency by 21-24 
hours (this will vary on passage number).  
 
The next variable tested was the plasmid ratio of C1q ABC, as C1q B seems lower in 
LMW C1q, the plasmid ratio tested were (a) 25μg/50μg 1A:1B:1C, (b) 25μg 
2A:1B:2C, and (c) 25μg 3A:1B:2C. The results indicated that the ratio of 1A:1B:1C 
seems most efficient; however there seems to be minimum difference for the 3 
different ratios of plasmids (Fig 28c and 28d).  
 
Hence the combined optimized parameters chosen are 25μg of total plasmids at 1:1:1 
ratio for 4hours of transfection duration, with 6 million cells seeded per T-75 flask. 
From experience, most conditions are easily controlled (plasmid concentration and 
time), with confluency being the most difficult variable to control, as the speed of cell 
division can vary with passage number and cell clustering occurring due to accidental 




expression levels of C1q are at an average yield of 3μg/ml with 20ml of media per T-




Figure 28: Optimization of calcium phosphate transfection of C1q into HEK293T cells. The cells were 
transfected with as indicated and examined with western blot against C1q.  Fig 28a: The cells were 
transfected with either 25μg or 50μg of total plasmid for 2, 4 or 6 hours. Fig 28b: The cells were seeded 
with varying density of 4, 6, 10 or 15 million per T-75 flask 21-24 hours prior to transfection. Fig 28c: 











The supernatant obtained from calcium phosphate transfection is spun down and 
filtered through 0.22μm to remove cellular debris and loaded onto the anti-C1q 
column (the filtrate is also collected to measure the capture efficiency), and washed 
with 5 column volumes of 1M NaCl, 1mM EDTA in Tris pH 7.4. The column is then 
eluted with pH 11.5 in 1ml fractions, and neutralise to pH 7.4.  The pH 11.5 eluted 
fractions are run on a SDS-PAGE gel and stained with blue silver coomassie to 
determine the purity (Fig 29a). The C1q obtained is approximately 90-95% pure, a 
marked improvement as compared to C1q obtained from human serum.  
 
The eluted fractions (1x) and the filtrate that passed through the column prior to 
elution was also concentrated (10x) to determine the capture efficiency (Fig 29b). The 
eluted fractions peak at the 4
th
 ml, and compared against the C1q standards, range 
between 5-20μg/ml, the 10x filtrate indicate less than 5μg/ml. A total of 80ml of 
sample (~2-3μg/ml of C1q), thus a total of 160μg of C1q, and a filtrate of <5μg/ml of 
a total 8ml volume (10x concentrated), thus a conservative estimate is that >75-90% 
of C1q was captured. Though from the eluted fractions, it can be seen that a 
significant fraction of C1q is lost from 1M NaCl wash, but this wash is necessary to 
remove impurities (not detectable by coomasie, as it is a chemical constituent in the 





Figure 29: Recombinant C1q is purified via anti-C1q column. Fig 29a shows a blue silver coomassie 
stain of the pH 11.5 eluted fractions obtained from calcium phosphate transfected samples purified with 
anti-C1q column. Fig 29b shows the western blot of C1q obtained from the pH 11.5 eluted fractions 
and the 10x concentrated filtrate (which pass through the column immediately after sample loading), 
and a C1q (Sigma) semi-quantitative standard.  
 
The pH 11.5 eluted fractions are pooled together and tested with size exclusion via 
FPLC, and detected with western blot against the fractions (Fig 30). It would seem 
that the dominant peak is at A15-B1, the expected fractions for LMW C1q.  
 
Figure 30: Size exclusion of C1q obtained from anti-C1q purification of recombinant C1q transfection. 
The pH 11.5 eluted fractions from anti-C1q column was run through a Superose 6 10x 300 column in 





The presence of LMW C1q was further validated by checking the dimeric 
composition, thus the sample obtained from gel filtration was checked with the 
various anti-C1q antibodies (Fig 31). The presence of LMW C1q dimers similar to 
those found in MMFs was detected.  
 
 
Figure 31a: Dimeric Composition of LMW C1q from HEK293T transfection. The non-reducing 
western blot against C1q was performed together with C1q (Sigma) as control.  
 
An interesting observation was made with single chain transfection into HEK293T, 
specifically HEK293T was transfected with C1q A,B or C individually and compared 




chains of ABC are different when transfected together as opposed to single chain 
transfection. In single chain transfection, C1q A comes in two bands, and C1q B 
comes out larger than A, and C1q C comes out normally as a dominant band, and a 
slightly weaker higher band (Fig31). However in the presence of all 3 bands, the 
individual sizes become aligned with the standard C1q (Sigma) reduced chains. It is 
speculated that the C1q chains are differentially modified or complexed when in the 
presence of all three as opposed to single chains.  
 
 
Figure 31b: Single chain transfection of C1q A,B or C into HEK293T. Calcium phosphate transfection 
of C1q A,B or C single chains were performed and compared to the triple transfection, and western blot 
against the reduced chains of C1q was examined.  
 
In summary, the HEK293T were calcium phosphate transfected with equi-molar ratio 
of C1qABC, and incubated for 48 hours in serum free media. The supernatant was 
aspirated, spun down and filter sterile through 0.22μm. The sample is then purified 
via anti-C1q column, eluted with pH 11.5, neutralised to pH 7.4. The samples are then 
concentrated and dialyzed with PBS, filter sterile with 0.22μm and quantitated with 
Braford assay prior to use. For subsequent investigations in chapter 5, the 





Chapter 5: LMW C1q role in DC regulation  
5.1 Immobilized LMW C1q primes monocyte differentiation to GMDC towards Th1 
by increasing IL-12p70 and decreasing IL-10 secretion  
 
DCs are the sentinels of the immune system and aid in the shaping of the adaptive 
immune system (section 1.2.1). The aim of the project is to determine if LMW C1q 
could differentially modulate DCs as compared to Normal C1q. As previously 
discussed (section 1.5.5), various methodologies were utilised in the study of C1q’s 
immunomodulatory role in DC differentiation and maturation. Recently our lab has 
proven that the differentiation of monocytes in the presence of immobilized (coated) 
Normal C1q resulted in GMDCs which secrete less IL-12p70 and more IL-10 in 
response to LPS and/or IFN-γ (Teh, Yeo et al. 2011). It was also shown that C1q 
deposits around the vicinity of atherosclerotic lesions (Cao, Bobryshev et al. 2003), 
and it is believed that tissue deposited C1q could be structurally different and 
physiologically relevant in modulating monocytic differentiation to DCs. 
 
To examine the properties of immobilized LMW C1q on GMDC differentiation from 
monocytes, the culture wells (6 well format) were coated with varying amounts of 
recombinant LMW C1q (5,10 or 20μg/ml) or BSA dissolved in PBS. The coated 
wells are incubated at 37
o
C for 1.5 hours and monocytes harvested from buffy coat 
are seeded onto the coated wells at 1.5 x 10
6
 cells/ml (total of 2ml per well), and 
differentiated as per normal to GMDCs with IL-4 (40ng/ml) and GM-CSF (20ng/ml) 




After 6 days of culture, the GMDCs are harvested and stimulated with IFN-γ 
(100ng/ml) and/or LPS (500ng/ml) in 96 well formats with 5x10
4
 cells per well, for 
24 hours in a humified incubator at 37
o
C in the presence of 5% CO2. The cells are 
then spun down, and the supernatant aspirated and examined for the various cytokines 
with the respective ELISA kits.  
 
The dose titration of LMW C1q was compared against the BSA control, and it would 
seem that the presence of LMW C1q increases the secretion of IL-12p70 and deceases 
the secretion of IL-10, an effect opposite to that of Normal C1q (Fig 32a-b). At 
10μg/ml of LMW C1q, there is an increase of two-fold of IL-12p70 as compared to 
BSA control, and concomitantly a two-fold drop in Il-10 secretion. Since the effect is 
most pronounced at 10μg/ml, this concentration of LMW C1q was utilised for future 
experiments.   
 
To compare the cytokine regulation properties of LMW and Normal C1q, the 
monocytes from the same donor were then differentiated in the presence of 10μg/ml 
of either LMW C1q, Normal C1q or BSA, and harvested on the day 6 and stimulated 
with IFN-γ (100ng/ml) and/or LPS (500ng/ml) for 24 hours and the supernatant were 
tested for IL-10 and IL-12p70 (Fig 33a-b). The results indicated that within the same 
donor, IL-12p70 increases in the presence of LMW C1q, and decreases in the 
presence of Normal C1q as compared to the BSA control when stimulated with IFN-γ 
and LPS (Fig 33a). In the presence of LPS stimulation, LMW C1q decreases IL-10 
secretion, while Normal C1q increases IL-10 secretion as compared to the BSA 




   
 
Figure 32: Dose titration of LMW C1q on monocyte differentiation to GMDC in the secretion of IL-10 
and IL-12p70. The monocytes were seeded at 1.5x10
6
 cells/ml in the presence of LMW C1q at 5, 10 or 
20μg/ml or BSA for 6 days and differentiated with IL-4 (40ng/ml) and GM-CSF (20ng/ml) to GMDCs. 
The GMDCs were harvested on day 6 and seeded onto 96 wells at 5x10
4
 cells per well, and stimulated 
with IFN-γ (100ng/ml) and/or LPS (500ng/ml) for 24 hours. The supernatant was spun down and 
examined for IL-10 and IL-12p70 secretion with the respective ELISA kits. Statistical analysis was 





Figure 33: Comparison of LMW C1q and Normal C1q in GMDC differentiation in the secretion of IL-
10 and IL-12p70. The monocytes were seeded at 1.5x10
6
 cells/ml in the presence of 10μg/ml of LMW 
C1q, Normal C1q or BSA for 6 days and differentiated with IL-4 (40ng/ml) and GM-CSF (20ng/ml) to 
GMDCs. The GMDCs were harvested on day 6 and seeded onto 96 wells at 5x10
4
 cells per well, and 
stimulated with LPS (500ng/ml) and/or IFN-γ (100ng/ml) for 24 hours. The supernatant was spun 
down and examined for IL-10 and IL-12p70 secretion with the respective ELISA kits. Statistical 
analysis was performed with Prism GraphPad with unpaired two tailed T test, * p< 0.05, ** p < 0.01, 




Il-12p70 is a hallmark cytokine of the Th-1 pathway, where the production of IL-
12p70 from antigen presentation cells such as DCs could prime naive CD4
+
 T cells to 
adopt Th-1differentiation resulting in the production of the Th-1 effector cytokine 
IFN-γ (Gee, Guzzo et al. 2009). In contrast, IL-10 is a key immuno-suppressive 
cytokine that is known to inhibit I-kappa B kinase (IKK), and thereby reduce NFκB 
nuclear translocation (Moore, de Waal Malefyt et al. 2001). Il-10 has been shown 
downregulate the production of IL-12 from DCs (McBride, Jung et al. 2002) and 
inhibit the production of IFN-γ from T cells (Romagnani 1995) by decreasing T cell 
proliferation (Joss, Akdis et al. 2000). 
 
 The antagonistic relationship between IL-12p70 Th-1 pathway and IL-10 immuno-
suppressive effects is well established, it is interesting to note that a similar difference 
occurs for LMW C1q and Normal C1q. This suggests that the differential regulation 
and production of the different forms of C1q could potentially prime monocyte 
differentiation towards either a Th-1 prone pathway or immuno-suppressive pathway. 
As one of the key functionality of DCs is to shape the adaptive immunity through 
antigen presentation and cytokine production, it would be interesting to examine if 
DCs primed with C1q during differentiation could also affect T cell differentiation 








5.2 LMW C1q primes T cell differentiation towards the Th-1 pathway 
 
As DC-T cell interaction depends also on CD40-CD40L interaction, and reports of  
C1qa
-/-
 mice bone marrow DCs secreting lower levels of IL-12p70 via a CD40-
CD40L interaction between DCs and T cells (Baruah, Dumitriu et al. 2009), it was 
first important to determine if there is any CD40 upregulation in GMDCs cultured 
with LMW C1q. GMDCs differentiated from monocytes in the presence of LMW 
C1q, Normal C1q or BSA for 6 days, were harvested and stimulated with IFN-γ 
(100ng/ml) and/or LPS (500ng/ml)  for 24 hours. The cells were then harvested and 
stained for CD40 surface expression (Fig 34), and the results indicated no significant 
difference between the BSA, LMW C1q or Normal C1q differentiated DCs for any of 
the stimulated or control conditions.    
 
Next the T cells were purified via magnetic sorting from PBMCs isolated from Ficoll-
paque density centrifugation of buffy coats obtained from hospital donors. The CD4
+
 
naive T cells were isolated via negative selection (depleting all other non-CD4
+
 cells), 
and as indicated (Fig 35), typical purity is usually above 90%. The T cells isolated 
from one donor are then incubated with the GMDCs cultured from a separate 
allogenic donor, in a mixed leukocyte/lymphocyte reaction (MLR). Specifically, the T 
cells are incubated in a 10 T cell to 1 GMDC ratio in a 96 well format for 7 days, 
stimulated with IFN-γ (100ng/ml) and/or LPS (500ng/ml) with the respective GMDCs 
only and T cells only controls. The supernatant is then aspirated and examined with 





Figure 34: Flow cytometric analysis of surface CD40 expression in GMDCs differentiated from 
monocytes in the presence of LMW C1q, Normal C1q or BSA. Briefly the monocytes were 
differentiated in the presence of LMW C1q (10μg/ml), Normal C1q (10μg/ml) or BSA (10μg/ml) for 6 
days to GMDCs, and harvested on the 6
th
 day. The cells were stimulated for 24 hours in the presence of 
IFN-γ (100ng/ml) and/or LPS (500ng/ml) and stained with CD40-PE or its isotype. The cells were then 
examined under flow cytometry.    
 
 
Figure 35: Purity of T cell isolated from PBMCs via magnetic sorting. The PBMCs isolated from 
Ficoll-paque density centrifugation of buffy coat obtained from hospital donors, were negatively 
selected via magenetic sorting and depleted of all non-CD4 T cells. The purified cells are stained with 




The GMDCs were cultured and differentiated from monocytes as usual in the 
presence of LMW C1q, Normal C1q or BSA, and on the 6
th
 day, were harvested and 
incubated with the T cells obtained from a separate allogenic donor. As with the 
previous experimental setup, there is a need to stimulate the GMDCs with IFN-γ 
(100ng/ml) to induce the production of detectable amounts of IL-12p70 (Fig 33). 
Although in this MLR setup, the exogenous addition of IFN-γ and the subsequent 
detection of secreted IFN-γ may seem contradictory, after 7 days, the presence of the 
exogenously added IFN-γ have decreased significantly (Fig 36) as indicated by the 
GMDCs and T cells only controls (with IFN-γ). 
 
 In the absence of exogenous IFN-γ stimulation, the allogenic differences between the 
donors are usually insufficient to produce significant amounts of secreted IFN-γ, 
though certain donors (Fig 36 MLR3), are sufficiently different to induce secretion of 
IFN-γ in the presence of LPS alone. Thus there is normally a need to add exogenous 
IFN-γ to induce the secretion of IL-12p70 from the GMDCs which results in the 
induction of IFN-γ from T cells. This results in a positive feedback loop with the 
secretion of the IFN-γ from the T cells inducing the secretion of IL-12p70 from the 
GMDCs. Hence the overall effect is the enhanced sensitivity of the MLR assay with 
the addition of exogenous IFN-γ.    
 





Figure 36: LMW C1q enhances IFN-γ seretion from T cells in a MLR setting. The T cells were 
incubated with GMDCs differentiated from monocytes in the presence of LMW C1q, Normal C1q or 
BSA. The MLR reaction is then stimulated with IFN-γ (100ng/ml) and/or LPS (500ng/ml) for 7 days, 
and the supernatant is aspirated and examined for secreted IFN-γ via ELISA. The respective T cell only 
and GMDCs only controls are also performed in similar conditions. Statistical analysis was performed 




As shown by the various MLRs done with multiple donors (Fig36), the GMDCs 
differentiated in the presence of LMW C1q (10μg/ml) were able to induce the 
secretion of usually 1.5 to 2 fold more IFN-γ from T cells as compared to the BSA 
GMDCs. Concomitantly the Normal C1q GMDCs suppressed the secretion of IFN-γ 
from T cells as previously reported (Teh, Yeo et al. 2011). The actual fold difference 
in enhancement or suppression in the MLR caused by the presence of C1q in GMDC 
differentiation, is dependent on the allogenic differences between the donors. 
 
 
Figure 37: Intracelluar staining of IFN-γ from T cells in day 7 of MLR. The cells from MLR were 
harvested and stimulated with ionomycin (1μg/ml) and PMA (100ng/ml) for 2hours and subsequently 
stimulated with brefledin-A (5μg/ml) for 4 hours. The cells are harvested, fixed and permeabilized and 






To exclude the possibility of exogenous added IFN-γ in confounding the results, the 
intracellular staining of IFN-γ was also performed. Specifically, the cells were 
harvested on day 7 of the MLR, and stimulated for 2hours with ionomycin (1μg/ml) 
and PMA (100ng/ml) to induce rapid secretion of IFN-γ, and the secretory pathway is 
inhibited with the addition of brefeldin-A (5μg/ml) for 4hours, to allow the 
accumulation of IFN-γ within the T cells. The cells were harvested, fixed and 
permeabilized and stained with anti-IFN-γ PE or isotype, and examined under flow 
cytometry.  
 
The flow cytometric analysis indicated (Fig 37) that the T cells incubated with 
GMDCs differentiated with LMW C1q had nearly 2 fold more IFN-γ positive cells as 
compared to the BSA control GMDCs, and conversely, the Normal C1q GMDCs had 
significantly lesser IFN-γ positive cells as compared to the BSA control GMDCs (Fig 
37). The results from the intracellular staining of IFN-γ are in line with the IFN-γ 
ELISA results (Fig 36), both indicating that LMW C1q GMDCs enhance the secretion 
of IFN-γ from T cells. Thus it would seem that LMW C1q prime the GMDCs to 
secrete more IL-12p70 and less IL-10, which then induces the secretion of higher 









Figure 38: Examining IL-17/IFN-γ positive T cells in MLR. The cells from MLR were harvested and 
stimulated with ionomycin (1μg/ml) and PMA (100ng/ml) for 2hours and subsequently stimulated with 
brefledin-A (5μg/ml) for 4 hours. The cells are harvested, fixed and permeabilized and stained with 







Since IL-17 is a cytokine involved in the Th-17 pathway with implications in 
autoimmune conditions (Marwaha, Leung et al. 2012), it was interesting to examine 
the presence of this cytokine in the MLR setting. As before the cells from MLR were 
harvested, fixed and permeabilized and co-stained with anti-IL-17 and anti-IFN-γ for 
flow cytometric analysis (Fig 38). There was very low levels of IL-17 positive cells 
(<1%), thus it was hard to determine if this cytokine was implicated by the LMW 
C1q/Normal C1q axis. However as before, the LMW C1q induces higher levels of 
IFN-γ positive cells and Normal C1q induces lesser IFN-γ positive cells as compared 
to the BSA control. 
 
To determine if the C1q GMDCs affected T cell proliferation, the T cell were stained 
with CFSE (1μM) after isolation and incubated with the GMDCs as in the previous 
setup. The cells were stimulated with LPS (500ng/ml) and IFN-γ (100ng/ml), and 
harvested on various timepoints ( day 1,3,5 or 7) to examine their CFSE intensity via 
flow cytometry. A dilution in the CFSE intensity is indicative of T cell proliferation. 
The LMW C1q GMDCs induce higher levels of T cell proliferation (Fig 39a-b), with 
the LMW C1q GMDCs having 58.14% of cells in second generation by day 7 as 
compared to 28.26% of cells in second generation for BSA GMDCs (Fig 39a-b). 
While the Normal C1q GMDCs interestingly reporting a suppression of T cell 
proliferation, with  17.72% of T cells in second generation at day 7 (Fig 39a-b). 
Hence in summary, LMW C1q GMDCs induces T cells to secrete higher levels 
(approximately 2 folds) of IFN-γ as compared to BSA GMDCs, with a parallel 
increase in T cell proliferation. Conversely, Normal C1q GMDCs suppresses 









Figure 39b: Tabulations of percentage of Tcells in first generation or second generation in the MLR 
setting. The T cell percentages are obtained from Fig 39a flow cytometric readings. This experiment is 







5.3 Expression profile of C1q from GMDCs with IFN-γ stimulation 
 
Since LMW C1q was bias in the direction of Th-1 pathway, it was interesting to 
observe if how endogenous C1q synthesis (LMW/Normal C1q) from GMDC would 
alter in the presence of IFN-γ (100ng/ml) stimulation, simulating the scenario of IFN-
γ secretion from T cells during DC-T cell interaction. Hence as previously done, the 
GMDCs were harvested on day 6 and incubated in serum free media CD-hybridoma 
for 72 hours, stimulated either in the presence of GM-CSF/IL-4 with/or IFN-γ. The 
supernatant was spun down, filtered through 0.22μm to remove cellular debris, and 
processed via size exclusion with FPLC (Fig 40) and the fractions were then 
examined with western blot against C1q. 
 
IFN-γ stimulation resulted in a dramatic increase in secretion of both forms of C1q in 
GMDCs (Fig 40a-b), similar to that observed for MMFs (Fig 16). As observed 
previously for MMFs (Fig 16), levels of LMW and Normal C1q are almost equivilent 
in the presence of IFN-γ alone. In the presence of GM-CSF and IL-4 levels of Normal 
C1q was attenuated downwards dramatically, but affected LMW C1q slightly.  
 
Thus it would seem that in the presence of Th-1 cytokine IFN-γ that is secreted from 
T cells during DC-T cell interactions, GMDCs would upregulate the synthesis of both 
forms of C1q. How C1q synthesis in such scenarios, would affect surrounding cells in 




Figure 40: Differential Expression of Normal and LMW C1q in the presence of IFN-γ. GMDCs were 
harvested and stimulated with (Fig 16a-b) GM-CSF (20ng/ml) and IL-4 (40ng/ml) and/or IFN-γ 
(100ng/ml) for 72 hours in CD-hybridoma. The secreted samples were processed via FPLC gel 









 mice revealed the increased presence of apoptotic bodies in 
the glomeruli (Botto, Dell'Agnola et al. 1998), and previously our lab showed that 
GMDCs differentiated from monocytes in the presence of Normal C1q resulted in 
GMDCs with increased capacity to uptake apoptotic cells (Teh, Yeo et al. 2011). 
More importantly it is hypothesized in the waste disposal hypothesis (section 1.6.1) 
that the deficiency of C1q resulted in a defect in the clearance of apoptotic cells, 
which leads to the presentation of autoantigens to the adaptive immune system, and 
the break down of peripheral tolerance. Since DCs are the main conduits to which 
autoantigens will be presented to the adaptive immune system, it is interesting to 
examine the uptake of apoptotic cells by GMDCs differentiated with LMW C1q.  
 
Firstly the model cells utilised in this study to form apoptotic cells are the Jurkat cells. 
Briefly the Jurkat cells are first stained with CFSE (2μM) and subsequently irridated 
in the presence of UV (Teh, Yeo et al. 2011), and incubated in serum free RPMI for 
3hours at 37
o
C in the presence of 5%CO2, to allow the induction of apoptotsis. Next 
the GMDCs and apoptotic cells are harvested and incubated at 1:1 ratio in the 
presence of 10% human serum for 2 hours at 37
o
C and 5% CO2. To determine if the 
apoptotic cells are truely ingested by the GMDCs, confocal microscopy was 
performed for GMDCs incubated with apoptotic cells or GMDCs alone (Fig 41).The 
cells were incubated on a cover slip, fixed, permeabilized and stained with rhodamine 
phallodin against the F-actin, and the apoptotic cells are stained with CFSE. The 




within the GMDCs for the different forms of GMDCs (LMW C1q,Normal C1q or 
BSA) by the first hour, thus confirming the ingestion of apoptotic cells by the 
GMDCs. However as it is hard to determine quantitativly via confocal imaging to 
access the differential uptake of apoptotic cells by the different forms of GMDCs, 
instead the phagocytic capacity of the GMDCs were determined via flow cytometry. 
 
 
Figure 41: Confocal Imaging of the uptake of apoptotic cells by GMDCs. The Jurkat cells are stained 
with CFSE (green), and irradiated with UV to induce apoptosis. The apoptotic cells are then incubated 
with GMDCs differentiated from monocytes in the presence of 10μg/ml of LMW C1q, Normal C1q or 
BSA at 1:1 ratio. The cells are incubated for 1hour in 10% human serum at 37
o
C, and later stained with 
rhodamine phallodin (targeting F-actin). Confocal images are taken using Leica TCS SP5 Confocal 
Microscope System at 40x oil immersion objective. The images are then analyzed with Leica 







The phagocytosis assay was performed as described previously, with the exception of 
additional controls, specifically GMDCs and apoptotic cells alone, and GMDCs with 
apoptotic cells at 4
o
C. Hence after the GMDCs are incubated with apoptotic cells at 
37
o
C or at 4
o
C for 2hours, they are subsequently washed and stained with anti-
CD11c-PE targeting the GMDCs, and the apoptotic cells are previously stained with 
CFSE prior to UV irradiation. The cells are then fixed and later examined with flow 
cytometry. 
 
Flow cytometric analysis of the phagocytic cells (Fig 42a-b) revealed the profiles of 
two typical forms of donors, namely a GMDC donor (Fig 42a) with weak phagocytic 
uptake (< 10% uptake by BSA GMDC), or a moderate (Fig 42b) phagocytic uptake 
ability (>10% uptake by BSA GMDC). Both donor profiles reveal the same trend, and 
as previously shown Normal C1q GMDCs have increased 20%-50% phagocytic 
uptake of apoptotic cells as compared to BSA GMDCs (Fig 42c). While the LMW 
C1q GMDCs have a greatly suppressed phagocytic uptake that is 30%-50% of the 
BSA GMDCs (Fig 42a-c).     
 
As it can seen, the ability of the different forms of C1q to either enhance or suppress 
the uptake of apoptotic cells depend on the basal phagocytic capacity of the GMDC 
donors, with the weaker phagocytic profile revealing a stronger enhancement and 






Figure 42: Flow cytometric analysis of the phagocytic uptake of apoptotic cells by C1q GMDCs. The 
GMDCs differentiated with either LMW C1q, Normal C1q or BSA were incubated with apoptotic cells 
as described earlier. The GMDCs are stained with anti-CD11-PE and the apoptotic cells are stained 
with CFSE, and later fixed and analysed via flow cytometry. Fig 42a shows the typical profile of a 





Figure 42: Flow cytometric analysis of the phagocytic uptake of apoptotic cells by C1q GMDCs. The 
GMDCs differentiated with either LMW C1q, Normal C1q or BSA were incubated with apoptotic cells 
as described earlier. The GMDCs are stained with anti-CD11-PE and the apoptotic cells are stained 
with CFSE, and later fixed and analysed via flow cytometry. Fig 42b shows the typical profile of a 





Figure 42: Flow cytometric analysis of the phagocytic uptake of apoptotic cells by C1q GMDCs. The 
GMDCs differentiated with either LMW C1q, Normal C1q or BSA were incubated with apoptotic cells 
as described earlier. The GMDCs are stained with anti-CD11-PE and the apoptotic cells are stained 
with CFSE, and later fixed and analysed via flow cytometry. Fig 42c shows the relative fold difference 










Next a time-point experiment was performed for the phagocytosis assay, the GMDCs 
and apoptotic cells were incubated together for 1, 1.5 or 2hrs at 37
o
C, or at 4
o
C, and 
examined via flow cytometry as described earlier. The results indicated a gradual 
increase of uptake of apoptotic cells from 1 to 1.5 hour and a drop at 2 hours for all 
forms of GMDCs (Fig 43). The drop at 2 hours is probably due to the lysosomal 
degradation of CFSE stain of the ingested apoptotic cells in the endosomal-
phagolysomal. The profile of this donor is a strong phagocytic GMDC with the BSA 
GMDC taking up 26.59% at 1hour (Fig 43a).  
 
Consistent with previous results, Normal C1q GMDCs consistently takes up more 
apoptotic cells as compared to BSA GMDC for all timepoints, while LMW C1q 
GMDCs consistently taking up lesser apoptotic cells as compared to BSA GMDCs 
(Fig 43a-b). The relative fold difference in this donor is not as significant as the 
previous donor profiles (Fig 43c), but this is expected, since the donor is quite 
aggressive in phagocytic uptake, however the trend of C1q GMDCs is still consistent 













Fig 43b: The percentages of cells phagocytosed by C1q GMDCs are plotted against the various time 
intervals. Fig 43c: The relative fold difference for the phagocytosed cells is plotted for the various C1q 





5.5 Cytokine profile of GMDCs incubated with apoptotic cells 
 
As previously highlighted, DCs are a critical link in the presentation of self antigens 
to T cells, resulting in a break down in peripheral tolerance. The cytokine profile of 
the DCs is one of the key elements which can determine whether the presentation of 
self antigens is in a suppressive or a pro-inflammatory scenario. Since LMW C1q 
GMDCs secrete higher levels of IL-12p70 and lower levels of IL-10 as compared to 
the BSA GMDCs (Fig 33), and possesses the capacity to induce greater number of 
IFN-γ positive Th-1 cells (Fig 36-37) and effectively result in greater T cell 
proliferation (Fig 39), it was interesting to ask if LMW C1q GMDCs could also skew 
the cytokine response towards Th-1(as opposed to the IL-10 suppressive pathway) in 
the presence of apoptotic cells.   
 
According to the waste disposal hypothesis, a defect in apoptotic cell clearance results 
in the gradual increase of self-antigens which lead ultimately to the break down in 
peripheral tolerance. In this aspect, to mimic this gradual increase of apoptotic cells, 
the Jurkat cells were irradiated as usual with UV, and incubated for 3 hours at 37
o
C to 
allow apoptotsis to occur, and were mixed with GMDCs in increasing ratio from 1:1, 
1:10 and 1:20 ( GMDCs: Apoptotic cells) for 24 hours. After incubating the GMDCs 
with the varying ratio of apoptotic cells for 24 hours, the GDMCs are then tested for 
their ability to secrete IL-12p70 and IL-10 with IFN-γ and/or LPS for another 24 
hours. The supernatant is then aspirated to examine the IL-12p70 and IL-10 profiles 
via ELISA. The appropriate apoptotic cells or GMDCs alone controls are also 





The gradual increase of apoptotic cells resulted in a dose dependent increase of IL-
12p70 secretion from the GMDCs, and a concomitant decrease in secretion of IL-10 
(Fig 44). It is interesting to note that the intrinsic cytokine biasness resulting from 
C1q differentiation of GMDCs during the monocyte phase was inherently retained, as 
LMW C1q GMDCs secreted more IL-12p70 and less IL-10 as compared to BSA 
GMDCs, while the converse is true for Normal C1q GMDCs. This means that the 
presence of C1q during the differentiation phase of GMDCs could determine whether 
the self antigens obtained from apoptotic cells are presented in either a pro-
inflammatory or suppressive manner. 
 
Since Normal C1q GMDCs have a propensity to take up more apoptotic cells as 
compared to BSA GMDCs, this could have contribute to less apoptotic cells in the 
extracellular milieu and thus a less inflammatory environment (as apoptotic cells 
gradually progress to necrotic cells during the 24 hour incubation). Similarly LMW 
C1q GMDCs which have a lower capacity to take up apoptotic cells could have 
resulted in more apoptotic cells in the extracellular milieu, which contributes to a 









Figure 44: Cytokine profile of C1q GMDCs treated with apoptotic cells. The Jurkat (J) cells were 
irradiated with UV and allowed to undergo apoptosis for 3hours prior to incubation with GMDCs 
differentiated from monocytes with LMW C1q, Normal C1q or BSA for 24hours at varying ratio of 
1:1, 1:10, 1:20 GMDC : Apoptotic cells. After 24hours, the cells were stimulated with IFN-γ 
(100ng/ml) and/or LPS (500ng/ml), and further incubated for another 24 hours. The supernatant is spun 
down and aspirated, and examined for cytokine expression with the respective ELISA kits. Statistical 
analysis was performed with Prism GraphPad with unpaired two tailed T test, * p< 0.05, ** p < 0.01, 




  5.6 Balancing the ratio of LMW/Normal C1q 
 
The consistent antagonistic feature between LMW C1q and Normal C1q beckons the 
question whether the simultaneous presence of both forms of C1q could counteract 
each other. Thus to address this issue, increasing amounts of LMW C1q was titrated 
against a fix amount of Normal C1q during the differentiation phase of GMDCs, and 
the cytokine profile of IL-12p70/IL-10 was examined as before. Briefly the C1q 
GMDCs were harvested on day 6 and stimulated with IFN-γ (100ng/ml) and/or LPS 
(500ng/ml) for 24 hours, and the supernatant was spun down and aspirated. The 
supernatant was examined with the respective ELISA kits.  
 
As previously shown, the LMW C1q GMDCs secrete more IL-12p70 and less IL-10 
as compared to BSA GMDCs and the converse is true for Normal C1q GMDCs. With 
increasing presence of LMW C1q (from 2.5 μg/ml to 10μg/ml), the suppression of IL-
12p70 by Normal C1q could be lifted (Fig 45a), with Il-12p70 reaching close to BSA 
GMDCs levels at 10μg/ml of Normal C1q and 10μg/ml of LMW C1q. For IL-10 
secretion, increasing concentrations of LMW C1q resulted in a dose dependent 
suppression of IL-10 secretion by Normal C1q (Fig 45b). Thus it would seem that 
LMW C1q could counteract the cytokine biasness of Normal C1q, and this highlights 






Figure 45: Balancing the ratio of LMW/Normal C1q. The GMDCs were differentiated from monocytes 
in the presence of varying amounts of LMW C1q and/or Normal C1q, or BSA. Briefly the GMDCs 
were titrated with increasing concentrations of LMW C1q (2.5 μg/ml, 5μg/ml, 10μg/ml) against a fixed 
concentration of Normal C1q (10μg/ml). The cells were harvested on the 6th day and stimulated with 
IFN-γ (100ng/ml) and/or LPS (500ng/ml) for 24 hours. The supernatant is spun down and aspirated and 
examined for cytokine expression with the respective ELISA kits. Statistical analysis was performed 








Chapter 6: Discussion  
6.1 LMW C1q weak activation of the classical pathway 
 
LMW C1q’s ability to elicit complement activation is considerably weaker as 
compared to Normal C1q (Fig 13). This was further attributed to its weaker binding to 
immobilised antibodies (Fig 15). In the case of Normal C1q, the binding of 
immobilised antibodies occurs within the globular region of C1q B (Gaboriaud, 
Frachet et al. 2011), and from careful observation of the various C1q chains in LMW 
C1q, it seems to be deficient in C1q B chains (Fig 13, 29 and 32). This deficiency in 
C1q B chain in LMW C1q could explain its weaker capacity to bind to immobilised 
antibodies and thus its weaker complement activation.  
 
The weaker capacity to elicit complement activation means effectively that LMW C1q 
could potentially be weaker than Normal C1q in activating complement on apoptotic 
cells. This ultimately leads to poorer opsonisation of the apoptotic cells with 
molecules such as iC3b which facilitates clearance of apoptotic cells by phagocytes. 
Thus in situations which favour the production of LMW C1q as opposed to Normal 
C1q, the decreased clearance of apoptotic cells could lead to excess release of auto-
antigens when apoptotic cells are not cleared promptly. This leads to a propensity for 




6.2 Regulation of LMW/Normal C1q ratio by M-CSF in macrophages 
 
The MMFs stimulated in the presence of IFN-γ resulted in an increase of both forms 
of C1q, however with the concurrent presence of M-CSF, the ratio of C1q tilted in the 
favour of LMW C1q (Fig 16). It was interesting to question the significance of the 
secreted forms of C1q in this particular scenario. 
 
The predominant source of C1q is believed to be from macrophages (section 1.5.2). 
Macrophages make up to 10-15% of tissue mass (Niemi, Sharpe et al. 1986) and 
participate as first responders to infections, aiding in the coordination of the adaptive 
immune response, supporting and resolving inflammation and the maintenance of 
tissue homeostasis (Martinez, Helming et al. 2009). 
 
 M-CSF or macrophage colony stimulating factor also known as CSF-1 (colony 
stimulating factor 1) was discovered as one of the first hemopoietic factors that 
promoted the formation of pure colonies of macrophages from bone marrow 
progenitors in vitro (Stanley, Cifone et al. 1976). Mice deficient in M-CSF among 
several defects are severely deficient in tissue macrophages (Cecchini, Dominguez et 
al. 1994). In addition to survival, M-CSF is now known to regulate macrophage 





 M-CSF exists in 3 different isoforms through alternative splicing, namely the 
dominant form being the secreted proteoglycan, a secreted glycoprotein or a cell 
membrane form that could be released via proteolytic cleavage (Chitu and Stanley 
2006). In circulation, M-CSF predominantly exists as the proteoglycan form at 
concentrations of approximately 10ng/ml (Hume and MacDonald 2012), which 
elevates in pathological conditions such as chronic inflammatory diseases (Chitu and 
Stanley 2006; Hamilton 2008) and cancer, as well as physiological processes such as 
pregnancy (Bartocci, Pollard et al. 1986).  
 
In vivo administration of M-CSF into mice resulted in a 10 fold increase in blood 
monocyte numbers (Hume, Pavli et al. 1988), and parallel increase in numbers of 
conventional and plasmacytoid DCs (Fancke, Suter et al. 2008). Clinical trials in 
humans confirmed the ability of M-CSF to increase monocyte numbers (Cole, Sanda 
et al. 1994). 
 
 Intriguingly, M-CSF serum and kidney levels are elevated in murine autoimmune 
prone model for lupus nephritits, with M-CSF driven production and regulation of 
macrophages contributing to the inflammation and tissue damage in kidneys (Kelley 
2007). Particularly it was noted that in the MRL mice, which develops SLE 
autoimmune phenotype, elevated numbers of M-CSF sensitive progenitors in the 
blood and bone marrow were found, as determined by colony forming assays (Davis 
and Lennon 2005). Concomitantly recent investigations into lupus prone mice, 
indicated that M-CSF drives the phenotype of macrophages infiltrating the kidney 




human patients with active lupus nephritis have elevated levels of M-CSF in the 
blood, kidney and urine (Menke, Rabacal et al. 2009). Taken together, it would seem 
that M-CSF plays a significant role in promoting macrophage driven pathology in 
lupus nephritis. It is interesting to note that LMW C1q has shown to be elevated 
relative to Normal C1q in M-CSF differentiated in macrophages as compared to GM-
CSF differentiated macrophages (Fig 10).     
 
The activation of macrophages is generally classified into phenotypes, namely the M1 
or classically activated macrophages and the M2 or the alternatively activated 
macrophages (Martinez, Helming et al. 2009). The M1 phenotype is generated by the 
stimulation of macrophages with IFN-γ, and is typically characterized by its ability to 
deal with intracellular microbial infections via the Th-1 pathway. The alternatively 
activated M2 phenotype is generated by the presence of IL-4 or IL-13 resulting in 
macrophages generally associated with the capacity to deal with helminth infections 
via the Th-2 pathway.   
 
In M-CSF macrophages (MMF) stimulated in the presence of IFN-γ mimicking the 
M1 phenotype, the addition of M-CSF resulted in the decrease of Normal C1q, and 
the increase of LMW C1q (Fig 16). Similarly in MMF stimulated in the presence of 
IL-4 (the M2 phenotype), the addition of M-CSF increases LMW C1q (Fig 17) while 
having no effect on Normal C1q. Since C1q synthesis is believed to be hematopoietic 
in origin (Petry, Botto et al. 2001), and considering the prevalence of macrophages in 
tissues (10-15%), it is interestingly to speculate that if the ratio of C1q is tilted in 




could exacerbate the pro-inflammatory conditions via Th-1 pathway. Particularly, 
lupus nephritis patients reflect a predominant Th1 phenotype with high IFN-γ 
expression in peripheral blood and glomerular which parallels the severity of renal 
damage (Tucci, Lombardi et al. 2008) and LMW C1q has found to be elevated in SLE 
patients (Hoekzema, Swaak et al. 1990). Hence M-CSF elevation in lupus nephritis 
could result tilt the physiological balance from Normal C1q towards LMW C1q 
resulting in a Th-1 bias that contributes to renal pathology.    
 
6.3 Evidence augmenting that LMW C1q is a physiological differential form of C1q 
complex and not a product of artefact 
 
The first argument  against the possibility that LMW C1q is a degraded product  is 
clearly shown by the fact that the reduced (with DTT) bands of LMW C1q are clearly 
the same size as that of the Normal C1q (Fig 10, 16-18). If LMW C1q is a degraded 
product, its reduced bands would come out smeary along the entire lane.  
 
The next possibility is that LMW C1q is formed due to the technical processing 
during FPLC size exclusion, however, it is to be noted that the Normal C1q (Sigma) is 
also processed via the same manner (Fig 9), with clear distinction of size and dimers. 
In addition, pH manipulations of Normal C1q indicate the progression of larger forms 
of C1q in extreme acidic or basic pH rather than smaller forms (Fig 22). The 
possibility that LMW C1q is formed due to the usage of serum free media in the 




utilised macrophages cultured in serum media via radiolabeling, in addition the 
presence of LMW C1q is detected in human serum (Fig 20).   
 
LMW C1q is unlikely to be a dissociated product of Normal C1q as its dimeric 
composition is different from that of Normal C1q (Fig 12), thus arguing against the 
possibility that LMW C1q has “broken off” from Normal C1q. The differential 
regulation of M-CSF on the expression of LMW C1q over that of Normal C1q (Fig 
16-17) supports the notion that the production of LMW C1q is controlled rather than a 
dissociated product that fluctuates in parallel with Normal C1q concentrations. 
 
 The precedence of the ability of adiponectin, a member of the C1q globular head 
family of proteins, to exist in a variety of complexes (Tsao, Murrey et al. 2002) also 
indicates that such a phenomenon may not be unique to C1q itself. The fact that 
adiponectin utilises different cysteine residues for disulphide bonds (Tsao, Tomas et 
al. 2003) in the formation of various forms of complexes, gives a clue to how C1q 
complex formation may be controlled. One interesting candidate is DsbA-L 
(Disulfide-bond A oxidoreductase-like protein) which has been shown by yeast two 
hybrid studies to bind to adiponectin (Liu, Zhou et al. 2008), and more importantly its 
overexpression resulted in the multimerization of adiponectin. Other potential 
candidates include Ero1 (ER membrane-associated oxidoreductase 1)- Lα and its 
associated protein ERp44 which clearly shows preference in aiding the formation of 
higher order  complexes of adiponectin (Qiang, Wang et al. 2007), which the authors 
suggest that specific PDI (Protein disulphide isomerases) could be recruited by Ero1-




specific mechanisms in the preferential formation of disulphide bonds could 
potentially occur in the production of LMW C1q.  
 
The structural relevance of a different dimeric subunit cannot be over-emphasized. If 
LMW C1q is formed with different disulphide bonds, its overall conformation could 
be radically changed. Even if its general shape is retained, for instance the globular 
C1q head, the differential exposure of surface charges may change, indicating a 
change in binding profile. This is to be expected, as the C1q ABC globular heads in 
Normal C1q is bonded closely together with the exposure of certain residues while 
other residues are buried in close proximity of the chains, thus if the chains of LMW 
C1q are bonded with different disulphide bonds, the arrangement of exposed/buried 
residues can radically alter.  
 
6.4 Various methodologies employed in the study of C1q in DC regulation 
 
As stated earlier various methodologies were employed in the study of C1q in DC 
regulation (section 1.5.5), and this study utilised primarily the TLR 4 ligand, LPS and 
the Th-1 cytokine IFN-γ to investigate the cytokine secretion of IL-10 and IL-12p70. 
Previous studies reflected a less inflammatory profile in DCs cultured in the presence 
of Normal C1q with decrease in IL-12p40, IL-6, TNF-α and IL-23 secretion (section 
1.5.5). Various modalities were utilised such as the (a) presentation of Normal C1q in 
the immobilized format coated on wells or as a soluble format added directly to 




the differentiation of DCs, (c) or utilising C1qa
-/-
 mice. It is interesting to note that in 
the aspect of LPS stimulation, all the modalities used reflected a similar suppression 
in inflammatory cytokines.  
 
However in the aspect of phagocytosis and the expression of co-stimulatory 
molecules, it would seem that the format in which Normal C1q is presented (soluble 
or immobilized) would result in different outcomes. For instance it was noted that 
Normal C1q added in the soluble format to monocytes during the differentiation stage 
(Castellano, Woltman et al. 2007), resulted in down regulation of co-stimulatory 
molecules such as CD80 and CD86 and chemokines receptor CCR7. In contrast, the 
use of immobilized Normal C1q during the differentiation stage resulted in DCs with 
no significant difference in surface expression of co-stimulatory molecules or 
chemokines receptors (Teh, Yeo et al. 2011). Similarly in the aspect of phagocytosis, 
Normal C1q presented in soluble format during DC differentiation (Castellano, 
Woltman et al. 2007) had no effect in uptake of dextran beads, whereas immobilized 
C1q presented during differentiation resulted in increase in uptake of apoptotic cells 
by DCs (Teh, Yeo et al. 2011).  
 
C1q has been found to be deposited around the vicinity of atherosclerotic lesions 
(Cao, Bobryshev et al. 2003) where DCs and macrophages are simultaneously located 
in close proximity. Intriguingly solid phase assays measuring C1q concentrations 
revealed that C1q exposes a neoepitope upon being immobilized, which is targeted by 
autoantibodies found in SLE patients (Lewis and Botto 2006; Kallenberg 2008), and 




Autoantibodies to C1q has been found in SLE patients, specifically around 35-44% of 
SLE patients without nephritis indicated positivity, whereas in lupus nephritis 
patients, prevalence increases to 60-97% (Sinico, Radice et al. 2005; Trendelenburg, 
Lopez-Trascasa et al. 2006). One study revealed that C1q autoantibodies from SLE 
patients bind to C1q immobilized on early apoptotic cells, with the authors 
speculating that the neoepitope (exposed when immobilized) becoming antigenic as a 
result of simultaneous presentation with apoptotic cells (Bigler, Schaller et al. 2009). 
Interestingly the same study concluded that C1q bound in immune complexes do not 
attract autoantibodies from SLE patients. C1q autoantibodies are believed to play a 
pathogenic role (Kallenberg 2008) in the exacerbation of SLE, though the exact 
mechanism in humans is still speculative. If the autoantibodies specifically target 
immobilized C1q, and perhaps acting as neutralising antibodies, it is possible that 
immobilized C1q may play relevant physiological roles particularly in the context of 
SLE.   
 
It is noted that majority of the autoantibodies in SLE patients are IgG3 or IgG2 
subclass, with predominance of IgG3 in membranoproliferative glomerulonephritis 
and IgG2 predominance in lupus nephritis (Norsworthy, Theodoridis et al. 1999). 
Isotype class switching is complex and is dependent on a number of factors, one of 
which is the modality of B cells activation via T cell dependent or independent 
mechanism and the type of cytokine present (Deenick, Hasbold et al. 2005). Given 
that IFN-γ is strongly expressed in lupus nephiritis patients that parallels renal damage 
and that IFN-γ promotes antibody isotype switching to IgG2a (Snapper and Paul 




nephritis via autoantibody production. In addition it would be interesting to determine 
if the C1q autoantibodies produced in SLE patients target specifically immobilized 
Normal and/or LMW C1q.        
 
6.5 Possible signalling mechanisms of LMW C1q in the regulation of IL-10/IL-12p70 
secretion in dendritic cells  
 
LMW C1q differentiation of GMDCs resulted in the down regulation of IL-10 
secretion and the up regulation of IL-12p70 secretion (Fig 32 and 45). The exact 
signalling mechanism to which how LMW C1q modulates cytokine profile in 
GMDCs is still elusive. Two possible mechanisms are postulated; either (1) LMW 
C1q competes for the same surface receptor or (2) interferes at the level of cell 
signalling. Numerous C1q receptors have been described for Normal C1q, thus 
presenting a wide spectrum of candidates that LMW C1q could potentially compete 
for (Kishore and Reid 2000).Studies have shown that cross-linking of C1q receptor, 
gC1qR on DCs resulted in a drop in IL-12 secretion via LPS stimulation, with the 
activation of PI3K signalling cascade (Waggoner, Cruise et al. 2005). Normal C1q 
differentiation of GMDCs resulted in enhancement in PI3K, ERK, p38 signalling via 
increased phosphorylation of its intermediates (Teh, Yeo et al. 2011) upon IFN-γ 
and/or LPS stimulation, resulting in a decrease in IL-12p70 and an increase in IL-10 
secretion. It is highly likely that LMW C1q might act conversely on these signalling 





6.6 Role of IFN-γ and IL-10 in SLE 
 
LMW C1q primes the development of DCs from monocytes with an increased 
capacity to secrete IL-12p70 and suppression in IL-10 secretion (Fig 32) This is 
followed with a corresponding enhanced capacity to elicit increased IFN-γ secretion 
from T cells (Fig 36). It is interesting to postulate how this cytokine biasness could 
potentially influence SLE development. 
 
Evidence that IFN-γ is implicated in SLE is supported by multiple investigations in 
both human and murine studies (Su, Lu et al. 2012). IFN-γ is a hallmark Th-1 
cytokine produced mainly by T cells and NK cells, and signals through the IFN-γR-1 
and IFN-γR-2 subunits via JAK/STAT pathway (Gottenberg and Chiocchia 2007). 
Initial studies in the murine SLE model, MRL-lpr/lpr, indicated that prophylactic 
administration of murine IFN-γ from week 6 to 8, significantly reduce the onset of the 
disease, with decrease production of autoantibodies against DNA, reduced 
inflammatory infiltration of kidneys and lungs, and markedly reduced mortality rate 
(Nicoletti, Di Marco et al. 2000). However in the same study, the administration of 
murine IFN-γ after the onset of SLE from week 8 to 12 resulted in aggravation of the 
disease with higher autoantibody production, aggressive nephritis and higher 
mortality rate. The dichotomy of IFN-γ effects seems dependent on the stage of the 
disease, with a protective in prior to the onset and a pathogenic role in the later onset. 
In another murine SLE model, NZB/W, neutralising monoclonal antibody against 
IFN-γ administered from 4 to 7 months of age (later onset of disease) ameliorates 




administered plasmids expressing IFN-γ every 4 weeks from 3 months of age in the 
same murine model aggravated the disease pathology (Hasegawa, Hayashi et al. 
2002). Administration of soluble IFN-γR as a decoy receptor commencing at 4 
months of age in NZB/W SLE mice revealed reduced serologic and histologic 
indicators as compared to controls (Ozmen, Roman et al. 1995), with all mice treated 
with soluble IFN-γR alive 4 weeks after commencement of treatment while 50% of 




 mice study, deletion of the IFN-γ gene resulted in addition to 
previous improvements in mortality and various histologic parameters, revealed a 
switch of autoantibodies from IgG2a to IgG1, though remarkably the drop in IgG2a 
anti-dsDNA did not result in an increase in IgG1 dsDNA autoantibodies (Balomenos, 
Rumold et al. 1998). The same study also revealed that heterozygous deletion of IFN-
γ (IFN-γ+/-) resulted in similar levels of autoantibodies and renal deposits of immune 
complexes but a drop in early mortality and prevention of glomerulonephritis, 
indicating that a modulation of IFN-γ levels could potentially alleviate symptoms.   
 
Astonishingly transgenic mice, with normal genetic background not prone to 
autoimmunity, over-expressing IFN-γ via a skin promoter, developed lupus like 
syndromes, with inflammatory skin disease, anti-nuclear autoantibodies, and kidney 
deposits of immune complexes (Seery, Carroll et al. 1997). In the same over-
expression system for IFN-γ combined with TCR transgenic mice, it was revealed that 




resultant abolishment of kidney disease (Seery, Wang et al. 1999). This indicates that 
T cell immunity is required for the pathogenesis of IFN-γ driven SLE pathogenesis in 
mice.  
  
Reports of elevation of IL-12 and IFN-γ serum concentrations in human SLE patients 
are notable, particularly those in active stages of the disease (al-Janadi, al-Balla et al. 
1993; Tokano, Morimoto et al. 1999; Tucci, Lombardi et al. 2008). Interestingly T 
cells from SLE patients stimulated with anti-CD3 express significantly higher levels 
of IFN-γ (Harigai, Kawamoto et al. 2008) and PBMCs from SLE patients stimulated 
with LPS or PHA revealed an elevation of IFN-γ and positive correlation of IFN-γ 
with disease severity (Viallard, Pellegrin et al. 1999; Shah, Kiran et al. 2010). 
Interestingly in one study where SLE patients were scored with 37 for the SLEDAI 
index, the PBMCs from SLE patients revealed a 10 fold increase in IFN-γ as 
compared to healthy controls (Shah, Kiran et al. 2010; Dolff, Bijl et al. 2011), 
whereas in another study with a lower SLEDAI score of 3.7 (where >4 is active), the 
levels of IFN-γ from PBMCs is suppressed in SLE patients. It would seem that the 
role of IFN-γ in the pathogenesis of SLE in humans must be interpreted carefully in 
terms of disease severity and onset, as well as concurrent medications.  
 
Since LMW C1q could significantly increase the levels of IFN-γ particularly in the 
context of DC-T cell immunity (Fig 36), it is interesting to ask whether in a scenario 
where a dysregulation in the ratio of LMW/Normal C1q could affect the outcome in 




IL-10 is generally known as an immuno-suppressive cytokine which down regulates 
expression of co-stimulatory molecules, MHC-II and inhibits the production of IL-12 
and IFN-γ (Ding, Linsley et al. 1993; McBride, Jung et al. 2002). T regulatory cells 
typically employ a variety of methods of immune suppression, one of which is the 
secretion of IL-10 (Peterson 2012). The role of IL-10 in SLE is however unclear, and 
often conflicting, though it is clear that IL-10 is intimately involved in SLE (Su, Lu et 
al. 2012). In a murine autoimmune model of SLE, MRL-Fas
lpr
 crossed with transgenic 
IL-10 deficient mice, it was shown that the deficiency of IL-10 exacerbated the 
severity of SLE, with increased glomerulonephritis, skin lesions and higher mortality 
(Yin, Bahtiyar et al. 2002). In the same study, it was shown that with IL-10 
deficiency, reflected a concomitant increase in IFN-γ with parallel increase in 
production of IgG2a autoantibodies against dsDNA, and the administration of 
recombinant IL-10 reduced the production of autoantibodies. In a separate study with 
another murine autoimmune SLE model, NZB/W, it was shown that mice tolerized 
with SmD1 antigen resulted in the formation of IL-10 producing CD4 T cells, which 
when adoptively transferred to naive NZB/W mice resulted in suppression of 
autoantibody production and suppress even full blown SLE disease (Undeutsch, 
Humrich et al. 2011). In contrast, a study conducted with NZB/W mice with 
neutralising anti-IL-10 antibody from birth till 8-9 months of age indicated a delay in 
SLE disease onset(Ishida, Muchamuel et al. 1994).  
 
In human SLE patients, prophylactic administration of anti-IL-10 in 6 patients were 
reported to acquire remission in disease activity in 5 out of the 6 patients with 
SLEDAI score dropping from 8 to 1 across 6 months (Llorente, Richaud-Patin et al. 




harvested and treated with IL-10, and the production of autoantibodies was measured, 
it was shown that the administration of IL-10 for inactive disease patients, resulted in 
3.5-1.8 fold increase in autoantibody production, however for active disease patients, 
a converse drop of 91-97% drop occurred (Tyrrell-Price, Lydyard et al. 2001). Taken 
together it would seem that IL-10 effects must be interpreted carefully in 
consideration of the disease severity and onset. It would seem that IL-10 acts in 
concert or rather in opposite to that of IFN-γ, where IL-10 promotes autoantibody 
production in early stage and inhibits disease progression in later stages.  
 
In summary, the regulation of LMW/Normal C1q could possibly work in concert with 
either protective or pathogenic roles (Fig 46) depending on the disease stage by 
manipulating the production of IL-12p70/IFN-γ and IL-10 via DCs and T cell 
interaction. In light of the complex etiological and pathological nature of SLE, C1q 
regulation of DC in the aspect of cytokine production could potentially play an 






Figure 46: Diagram depicting possible pathogenic or protective scenario in the implications of IFN-
γ/IL-12p70 and IL-10 in SLE in light of LMW/Normal C1q ratio. The left half of the diagrams depicts 
the protective scenario where higher LMW/Normal ratio could act to regulate secretion of IFN-γ/IL-
12p70 and IL-10, and the converse occurring where a dysregulation of LMW/Normal C1q could lead to 











6.7 Presentation of self antigens by DCs in SLE 
 
DCs are implicated in the maintenance of peripheral tolerance (section 1.2.2), and 
presents self antigens in an anti-inflammatory environment, for instance with the 
secretion of IL-10, allowing the induction of T regulatory cells. In SLE, the failure to 
efficiently clear apoptotic cells has been postulated to result in the presentation of 
intracellular self-antigens in a pro-inflammatory manner, leading to the breakdown of 
peripheral tolerance (Fairhurst, Wandstrat et al. 2006). Indeed there are multiple lines 
of evidence indicating a decrease in the capacity of phagocytes from SLE patients to 
engulf apoptotic material (Ren, Tang et al. 2003; Bijl, Reefman et al. 2006). In mice 
deficient for C1q which develops SLE, there is an increased presence of apoptotic 
cells in the glomeruli (Botto, Dell'Agnola et al. 1998), and C1q has been implicated in 
the direct binding to apoptotic cells, aiding in the clearance of apoptotic cells (section 
1.5.4).  
 
The pivotal role of DCs mediating the breakdown in peripheral tolerance in SLE was 
shown by adoptive transfer of DCs loaded with apoptotic cells in murine models 
(Tzeng, Suen et al. 2006) . This study revealed that BM DCs from lupus prone mice 
pulsed with syngeneic apoptotic thymocytes cells were able to induce CD4 T cell 
proliferation specific to histone peptides, and in contrast, BMDCs from non-lupus 
prone mice could not induce CD4 T cell proliferation. A separate study with DCs 
pulsed with necrotic or apoptotic cells, indicated that the presence of DCs is critical, 
where the injection of necrotic or apoptotic cells alone reveal no significant effects on 




the second study, it is revealed that it is necrotic rather than apoptotic cells that trigger 
the clinical manifestations of lupus. The difference in the two studies could be in the 
experimental setup, where the first study titrated the levels of apoptotic cells to reach 
significant results as compared to the second study which utilised a fix ratio of 
apoptotic cells to DCs.  
 
In our setup with DCs and apoptotic cells, it was noted that with increasing ratio of 
apoptotic cells to DCs (1:1 to 20:1), the levels of IL-12p70 increases, while the levels 
of IL-10 decreases (Fig 44). The apoptotic cells were incubated with GMDCs for 
24hours prior to stimulation with IFN-γ and/or LPS, thus those apoptotic cells not 
phagocytosed would have progress to necrotic cells resulting in an inflammatory 
environment as indicated by the increasing levels of IL-12p70 and decreasing levels 
of IL-10. Given the pivotal role of DCs in the presentation of self antigens, the 
cytokine environment influenced by the presence of apoptotic/necrotic cells is 
important in determining whether a tolerogenic or inflammatory outcome. It is highly 
possible that a deficiency in clearance of apoptotic cells could lead to an inflammatory 
environment with necrotic cells, resulting in presentation of self antigens by DCs in 
an inflammatory rather than tolerogenic scenario, thereby contributing to the 
pathogenesis of SLE. The threshold determining whether the presentation of self 
antigens whether in a tolerogenic or pro-inflammatory context, could be influenced by 
the presence of LMW/Normal C1q during the differentiation stage of DCs. A 
dysregulation of the ratio of C1q could lead to a lower threshold (inflammatory to 
suppressive cytokines) that could be bridged with lower ratio of apoptotic cells.  




6.8 IFN-α regulation of LMW/Normal C1q expression 
 
The pathogenic role of IFN-α in SLE is supported by multiple studies (Su, Lu et al. 
2012). The most remarkable evidence that IFN-α plays a pathogenic role in SLE 
comes from clinical reports that the treatment of patients suffering from chronic viral 
infections and malignant diseases with IFN-α, resulted in lupus like symptoms 
(Wandl, Nagel-Hiemke et al. 1992). These patients develop anti-nuclear antibodies, 
cerebritis, anemia and lymphopenia (Schilling, Kurzrock et al. 1991; Mehta, 
Hooberman et al. 1992) and remission of symptoms occurs upon discontinuation of 
IFN-α treatment.  
 
The pathogenic role of IFN-α is also supported by murine studies. Lupus prone mice, 
B6/lpr crossed with transgenic mice with a null mutation in IFN-1-receptor, resulted 
in dramatic decrease in immune complexes deposition in kidneys and reduced 
lymphadenopathy (Braun, Geraldes et al. 2003). However the genetic background of 
the mice could influence the effects of IFN-α, it was shown that administration of 
IFN-α in NZB/W mice resulted in production of autoantibody secreting cells in 
secondary lymphoids but not in BALB/c mice (Mathian, Gallegos et al. 2011).  
 
Plasmacytoid DCs (pDCs) are potent producers of IFN-α, and the stimulation of pDCs 
with immune complexes result in the secretion of IFN-α via TLR-7 or TLR-9 (Bave, 
Magnusson et al. 2003; Means, Latz et al. 2005). Intriguingly the expression of IFN-α 




C1q (Lood, Gullstrand et al. 2009). C1q added simultaneously in the presence of 
immune complexes, resulted in a C1q dose dependent decrease in IFN-α secretion. In 
a separate study, IFN-α stimulation of human moDCs resulted in a decrease in C1q 
secretion (Castellano, Woltman et al. 2004). Thus it would seem that IFN-α and C1q 
behaves antagonistically, where the presence of C1q inhibits the secretion of IFN-α 
and the presence of IFN-α inhibits C1q secretion.  
 
Stimulation of MMFs with IFN-α (Fig 18b) resulted in the down regulation of both 
LMW and Normal C1q secretion, and the presence of M-CSF could not significantly 
alter the affects of IFN-α suppression of either. This blanket suppression of both 
forms of C1q could potentially suppress any form of biasness in either Th-1 or IL-10 
pathways.    
 
6.9 DC and NK cell interactions and implications on SLE 
 
Human blood NK cells can be broadly divided into two main populations based on the 




NK cells compromise 90% of blood NK cells population, and exhibit high 




NK cells represent the remaining 
10% of the blood NK cell population with the capacity to secrete high levels of IFN-γ 
and TNF-α. It is now established that activated moDCs could interact with NK cells 
resulting in the upregulation of CD69, an activation marker on NK cells (Gerosa, 








NK cells (Vitale, Della Chiesa et al. 2004), via soluble mediators 
such as IL-2, and cell contact interactions via CD40 and co-stimulatory molecules on 
DCs with CD40L and CD28 respectively on NK cells (Amakata, Fujiyama et al. 
2001). The surface expression of IL-15 on activated moDCs seems to play a 
significant role in aiding NK activation and proliferation (Ferlazzo, Pack et al. 2004) 
and the secretion of IL-12 from moDCs is essential for IFN-γ secretion by NK cells.    
 
 This interaction between DCs and NK cells is bidirectional (Wehner, Dietze et al. 
2011), with the secretion of IFN-γ from NK cells facilitating a positive feedback loop, 
with increased IL-12p70 secretion from moDCs (Mailliard, Son et al. 2003). In 
addition NK cells could enhance the capacity of DCs to stimulate T cell proliferation 
and differentiation of CD4 T lymphocytes to IFN-γ producing Th-1 Cells (Mailliard, 
Son et al. 2003).  
 
A recent study in human SLE patients indicated that NK cells in active disease state 
SLE patients had enhanced capacity to secrete IFN-γ as compared to control healthy 
humans or inactive SLE patients (Hervier, Beziat et al. 2011). This indicates that a 
dysregulation in LMW/Normal C1q ratio towards LMW C1q could result in higher 
IL-12p70 secretion from GMDCs, thereby skewing NK cells maturation towards 
enhanced IFN-γ production. The bidirectional nature of DC-NK cells interaction 
could also further enhance T cell proliferation and differentiation towards Th-1 
pathway, exacerbating the disease pathology of SLE during the active stage. The 
converse of higher Normal C1q levels during the active disease stage could also 




Direct C1q interaction with NK cells was also recently highlighted in a study (though 
just as a minor diagram in the paper). A flow cytometric analysis examining C1q 
binding to a variety of immune cells (lymphocytes, monocytes, NK cells and pDCs), 
revealed that monocytes and NK cells has the highest binding, with NK cells far 
exceeding that of monocytes (Lood, Gullstrand et al. 2009). This indicates that LMW 
/Normal C1q could potentially affect NK cell maturation, thereby directly having an 
impact on IFN-γ secretion from NK cells. 
 
 Indeed DCs have been shown to possess the capacity to synthesize and secrete C1q 
(Castellano, Woltman et al. 2007) and the ability of GMDCs to secrete LMW C1q 
was shown in this project (Fig 9) and the secretion of C1q in GMDCs and MMFs is 
enhanced in the presence of IFN-γ (Fig 40 and 16). Intriguingly the ratio of 
LMW/Normal C1q favours that of Normal C1q in the presence of IFN-γ alone (Fig 40 
and 16), though this ratio can be modulated in the presence of M-CSF or GM-CSF/IL-
4 for MMFs and GMDCs respectively. At this moment it is not clear if LMW/Normal 
C1q would prime NK cells in the same fashion as GMDCs, though it could be 
speculated that the ratio of LMW/Normal C1q in priming NK cells may be important.  
 
Taken together, not only could LMW/Normal C1q prime GMDCs, but also the 
reciprocal endogenous production of C1q from GMDCs due to cytokine secretion and 
modulation by NK cells could also bind to NK cells and affect the final outcome.  





6.10 Limitations of study 
 
The DCs cell model utilised in this study are derived from blood monocytes which 
represents a subset of DCs found during inflammation rather than in steady state 
(section 1.3.5). It is a contentious issue whether this form of DCs constitute a key 
player in the pathogenesis of SLE. Increased levels of blood monocytes or 
monocytosis have been described for SLE patients (Crispin, Vargas-Rojas et al. 2012) 
and likewise in murine lupus models, the same phenomenon has been noted (Vieten, 
Hadam et al. 1992; Amano, Amano et al. 2005; Kikuchi, Santiago-Raber et al. 2006). 
Although elevated level of blood monocytes has been noted in SLE, this is no clear 
indication yet that monocyte derived DCs contribute significantly to its pathology. 
Perhaps an interesting DC player in SLE would be the plasmacytoid DCs (pDCs), 
which are established to be potent producers of IFN-α, a cytokine believed to play a 
pathogenic role in SLE (section 6.7). It was shown that circulating pDCs decreases in 
conjunction with an increase in glomeruli infiltration in active lupus nephritis patients 
possibly through IL-18 interaction with IL-18 receptors expressed on pDCs (Tucci, 
Calvani et al. 2005). The bottle neck however in study of pDCs is the yield of pDCs 
that could be obtained for experimental studies as compared to moDCs which could 
made more readily available. 
 
Donor variability is another prickly issue in the study of moDCs. Though the blood 
donors are supposedly healthy donors, the genetic composition and immune status of 




encompasses the general dose sensitivity and response expected from a population of 
heterogeneous individuals.   
 
A complication in the study of moDCs is the heterogeneity of monocytes. At least 3 
main subsets of human monocytes exist based on the characterization of surface 




 monocytes are 
considered the classic monocytes and generally considered as the inflammatory 
monocytes (Robbins and Swirski 2010), which expresses higher levels of CCR2 
(Wildgruber, Lee et al. 2009), with circulating numbers rising after cardiac infarction 
(Tsujioka, Imanishi et al. 2009), and lower expression of anti-inflammatory surface 
molecule PD-1 (Said, Dupuy et al. 2010). For the two remaining CD16
+
 subsets of 
monocytes, it was shown that cytokine expression profiles differs in response to 









 monocytes producing TNF-α in response to LPS stimulation 
(Skrzeczynska-Moncznik, Bzowska et al. 2008). Since the use of plate adhesion to 
pull down monocytes after the ficoll density centrifugation does not differentiate the 
various subsets of monocytes, and given the nature that the percentage of the 
monocyte subsets can fluctuate between donors, this is a variability not accounted for 
in our study of DC regulation.  
 
 Another setback is the current arrangement with the hospital which requires the 
anonymization of samples that precludes the tracing back of samples with interesting 
data. This can be a frustrating issue in understanding especially the mechanism 




In the study of DC regulation, the rationale of the use of immobilized C1q was 
touched on previously (section 6.3); however the issue of how C1q is immobilized is 
currently unclear. It could be envisioned that C1q could potentially bind differently to 
various substrates in the extracellular matrix or in the context of an immune complex, 
be subtly or radically different in conformation. How this difference in conformation 
relates to its binding with monocytic surface receptors, is currently unclear. Globally, 
the structure of C1q could be divided into the collagenous tail or the globular head 
regions and these regions could engage different receptors. Subtle changes in 
conformation could also affect binding affinity and thus the signal threshold required 
for a functional change in DC regulation. The use of immobilized C1q in our model 
does not take into account the various possible conformations that C1q could assume 
in specific contexts particularly in pathological scenarios.   
 
In the study of cytokine secretion from GMDCs stimulated with apoptotic cells, the 
use of the Jurkat cell line as a source of apoptotic cells is widely utilised but could be 
a potential caveat. Though a human cell line, it may possess certain inter-individual 
differences that can signal as a foreign component rather than a host apoptotic cell. 
Without a doubt the use of autologous apoptotic cells would definitely be a better 
physiological counterpart in the investigation. For instance the use of floating PBMCs 
from the same donor after the adhesion phase of buffy coat purification, as a source of 
autologous apoptotic cells, may be more representative. But it must be noted that the 
UV irradiation protocol used in this study may not work with equal efficacy for all 
donors. Using autologous cells entail the possibility that the population of early/late 




standard source of apoptotic cells help delineate the trend of cytokine production with 
higher reproducibility.      
 
The lack of a specific inhibitor against C1q hinders the study of autocrine or paracrine 
effects of endogenously secreted C1q from GMDCs. Effort was made to develop Fab2 
constructs of anti-C1q from a goat polyclonal mixture of anti-C1q with the use of 
pepsin. The use of the anti-C1q Fab2 indicated no effects on the cytokine regulation of 
GMDCs with immobilized Normal C1q. It is believed that the neutralising antibody 
component (if any) may constitute a small percentage of the polyclonal mixture. 
Perhaps more favourable results could be obtained with the development of a specific 
monoclonal neutralising antibody, particularly if the antibody could differentiate 
LMW C1q and Normal C1q.  
 
6.11 Future Work 
 
The LMW C1q possesses a differential set of disulphide bonds arrangements as 
compared to the Normal C1q (Fig 12). As previously highlighted the differential 
regulation of disulphide bonds could be the pivotal mechanism in regulating which 
form of C1q is favoured (section 6.2). It was shown in adiponectin, that different 
cysteine residues were used for disulphide bond formation in the different oligomers 
(Tsao, Tomas et al. 2003). Preliminary work in this area could start off utilising the 
recombinant mammalian expression system developed in this study, to understand 




mutagenesis could be performed against the four cysteine residues present within each 
of the C1q ABC genes with the recombinant expression platform, and by examining 
the dimers in western blot, it is possible to determine which cysteine residues are 
critical. It is currently known that the Normal C1q uses cysteine residues located at 
C1qA4 and C1qB4 at the N-terminus for the A-B dimers, and the C1qC4 residues at 
the N-terminus for the C-C dimers(Ghebrehiwet, Hosszu et al. 2012). If LMW and 
Normal C1q utilises different cysteine residues, a knockout mice specific for LMW or 
Normal C1q could be generated. However if both C1qs uses the same cysteine 
residues, then the regulation of disulphide bonds in C1q has to be investigated further 
downstream, examining the aspects of PDI and oxidoreductases as previously 
mentioned (section 6.2).   
 
The mutagenesis for recombinant LMW C1q could also be used for understanding the 
various forms of mutations in C1q (functional rather than truncated) characterized for 
SLE patients (Schejbel, Skattum et al. 2011). Dissecting the mutations in terms of the 
various functional assays (cytokine regulation, apoptotic cell uptake, and complement 
activation) could further advance the understanding of which mechanisms that C1q is 
known to participate in, is protective/pathogenic in the perspective of SLE.  
 
The role of IFN-α in the pathogenesis of SLE was previously highlighted (section 
6.7), and apoptotic cells are known to release intracellular components such as DNA, 
nucleosomes and inflammatory components as it progresses towards secondary 
necrosis, which are postulated to play a role in the breakdown of peripheral tolerance 




Nieuwenhuijze, van Lopik et al. 2003; Bell, Jiang et al. 2006; Urbonaviciute and Voll 
2011). Since the release of DNA from apoptotic cells could result in IFN-α secretion 
from DCs, it would be interesting to study how differential binding of LMW/Normal 
C1q to apoptotic cells could regulate the uptake of apoptotic cells and IFN-α secretion 
from DCs. Alternatively the usage of LMW/Normal C1q differentiation of DCs, could 
also be examined for IFN-α secretion through apoptotic stimulation of DCs.  
 
T regulatory cells are known to participate in maintaining peripheral tolerance, and its 
dysregulation could be implicated in SLE (Sawla, Hossain et al. 2012). It would be 
interesting to examine how LMW/Normal C1q differentiation of DCs could affect 
induction of T regulatory cells, particularly since it has been shown that IL-10 
secretion is affected via the LMW/Normal C1q ratio (Fig 45). Furthermore, this 
aspect of T regulatory cell induction should be examined particularly in the context of 
apoptotic cell stimulation of LMW/Normal C1q DCs.  
 
Though LMW C1q has been reported to be elevated in SLE patients (Hoekzema, 
Hannema et al. 1985), it would be interesting to determine if LMW C1q levels change 
in respect to disease severity and its localisation in specific organs. Importantly, it 
would require the development of specific monoclonal antibodies against LMW C1q 
to facilitate such a study. Concurrently, it would be interesting to determine if 
autoantibodies against LMW C1q or Normal C1q occurs in SLE patients, and 
mapping the targeted epitopes of neutralising antibodies would allow the elucidation 




cloned out into commercial vectors available for antibody production, and be utilised 




The presence of LMW C1q was validated and detected from both human monocyte 
derived macrophages and dendritic cells, and is approximately 3-4 times smaller in 
size in comparison to Normal C1q. For the first time, C1q chain specific antibodies 
were used to decipher the dimeric composition of LMW C1q, and the existence of 
differential dimeric composition of LMW C1q was compared against the known 
Normal C1q dimers (AB and CC). The expression of Normal and LMW C1q from 
MMF stimulated in the presence of various cytokines (IFN-γ, IL-4 and IFN-α) and 
LPS was examined, and intriguingly LMW and Normal C1q expression was 
differentially regulated in the presence of M-CSF during IFN-γ and IL-4 stimulation. 
This differential regulation was also reflected by the preference of MMF to produce 
higher ratio of LMW C1q as compared to GM-CSF differentiated macrophages 
(GMMF).   
 
The presence of minute amounts of LMW C1q was detected in human serum though a 
predominance of Normal C1q was typical. A mammalian recombinant expression 
platform was developed concurrently with a purification protocol to obtain LMW C1q 





Immobilized LMW C1q was utilised to differentiated monocytes to GMDCs, and the 
cytokine expression profile of GMDCs were examined under stimulation with LPS 
and IFN-γ. It was determined that LMW C1q increase IL-12p70 and suppresses IL-10 
secretion from GMDCs, while the converse was true for Normal C1q. This capacity to 
drive the Th-1 pathway by LMW C1q GMDCs was able to influence allogenic mixed 
lymphocyte reaction (MLR), with an increased capacity to enhance Th-1 
differentiation reflected by an increase in IFN-γ secretion and IFN-γ positive T cells. 
This increased in Th-1 differentiation was supported by a parallel increase in T cell 
proliferation tracked across 7 days. Intriguingly Normal C1q indicated opposite trend 
to LMW C1q in terms of cytokine expression and T cell proliferation in the MLR 
setting.  
 
The ability of LMW C1q to influence apoptotic cell uptake by GMDCs was also 
examined, and results indicate that LMW C1q GMDCs had a suppressed capacity to 
ingest apoptotic cells shown across 2 hours, and this effect was again in opposite 
trend to that of Normal C1q GMDCs, which had higher phagocytic capacity. GMDCs 
primed with apoptotic/necrotic cells in increasing ratio, reflected a gradual increase in 
IL-12p70 and decrease in IL-10, and the priming of GMDCs once again determines 
the initial threshold of cytokine expression, and thus the propensity to present self 
antigens in either proinflammatory (LMW C1q GMDCs) or tolerogenic (Normal C1q 
GMDCs) scenarios.  
 
Overall it was also shown that a gradual titration of LMW C1q against a fixed 




IL-10. This indicates that a balance of LMW/Normal C1q ratio may influence GMDC 
propensity to secrete an inflammatory or suppressive cytokine profile. 
 
 Hereditary C1q deficiency is known to result in SLE in both humans and murine 
counterparts, but the occurrence of genetic deficiency of C1q is rare in SLE patient 
population, with few documented cases. However functional depletion of C1q could 
occur either due to consumption by complement activation or neutralisation by 
autoantibodies, the frequency of functional depletion is believed to occur in higher 
prevalence in SLE patients. It is currently unknown if a differential ratio of 
LMW/Normal C1q would affect SLE, though there are reports of elevated LMW C1q 
levels in SLE patients, but from the results garnered in this project, such a hypothesis 
is put forth. It would be exciting to delineate which subset of SLE patients is affected 
by the LMW/Normal C1q axis, and cross reference the ratios to the disease severity 
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